U.S. patent application number 14/404252 was filed with the patent office on 2015-06-18 for dihydroorotic acid dehydrogenase inhibitor.
This patent application is currently assigned to NAI INC.. The applicant listed for this patent is NAI INC.. Invention is credited to Ken Daniel Inaoka, Kiyoshi Kita, Hiroyuki Saimoto, Masaichi Yamamoto.
Application Number | 20150166498 14/404252 |
Document ID | / |
Family ID | 49673332 |
Filed Date | 2015-06-18 |
United States Patent
Application |
20150166498 |
Kind Code |
A1 |
Kita; Kiyoshi ; et
al. |
June 18, 2015 |
DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR
Abstract
The present invention provides a novel dihydroorotic acid
dehydrogenase inhibitor which is applicable to various diseases.
When used as an active ingredient, a compound represented by
formula (I): ##STR00001## (wherein X represents a halogen atom,
R.sup.1 represents a hydrogen atom, R.sup.2 represents an alkyl
group containing 1 to 7 carbon atoms, R.sup.3 represents --CHO, and
R.sup.4 represents --CH.sub.2--CH.dbd.C(CH.sub.3)--R.sup.0 (wherein
R.sup.0 represents an alkyl group containing 1 to 12 carbon atoms
which may have a substituent on the terminal carbon and/or on a
non-terminal carbon, etc.)), an optical isomer thereof or a
pharmaceutically acceptable salt thereof has a high inhibitory
effect on dihydroorotic acid dehydrogenase and can be used as an
immunosuppressive agent, a therapeutic agent for rheumatism, an
anticancer agent, a therapeutic agent for graft rejection, an
antiviral agent, an anti-H. pylori agent, a therapeutic agent for
diabetes or the like.
Inventors: |
Kita; Kiyoshi; (Tokyo,
JP) ; Inaoka; Ken Daniel; (Tokyo, JP) ;
Saimoto; Hiroyuki; (Tottori-shi, JP) ; Yamamoto;
Masaichi; (Tokyo, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
NAI INC. |
Minato-ku, Tokyo |
|
JP |
|
|
Assignee: |
NAI INC.
Minato-ku, Tokyo
JP
|
Family ID: |
49673332 |
Appl. No.: |
14/404252 |
Filed: |
May 28, 2013 |
PCT Filed: |
May 28, 2013 |
PCT NO: |
PCT/JP2013/064806 |
371 Date: |
November 26, 2014 |
Current U.S.
Class: |
514/473 ;
514/475; 514/545; 514/546; 514/678; 514/689; 514/701; 549/475;
549/554; 560/129; 560/53; 568/308; 568/442 |
Current CPC
Class: |
A61K 31/341 20130101;
A61P 37/06 20180101; C07C 47/56 20130101; A61K 31/216 20130101;
A61P 3/10 20180101; A61P 43/00 20180101; A61K 31/351 20130101; A61P
31/04 20180101; C07C 69/738 20130101; C07C 47/565 20130101; C07C
49/258 20130101; C07C 47/575 20130101; A61K 47/34 20130101; A61K
9/2018 20130101; A61K 31/357 20130101; A61K 31/222 20130101; A61P
31/12 20180101; C07C 49/255 20130101; A61P 35/00 20180101; A61K
31/336 20130101; A61K 9/2054 20130101; A61K 9/2059 20130101; A61K
31/121 20130101; A61K 9/1623 20130101; C07D 303/14 20130101; A61K
31/11 20130101; A61K 9/0019 20130101; A61K 47/02 20130101; A61K
9/2027 20130101; A61P 1/04 20180101; C07D 303/32 20130101; A61K
9/4866 20130101; A61P 29/00 20180101; C07D 309/12 20130101; C07C
49/248 20130101; A61K 47/12 20130101; C07C 69/63 20130101; C07D
307/20 20130101 |
International
Class: |
C07D 307/20 20060101
C07D307/20; C07C 49/255 20060101 C07C049/255; C07D 303/32 20060101
C07D303/32; C07C 49/248 20060101 C07C049/248; C07C 49/258 20060101
C07C049/258; C07C 69/738 20060101 C07C069/738; C07C 47/56 20060101
C07C047/56 |
Foreign Application Data
Date |
Code |
Application Number |
May 29, 2012 |
JP |
2012-122221 |
Claims
1. A dihydroorotic acid dehydrogenase inhibitor comprising, as an
active ingredient(s), one or two or more of compounds represented
by formula (I): ##STR00043## (wherein X represents a halogen atom,
R.sup.1 represents a hydrogen atom, R.sup.2 represents an alkyl
group containing 1 to 7 carbon atoms, R.sup.3 represents --CHO, and
R.sup.4 represents --CH.sub.2--CH.dbd.C(CH.sub.3)--R.sup.0 (wherein
R.sup.0 represents an alkyl group containing 1 to 12 carbon atoms
which may have a substituent on the terminal carbon and/or on a
non-terminal carbon, an alkenyl group containing 2 to 12 carbon
atoms which may have a substituent on the terminal carbon and/or on
a non-terminal carbon, or an alkynyl group containing 2 to 12
carbon atoms which may have a substituent on the terminal carbon
and/or on a non-terminal carbon)), optical isomers thereof and
pharmaceutically acceptable salts thereof, as well as a
pharmaceutically acceptable carrier.
2. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, wherein X represents a chlorine atom, R.sup.2 represents a
methyl group, and R.sup.4 represents
--CH.sub.2--CH.dbd.C(CH.sub.3)--R.sup.0 (wherein R.sup.0 represents
an alkyl group containing 1 to 12 carbon atoms which may have a
substituent on the terminal carbon and/or on a non-terminal carbon,
or an alkenyl group containing 2 to 12 carbon atoms which may have
a substituent on the terminal carbon and/or on a non-terminal
carbon), provided that when Ro has a substituent, the substituent
is selected from the group consisting of
--O--CO--C(CH.sub.3).sub.3, --O--CO--CH(CH.sub.3).sub.2,
--C(CH.sub.3).sub.2--O--CH.sub.3, --O-(2-furyl), --OH,
--CH(OCH.sub.3)--CH.sub.2--CO--C(CH.sub.3).sub.3, --CHO,
--CO--O--CH.sub.3, --CO--CH.sub.3, --O--CO--CH.sub.3 and
--CO--C(CH.sub.3).sub.3.
3. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, wherein the compounds represented by formula (I) are
selected from the group consisting of: ##STR00044## ##STR00045##
##STR00046##
4. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, which comprises glycerol.
5. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, which is used as an immunosuppressive agent.
6. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, which is used as a therapeutic agent for rheumatism.
7. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, which is used as an anticancer agent.
8. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, which is used as a therapeutic agent for graft rejection
in organ transplantation.
9. The dihydroorotic acid dehydrogenase inhibitor according claim
1, which is used as a therapeutic agent for diabetes.
10. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, which is used as an antiviral agent.
11. The dihydroorotic acid dehydrogenase inhibitor according to
claim 1, which is used as an anti-H. pylori agent.
12. A kit comprising a dihydroorotic acid dehydrogenase inhibitor
comprising, as an active ingredient(s), one or two or more of
compounds represented by formula (I): ##STR00047## (wherein X
represents a halogen atom, R.sup.1 represents a hydrogen atom,
R.sup.2 represents an alkyl group containing 1 to 7 carbon atoms,
R.sup.3 represents --CHO, and R.sup.4 represents
--CH.sub.2--CH.dbd.C(CH.sub.3)--R.sup.0 (wherein R.sup.0 represents
an alkyl group containing 1 to 12 carbon atoms which may have a
substituent on the terminal carbon and/or on a non-terminal carbon,
an alkenyl group containing 2 to 12 carbon atoms which may have a
substituent on the terminal carbon and/or on a non-terminal carbon,
or an alkynyl group containing 2 to 12 carbon atoms which may have
a substituent on the terminal carbon and/or on a non-terminal
carbon)), optical isomers thereof and pharmaceutically acceptable
salts thereof, as well as instructions for use thereof.
13. The kit according to claim 12, wherein X represents a chlorine
atom, R.sup.2 represents a methyl group, and R.sup.4 represents
--CH.sub.2--CH.dbd.C(CH.sub.3)--R.sup.0 (wherein R.sup.0 represents
an alkyl group containing 1 to 12 carbon atoms which may have a
substituent on the terminal carbon and/or on a non-terminal carbon,
or an alkenyl group containing 2 to 12 carbon atoms which may have
a substituent on the terminal carbon and/or on a non-terminal
carbon), provided that when Ro has a substituent, the substituent
is selected from the group consisting of
--O--CO--C(CH.sub.3).sub.3, --O--CO--CH(CH.sub.3).sub.2,
--C(CH.sub.3).sub.2--O--CH.sub.3, --O-(2-furyl), --OH,
--CH(OCH.sub.3)--CH.sub.2--CO--C(CH.sub.3).sub.3, --CHO,
--CO--O--CH.sub.3, --CO--CH.sub.3, --O--CO--CH.sub.3 and
--CO--C(CH.sub.3).sub.3.
14. The kit according to claim 12, wherein the compounds
represented by formula (I) are selected from the group consisting
of: ##STR00048## ##STR00049## ##STR00050##
15. The kit according to claim 12, which comprises glycerol.
16. The kit according to claim 12, which is used as an
immunosuppressive agent.
17. The kit according to claim 12, which is used as a therapeutic
agent for rheumatism.
18. The kit according to claim 12, which is used as an anticancer
agent.
19. The kit according to claim 12, which is used as a therapeutic
agent for graft rejection in organ transplantation.
20. The kit according to claim 12, which is used as a therapeutic
agent for diabetes.
21. The kit according to claim 12, which is used as an antiviral
agent.
22. The kit according to claim 12, which is used as an anti-H.
pylori agent.
Description
TECHNICAL FIELD
[0001] The present invention relates to an inhibitor of
dihydroorotic acid dehydrogenase (hereinafter abbreviated as
"DHOD"), which comprises a halogen-containing dihydroxybenzene
derivative with an alkyl side chain as an active ingredient. The
present invention also relates to an immunosuppressive agent, a
therapeutic agent for rheumatism, an anticancer agent, a
therapeutic agent for graft rejection, a therapeutic agent for
diabetes, an antiviral agent and an anti-Helicobacter pylori agent
("Helicobacter pylori" is expressed hereinafter as "H. pylori"),
each of which comprises a novel halogen-containing dihydroxybenzene
derivative with an alkyl side chain as an active ingredient.
BACKGROUND ART
[0002] The first inhibitor of human DHOD was reported in 1985, and
NSC368390 (renamed later as Brequinar) caused 90% or more
inhibition of the growth of human MX-1 breast, LX-1 lung, BL/STX-1
stomach and CX-1 colon carcinomas in nude mice at a dose of 20 to
40 mg/kg/day, and was also effective against HCT-15, clone A and
DLD-2 tumors, particularly its growth inhibition of DLD-2 colon
cancer was as high as 98% (Non-patent Document 1). In the next
year, UMP levels in NSC368390-treated cells were found to be
reduced by 50% after treatment with 25 .mu.M NSC368390, and
isotope-labeled substrates were used to measure the activity of all
enzymes responsible for the pyrimidine de novo synthetic pathway,
indicating that the fourth enzyme DHOD was strongly inhibited
(Ki=23.5 nM) (Non-patent Document 2). In 1989 (USA) and in 1990
(Netherlands), Phase I clinical trials were initiated, and 45 and
43 solid tumor patients, respectively, were administered one after
another. The results obtained are reported in Non-patent Document 3
and Non-patent Document 4. In the same year, Brequinar was reported
to be more effective than five drugs used for treatment of head and
neck squamous cell carcinomas.
[0003] In 1993, experiments in mice showed that allograft rejection
was caused later by Brequinar derivatives, suggesting that DHOD
inhibitors have an immunosuppressive effect. In 1994, Brequinar was
reported to suppress the growth of lymphocytes and was also
reported to inhibit cell cycle transition from the G0/G1 phase to
the S and G2+M phases (Non-patent Document 5). In 1995, there was a
report showing that the target of Leflunomide used for treatment of
rheumatoid arthritis was human dihydroorotic acid dehydrogenase
(hereinafter abbreviated as HsDHOD); and hence DHOD was confirmed
again to be promising as a target for anticancer and
immunosuppressive purposes, as in the case of Brequinar. DHOD
purified from mouse spleens was identified to bind to A771726
(Leflunomide metabolite) with high affinity, thus indicating that
Leflunomide is metabolized in vivo into A771726, and this A771726,
but not Leflunomide, has an immunosuppressive effect (Non-patent
Document 6, Non-patent Document 7). It should be noted that A771726
binds to the ubiquinone-binding site in known HsDHOD inhibitors. In
1996, NSC 665564 was reported to inhibit HsDHOD at the same level
as Brequinar and thereby suppress the growth of various cancer
cells (Non-patent Document 8). In 1998, Leflunomide was reported to
arrest the growth of T-lymphocytes in the G1 phase. In the same
year, esters of Leflunomide were found to suppress the growth of
B-lymphocytes and hence were proposed as therapeutic agents for
graft rejection in organ transplantation.
[0004] In 2000, A771726 suppressed diabetic symptoms in a
concentration-dependent manner in the NOD (non-obese diabetic)
mouse model of diabetes, and hence inhibitors of human DHOD were
found to be effective in T cell triggered disease, i.e.,
insulin-dependent diabetes mellitus (IDDM).
[0005] The following reports have been issued for DHOD in non-human
organisms. Membrane-bound DHOD is used as a drug target for malaria
(Non-patent Document 9, Non-patent Document 10) and also for
Helicobacter pylori (Non-patent Document 11, Non-patent Document
12) and Candida albicans (Non-patent Document 13, Non-patent
Document 14).
[0006] In addition, an analog (FK778) of Leflunomide has already
been reported to suppress the growth of human cytomegalovirus
(Non-patent Document 15). Moreover, Brequinar has been reported to
suppress the growth of flaviviruses (dengue virus, West Nile virus,
yellow fever virus, and Powassan virus), plus-strand RNA alphavirus
(Western equine encephalitis virus) and negative-strand RNA
rhabdovirus (vesicular stomatitis virus) (Non-patent Document 16).
At last, in March 2011, it was reported in PNAS (Proc Natl Acad Sci
USA) that a compound (Compound A3) suppressing the growth of a wide
range of viruses [negative-sense RNA viruses (influenza viruses A
and B, Newcastle disease virus, and vesicular stomatitis virus),
positive-sense RNA viruses (Sindbis virus, hepatitis C virus, West
Nile virus, and dengue virus), DNA viruses (vaccinia virus and
human adenovirus) and retroviruses (HIV)] was found through HTS
(high-throughput screening) (Non-patent Document 17). The
inhibitory effect of this compound on virus growth was suppressed
by orotic acid, but not suppressed by dihydroorotic acid which is a
substrate of DHOD, thus indicating that the target of Compound A3
inhibits dihydroorotic acid dehydrogenase present in human
mitochondria and thereby exerts an inhibitory effect on virus
growth (Non-patent Document 17). Further, as a result of analyzing
their toxicity on human cells, these compounds were found to show
1500-fold to 2400-fold or more selectivity between cytotoxicity
(CC.sub.50) and virus growth inhibition (IC.sub.50) depending on
the type of cells. The reason that these compounds have an
inhibitory effect on virus growth has been confirmed to be because
viral RNA-DNA synthesis is stopped upon reduction of the pyrimidine
pool in the infected cells (Non-patent Documents 19 to 21).
[0007] As described above, in humans, DHOD inhibitors have been
known to be promising as anticancer agents or immunosuppressive
agents since 1980s, and studies are also actively proceeding now.
As a mechanism for immunosuppression, DHOD inhibitors suppress the
growth of activated T-lymphocytes and B-lymphocytes. The pyrimidine
pool in normal cells is mediated by uracil transport, salvage
pathway and de novo synthesis. However, activated lymphocytes and
cancer cells depend on de novo synthesis. Since 1990s, it has been
reported that upon inhibition of DHOD, normal cells can survive due
to the uracil transport and salvage pathway, whereas lymphocytes
and cancer cells cannot grow.
[0008] Moreover, DHOD inhibitors are suggested as drug targets for
T-lymphocyte-mediated diabetes.
[0009] In the other organisms, membrane-bound DHOD is known as a
drug target in malaria and H. pylori, and many articles have been
reported for drug design using DHOD as a target. On the other hand,
DHOD inhibitors are known to be imperative for candidiasis because
they exert growth inhibition.
CITATION LIST
Non-Patent Documents
[0010] Non-patent Document 1: Daniel L. Dexter, 1 David P. Hesson,
Robert J. Ardecky, Ganti V. Rao, Davette L. Tippett, Betsy A.
Dusak, Kenneth D. Paull, Jacqueline Plowman, Barbara M. DeLarco, V.
L. Narayanan, and Martin Forbes. Activity of a Novel
4-Quinolinecarboxylic Acid, NSC 368390
[6-Fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic
Acid Sodium Salt], against Experimental Tumors. Cance Res. (1985)
45: 5563-5568 [0011] Non-patent Document 2: Shih-Fong Chen, Regina
L. Ruben and Daniel L. Dexter. Mechanism of action of the novel
anticancer agent
6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic
acid sodium salt (NSC 368390): inhibition of de novo pyrimidine
nucleotide biosynthesis. Cance Res. (1986) 46(10):5014-5019 [0012]
Non-patent Document 3: Arteaga C L, Brown T D, Kuhn J G, Shen H S,
O'Rourke T J, Beougher K, Brentzel H J, Von Hoff D D, Weiss G R.
Phase I Clinical and Pharmacokinetic Trial of Brequinar Sodium.
Cancer Res. (1989) 49(16):4648-4653 [0013] Non-patent Document 4:
Schwartsmann G, Dodion P, Vermorken J B, ten Bokkel Huinink W W,
Joggi J, Winograd B, Gall H, Simonetti G, van der Vijgh W J, van
Hennik M B, et al. Phase I study of Brequinar sodium (NSC 368390)
in patients with solid malignancies. Cancer Chemother Pharmacol.
(1990) 25(5): 345-351. [0014] Non-patent Document 5: Forrest T L,
Ware R E, Howard T, Jaffee B D, Denning S M. Novel mechanisms of
brequinar sodium immunosuppression on T cell activation.
Transplantation. (1994) 58(8): 920-926. [0015] Non-patent Document
6: Williamson R A, Yea C M, Robson P A, Curnock A P, Gadher S,
Hambleton A B, Woodward K, Bruneau J M, Hambleton P, Moss D,
Thomson T A, Spinella-Jaegle S, Morand P, Courtin O, Sautes C,
Westwood R, Hercend T, Kuo E A, Ruuth E. Dihydroorotate
dehydrogenase is a high affinity binding protein for A77 1726 and
mediator of a range of biological effects of the immunomodulatory
compound. J Biol Chem. (1995) 270(38): 22467-22472. [0016]
Non-patent Document 7: Davis J P, Cain G A, Pitts W J, Magolda R L,
Copeland R A. The immunosuppressant leflunomide inhibits lymphocyte
proliferation by inhibiting pyrimidine biosynthesis. Biochemistry.
(1996) 35(4): 1270-1273. [0017] Non-patent Document 8: Cleaveland E
S, Zaharevitz D W, Kelley J A, Paull K, Cooney D A, Ford H Jr.
Identification of a novel inhibitor (NSC 665564) of dihydroorotate
dehydrogenase with a potency equivalent to brequinar. Biochem
Biophys Res Commun. (1996) 223(3): 654-659. [0018] Non-patent
Document 9: Baldwin J, Michnoff C H, Malmquist N A, White J, Roth M
G, Rathod P K, Phillips M A. High-throughput Screening for Potent
and Selective Inhibitors of Plasmodium falciparum Dihydroorotate
Dehydrogenase. J Biol Chem. (2005) 280(23): 21847-21853 [0019]
Non-patent Document 10: Phillips M A, Gujjar R, Malmquist N A,
White J, El Mazouni F, Baldwin J, Rathod P K.
Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors
with potent and selective activity against the malaria parasite
Plasmodium falciparum. J Med Chem. (2008) 51(12): 3649-3653. [0020]
Non-patent Document 11: Copeland R A, Marcinkeviciene J, Haque T S,
Kopcho L M, Jiang W, Wang K, Ecret L D, Sizemore C, Amsler K A,
Foster L, Tadesse S, Combs A P, Stern A M, Trainor G L, Slee A,
Rogers M J, Hobbs F. Helicobacter pylori-selective Antibacterials
Based on Inhibition of pyrimidine biosynthesis. J Biol Chem. (2000)
275(43): 33373-33378. [0021] Non-patent Document 12: Haque T S,
Tadesse S, Marcinkeviciene J, Rogers M J, Sizemore C, Kopcho L M,
Amsler K, Ecret L D, Zhan D L, Hobbs F, Slee A, Trainor G L, Stern
A M, Copeland R A, Combs A P. Parallel synthesis of potent,
pyrazole-based inhibitors of Helicobacter pylori dihydroorotate
dehydrogenase. J Med Chem. (2002) 45(21): 4669-4678. [0022]
Non-patent Document 13: Elke Zameitat, Zoran Gojkovic, Wolfgang
Knecht, Jure Piskur and Monika Loffler. Biochemical
characterization of recombinant dihydroorotate dehydrogenase from
the opportunistic pathogenic yeast Candida albicans. FEBS J.
(2006); 273(14): 3183-3191. [0023] Non-patent Document 14:
Gustafson G, Davis G, Waldron C, Smith A, Henry M. Identification
of a new antifungal target site through a dual biochemical and
molecular-genetics approach. Curr Genet. (1996) 30(2): 159-165.
[0024] Non-patent Document 15: David L. Evers; Xin Wang, Shu-Mei
Huong, Kenneth A. Andreoni, Eng-Shang Huang. Inhibition of human
cytomegalovirus signaling and replication by the immunosuppressant
FK778. [0025] Non-patent Document 16: Min Qing, Gang Zou, Qing-Yin
Wang, Hao Ying Xu, Hongping Dong, Zhiming Yuan and Pei-Yong Shi.
Characterization of Dengue Virus Resistance to Brequinar in Cell
Culture. Antimicrob Agents Chemother, (2010) 54(9): 3686-3695.
[0026] Non-patent Document 17: Hans-Heinrich Hoffmann, Andrea
Kunza, Viviana A. Simona, Peter Palesea, and Megan L. Shawa.
Broad-spectrum antiviral that interferes with de novo pyrimidine
biosynthesis. Proc Natl Aced Sci USA. 2011 Mar. 21. [Epub ahead of
print]. [0027] Non-patent Document 18: June P. Davis, Gary A. Cain,
William J. Pitts, Ronald L. Magolda, and Robert A. Copeland. The
Immunosuppressive Metabolite of Leflunomide Is a Potent Inhibitor
of Human Dihydroorotate Dehydrogenase. Biochemistry (1996) 35:
1270-1273. [0028] Non-patent Document 19: Papageorgiou C, Albert R,
Floersheim P, Lemaire M, Bitch F, Weber H P, Andersen E, Hungerford
V, Schreier M H. Pyrazole bioisosteres of leflunomide as B-cell
immunosuppressants for xenotransplantation and chronic rejection:
scope and limitations. J Med Chem. (1998) 41(18): 3530-3538. [0029]
Non-patent Document 20: Stosic-Grujicic S, Dimitrijevic M, Bartlett
R. Leflunomide protects mice from multiple low dose streptozotocin
(MLD-SZ)-induced insulitis and diabetes. Clin Exp Immunol. (1999)
117(1): 44-50. [0030] Non-patent Document 21: Ittarat I,
Asawamahasakda W, Bartlett M S, Smith J W, Meshnick S R. Effects of
atovaquone and other inhibitors on Pneumocystis carinii
dihydroorotate dehydrogenase. Antimicrob Agents Chemother. (1995)
39(2): 325-358.
SUMMARY OF THE INVENTION
Problem to be Solved by the Invention
[0031] The problem of the present invention is to provide a novel
DHOD inhibitor which is applicable to various diseases.
Means to Solve the Problem
[0032] As a result of extensive and intensive efforts and studies
repeated to solve the problem stated above, the inventors of the
present invention have found that dihydroxybenzene derivatives
having a certain type of side chain have a high DHOD inhibitory
effect. The present invention has been completed on the basis of
this finding.
[0033] The present invention provides a DHOD inhibitor comprising,
as an active ingredient(s), one or two or more of compounds
represented by formula (I):
##STR00002##
[0034] (wherein
[0035] X represents a halogen atom,
[0036] R.sup.1 represents a hydrogen atom,
[0037] R.sup.2 represents an alkyl group containing 1 to 7 carbon
atoms,
[0038] R.sup.3 represents --CHO, and
[0039] R.sup.4 represents --CH.sub.2--CH.dbd.C(CH.sub.3)--R.sup.0
(wherein R.sup.0 represents an alkyl group containing 1 to 12
carbon atoms which may have a substituent on the terminal carbon
and/or on a non-terminal carbon, an alkenyl group containing 2 to
12 carbon atoms which may have a substituent on the terminal carbon
and/or on a non-terminal carbon, or an alkynyl group containing 2
to 12 carbon atoms which may have a substituent on the terminal
carbon and/or on a non-terminal carbon)), optical isomers thereof
and pharmaceutically acceptable salts thereof, as well as a
pharmaceutically acceptable carrier.
[0040] The present invention also provides an immunosuppressive
agent, a therapeutic agent for rheumatism, an anticancer agent, a
therapeutic agent for graft rejection, an antiviral agent, an
anti-H. pylori agent and a therapeutic agent for diabetes, each
comprising one or two or more of compounds represented by formula
(I), optical isomers thereof and pharmaceutically acceptable salts
thereof, as well as a pharmaceutically acceptable carrier.
[0041] The present invention further provides a kit comprising one
or two or more of compounds represented by formula (I), optical
isomers thereof and pharmaceutically acceptable salts thereof, as
well as instructions for use.
Advantageous Effects of the Invention
[0042] Because of having high DHOD inhibitory activity, the above
compounds represented by formula (I) are extremely useful as DHOD
inhibitors for use in therapeutic agents for various DHOD-related
diseases, such as various types of cancers, rheumatism, graft
rejection in organ transplantation, viral diseases, H.
pylori-induced diseases, diabetes and so on.
BRIEF DESCRIPTION OF THE DRAWINGS
[0043] FIG. 1 shows graphs indicating the growth inhibitory effect
on colorectal cancer cells (DLD-1 cells) provided by the compounds
of the present invention.
[0044] FIG. 2 shows a graph indicating the growth inhibitory effect
on pancreatic cancer cells (Panc-1 cells) provided by the compounds
of the present invention.
[0045] FIG. 3 shows graphs indicating the growth inhibitory effect
on normal skin cells (HDF cells) provided by the compounds of the
present invention.
DESCRIPTION OF EMBODIMENTS
[0046] The present invention will be described in more detail
below.
[0047] In the compounds to be used in the present invention, a
halogen atom refers to any of a fluorine atom, a chlorine atom, a
bromine atom and an iodine atom.
[0048] In the compounds to be used in the present invention, an
alkyl group containing 1 to 7 carbon atoms refers a linear or
branched alkyl group containing 1 to 7 carbon atoms, as exemplified
by a methyl group, an ethyl group, a n-propyl group, an i-propyl
group, a n-butyl group, an i-butyl group, a s-butyl group, a
t-butyl group, a n-pentyl group, a n-hexyl group, a n-heptyl group
and so on.
[0049] In the compounds to be used in the present invention, an
alkyl group containing 1 to 16 carbon atoms refers to a linear or
branched alkyl group containing 1 to 16 carbon atoms, as
exemplified by a methyl group, an ethyl group, a n-propyl group, an
i-propyl group, a n-butyl group, an i-butyl group, a s-butyl group,
a t-butyl group, a n-pentyl group, a n-hexyl group, a n-heptyl
group, a n-octyl group, a n-nonyl group, a n-decyl group, a
n-undecyl group, a n-dodecyl group, a n-tridecyl group, a
n-tetradecyl group, a n-pentadecyl group, a n-hexadecyl group and
so on.
[0050] In the compounds to be used in the present invention, an
alkenyl group containing 2 to 16 carbon atoms refers to a linear or
branched group containing 2 to 16 carbon atoms, which has one or
more double bonds, as exemplified by a vinyl group,
--CH.sub.2--CH.dbd.C(CH.sub.3)--(CH.sub.2).sub.2--CH.dbd.C(CH.sub.3).sub.-
2,
--CH.sub.2--CH.dbd.C(CH.sub.3)--(CH.sub.2).sub.2--CH.dbd.C(CH.sub.3)--(-
CH.sub.2).sub.2--CH.dbd.C(CH.sub.3).sub.2,
--CH.dbd.C--CH.sub.2--(CH.sub.2)n-(CH.sub.2).sub.2--CH.sub.3 (where
n is an integer of 1 to 3) and so on.
[0051] In the compounds to be used in the present invention, an
alkynyl group containing 2 to 16 carbon atoms refers to a linear or
branched group containing 2 to 16 carbon atoms, which has one or
more triple bonds or which has one triple bond and one double bond,
as exemplified by an ethynyl group, a 2-pentynyl group, a 2-hexynyl
group, a 2-octynyl group, a 7-methyl-6-octen-2-ynyl group and so
on.
[0052] In the compounds to be used in the present invention, an
alkyl group containing 1 to 16 carbon atoms, which has any type of
substituent on the terminal carbon, refers to a linear or branched
alkyl group containing 1 to 16 carbon atoms, which has a
substituent(s) on the carbon atom located at the most distant
position from the carbon atom in the alkyl group attached to a
carbon atom of the benzene ring in the compound of formula (I).
Examples of any type of substituent include --COOH, --COORa (where
Ra means an alkyl group containing 1 to 7 carbon atoms), --CHO,
--COOCH.sub.2CH(OH)CH.sub.2OH, --COO--CH.sub.2--Rb (where Rb means
a group obtained by removing one of the hydrogen atoms on the
carbons of an aromatic hydrocarbon such as benzene, naphthalene,
anthracene or the like), --O--CO-Rc (where Rc means an alkyl group
containing 1 to 7 carbon atoms), --OH, --O-Rd (where Rd means an
alkyl group containing 1 to 7 carbon atoms),
--O--CH.sub.2--O--CH.sub.3, -HET (where HET means a group obtained
by removing one hydrogen atom from the carbon or nitrogen atom(s)
of a heterocyclic compound (e.g., pyridine, furan, thiophene,
furanone, pyran, pyranone, imidazole, 1,3-dioxolane, oxirane,
3,3-dimethyloxirane)), --O-HET (where HET has the same meaning as
defined above) and so on.
[0053] In the compounds to be used in the present invention, an
alkyl group containing 1 to 16 carbon atoms, which has any type of
substituent on a non-terminal carbon, refers to a linear or
branched alkyl group containing 1 to 16 carbon atoms, which has a
substituent(s) on a carbon atom(s) other than the carbon atom
located at the most distant position from the carbon atom in the
alkyl group attached to a carbon atom of the benzene ring in the
compound of formula (I). Examples of any type of substituent
include --COOH, --COORa (where Ra means an alkyl group containing 1
to 7 carbon atoms), --CHO, --COOCH.sub.2CH(OH)CH.sub.2OH,
--COO--CH.sub.2--Rb (where Rb means a group obtained by removing
one of the hydrogen atoms on the carbons of an aromatic hydrocarbon
such as benzene, naphthalene, anthracene or the like), --O--CO-Rc
(where Rc means an alkyl group containing 1 to 7 carbon atoms),
--OH, --O-Rd (where Rd means an alkyl group containing 1 to 7
carbon atoms), --O--CH.sub.2--O--CH.sub.3, -HET (where HET means a
group obtained by removing one hydrogen atom from the carbon or
nitrogen atom(s) of a heterocyclic compound (e.g., pyridine, furan,
thiophene, furanone, pyran, pyranone, imidazole, 1,3-dioxolane,
oxirane, 3,3-dimethyloxirane)), --O-HET (where HET has the same
meaning as defined above) and so on.
[0054] In the compounds to be used in the present invention, an
alkenyl group containing 2 to 16 carbon atoms, which has any type
of substituent on the terminal carbon, refers to a linear or
branched alkenyl group containing 2 to 16 carbon atoms, which has a
substituent(s) on the carbon atom located at the most distant
position from the carbon atom in the alkenyl group attached to a
carbon atom of the benzene ring in the compound of formula (I). It
should be noted that the term "alkenyl" used herein also includes
those having two or more double bonds. Examples of any type of
substituent include --COOH, --COORa (where Ra means an alkyl group
containing 1 to 7 carbon atoms), --CHO,
--COOCH.sub.2CH(OH)CH.sub.2OH, --COO--CH.sub.2--Rb (where Rb means
a group obtained by removing one of the hydrogen atoms on the
carbons of an aromatic hydrocarbon such as benzene, naphthalene,
anthracene or the like), --O--CO-Rc (where Rc means an alkyl group
containing 1 to 7 carbon atoms), --OH, --O-Rd (where Rd means an
alkyl group containing 1 to 7 carbon atoms),
--O--CH.sub.2--O--CH.sub.3, -HET (where HET means a group obtained
by removing one hydrogen atom from the carbon or nitrogen atom(s)
of a heterocyclic compound (e.g., pyridine, furan, thiophene,
furanone, pyran, pyranone, imidazole, 1,3-dioxolane, oxirane,
3,3-dimethyloxirane)), --O-HET (where HET has the same meaning as
defined above) and so on.
[0055] In the compounds to be used in the present invention, an
alkenyl group containing 2 to 16 carbon atoms, which has any type
of substituent on a non-terminal carbon, refers to a linear or
branched alkenyl group containing 2 to 16 carbon atoms, which has a
substituent(s) on a carbon atom(s) other than the carbon atom
located at the most distant position from the carbon atom in the
alkenyl group attached to a carbon atom of the benzene ring in the
compound of formula (I). It should be noted that the term "alkenyl"
used herein also includes those having two or more double bonds.
Examples of any type of substituent include --COOH, --COORa (where
Ra means an alkyl group containing 1 to 7 carbon atoms), --CHO,
--COOCH.sub.2CH(OH)CH.sub.2OH, --COO--CH.sub.2--Rb (where Rb means
a group obtained by removing one of the hydrogen atoms on the
carbons of an aromatic hydrocarbon such as benzene, naphthalene,
anthracene or the like), --O--CO-Rc (where Rc means an alkyl group
containing 1 to 7 carbon atoms), --OH, --O-Rd (where Rd means an
alkyl group containing 1 to 7 carbon atoms),
--O--CH.sub.2--O--CH.sub.3, -HET (where HET means a group obtained
by removing one hydrogen atom from the carbon or nitrogen atom(s)
of a heterocyclic compound (e.g., pyridine, furan, thiophene,
furanone, pyran, pyranone, imidazole, 1,3-dioxolane, oxirane,
3,3-dimethyloxirane)), --O-HET (where HET has the same meaning as
defined above) and so on.
[0056] In the compounds to be used in the present invention, an
alkynyl group containing 2 to 16 carbon atoms, which has any type
of substituent on the terminal carbon, refers to a linear or
branched alkynyl group containing 2 to 16 carbon atoms, which has a
substituent(s) on the carbon atom located at the most distant
position from the carbon atom in the alkynyl group attached to a
carbon atom of the benzene ring in the compound of formula (I). It
should be noted that the term "alkynyl" used herein also includes
those having two or more triple bonds. Examples of any type of
substituent include --COOH, --COORa (where Ra means an alkyl group
containing 1 to 7 carbon atoms), --CHO,
--COOCH.sub.2CH(OH)CH.sub.2OH, --COO--CH.sub.2--Rb (where Rb means
a group obtained by removing one of the hydrogen atoms on the
carbons of an aromatic hydrocarbon such as benzene, naphthalene,
anthracene or the like), --O--CO-Rc (where Rc means an alkyl group
containing 1 to 7 carbon atoms), --OH, --O-Rd (where Rd means an
alkyl group containing 1 to 7 carbon atoms),
--O--CH.sub.2--O--CH.sub.3, -HET (where HET means a group obtained
by removing one hydrogen atom from the carbon or nitrogen atom(s)
of a heterocyclic compound (e.g., pyridine, furan, thiophene,
furanone, pyran, pyranone, imidazole, 1,3-dioxolane, oxirane,
3,3-dimethyloxirane)), --O-HET (where HET has the same meaning as
defined above) and so on.
[0057] In the compounds to be used in the present invention, an
alkynyl group containing 2 to 16 carbon atoms, which has any type
of substituent on a non-terminal carbon, refers to a linear or
branched alkynyl group containing 2 to 16 carbon atoms, which has a
substituent(s) on a carbon atom(s) other than the carbon atom
located at the most distant position from the carbon atom in the
alkynyl group attached to a carbon atom of the benzene ring in the
compound of formula (I). It should be noted that the term "alkynyl"
used herein also includes those having two or more triple bonds.
Examples of any type of substituent include --COOH, --COORa (where
Ra means an alkyl group containing 1 to 7 carbon atoms), --CHO,
--COOCH.sub.2CH(OH)CH.sub.2OH, --COO--CH.sub.2--Rb (where Rb means
a group obtained by removing one of the hydrogen atoms on the
carbons of an aromatic hydrocarbon such as benzene, naphthalene,
anthracene or the like), --O--CO-Rc (where Rc means an alkyl group
containing 1 to 7 carbon atoms), --OH, --O-Rd (where Rd means an
alkyl group containing 1 to 7 carbon atoms),
--O--CH.sub.2--O--CH.sub.3, -HET (where HET means a group obtained
by removing one hydrogen atom from the carbon or nitrogen atom(s)
of a heterocyclic compound (e.g., pyridine, furan, thiophene,
furanone, pyran, pyranone, imidazole, 1,3-dioxolane, oxirane,
3,3-dimethyloxirane)), --O-HET (where HET has the same meaning as
defined above) and so on.
[0058] Among the compounds to be used in the present invention,
some compounds have optical isomers. The respective optical isomers
and mixtures thereof are all included in the present invention.
Either a racemic mixture or an optical isomer may be used as the
DHOD inhibitor of the present invention. It should be noted that
optical isomers may be obtained by resolving their racemic mixture
in a well-known manner (e.g., preferential crystallization, column
chromatography with an optically active stationary phase,
techniques used to obtain diastereomers).
[0059] Examples of pharmaceutically acceptable salts of the
compounds to be used in the present invention or optical isomers
thereof include the following salts.
[0060] When a salt is formed with OH of the phenol, examples
include a Na salt, a K salt, a Li salt, an ammonium salt, etc.
[0061] When X in formula (I) is COOH, examples include a Na salt, a
K salt, a Li salt, an ammonium salt, etc.
[0062] The compounds to be used in the dihydroorotic acid
dehydrogenase inhibitor of the present invention may be
specifically exemplified by a dihydroorotic acid dehydrogenase
inhibitor comprising one or two or more of compounds represented by
formula (I):
##STR00003##
[0063] wherein
[0064] X represents a chlorine atom,
[0065] R.sup.1 represents a hydrogen atom,
[0066] R.sup.2 represents a methyl group,
[0067] R.sup.3 represents --CHO, and
[0068] R.sup.4 represents --CH.sub.2--CH.dbd.C(CH.sub.3)--R.sup.0
(wherein R.sup.0 represents an alkyl group containing 1 to 12
carbon atoms which may have a substituent on the terminal carbon
and/or on a non-terminal carbon, or an alkenyl group containing 2
to 12 carbon atoms which may have a substituent on the terminal
carbon and/or on a non-terminal carbon), provided that when Ro has
a substituent, the substituent is selected from the group
consisting of --O--CO--C(CH.sub.3).sub.3,
--O--CO--CH(CH.sub.3).sub.2, --C(CH.sub.3).sub.2--O--CH.sub.3,
--O-(2-furyl), --OH,
--CH(OCH.sub.3)--CH.sub.2--CO--C(CH.sub.3).sub.3, --CHO,
--CO--O--CH.sub.3, --CO--CH.sub.3, --O--CO--CH.sub.3 and
--CO--C(CH.sub.3).sub.3,
optical isomers thereof and pharmaceutically acceptable salts
thereof, as well as a pharmaceutically acceptable carrier.
[0069] Further, the compounds to be used in the dihydroorotic acid
dehydrogenase inhibitor of the present invention may be
specifically exemplified by a dihydroorotic acid dehydrogenase
inhibitor comprising one or two or more of the above compounds
represented by formula (I), which are selected from the group
consisting of:
##STR00004## ##STR00005## ##STR00006##
optical isomers thereof and pharmaceutically acceptable salts
thereof, as well as a pharmaceutically acceptable carrier. When the
DHOD inhibitor of the present invention is administered in vivo, it
may be administered orally or parenterally (e.g., intrarectal,
subcutaneous, intraspinal, intravenous, intraarterial or
percutaneous route). When administered in vivo, the compounds or
salts thereof to be used in the present invention are preferably
used by being formulated into any suitable dosage form, and may be
used in the form of formulations such as tablets, powders,
granules, fine granules, pills, capsules, troches, chewables,
solutions, emulsions, suspensions, suppositories, syrups, lotions,
ointments, poultices, etc. For formulation into these dosage forms,
a pharmaceutically acceptable carrier suitable for each dosage form
may be used.
[0070] As a carrier to be used in the DHOD inhibitor of the present
invention, any additive well known in the art of pharmaceutical
manufacturing may be used. Such a carrier may be exemplified by an
excipient, a diluent, a wetting agent, a suspending agent, an
emulsifier, a dispersant, an auxiliary, a sweetener, a coloring
agent, a flavoring agent, a buffering agent, an antiseptic, a
preservative, a buffering agent, a binder, a stabilizing agent and
so on. From among well-known and commonly-used carriers, those
required for the intended dosage form may be selected. It should be
noted that examples of an excipient or an auxiliary include
lactose, various starches (e.g., corn starch), chitin, chitosan,
glucose, sucrose, cellulose, methylcellulose, carboxymethyl
cellulose, magnesium stearate, lauryl sulfate, talc, vegetable oils
(e.g., soybean oil, peanut oil, olive oil), lecithin and so on.
[0071] It should be noted that the DHOD inhibitor of the present
invention may comprise glycerol. The amount of glycerol to be added
is not limited in any way and may be adjusted as appropriate if
necessary.
[0072] When the DHOD inhibitor of the present invention is
administered by the intravenous or intraspinal route, preferred
dosage forms are solutions. For preparation of solutions, they may
be prepared, for example, by using purified water, physiological
saline, an alcohol (e.g., ethanol, propylene glycol, glycerine,
polyethylene glycol), a solvent (e.g., triacetin), etc. The thus
prepared solutions may be used by being diluted with, for example,
lactated Ringer's solution, maintenance solution, a solution for
postoperative recovery, a replenisher for dehydration,
physiological saline for drip infusion, etc. Such formulations may
further comprise auxiliaries such as an antiseptic, a wetting
agent, an emulsifier, a dispersant and a stabilizer. Moreover,
administration in the form of suspensions can also be regarded as
one of the preferred dosage forms.
[0073] Likewise, for preparation of solid formulations including
tablets, pills, powders, granules, fine granules, troches,
chewables and so on, they may be prepared in a standard manner, for
example, by adding a carrier (e.g., sodium bicarbonate, calcium
carbonate, starch, sucrose, mannitol, carboxymethyl cellulose) and
additives (e.g., calcium stearate, magnesium stearate, glycerine).
Moreover, they may be formulated as enteric-coated formulations by
being provided with an enteric coating by spraying a solution of an
enteric material (e.g., cellulose acetate phthalate, hydroxypropyl
methylcellulose phthalate, polyvinyl alcohol phthalate, a
styrene-maleic anhydride copolymer, a methacrylic acid-methyl
methacrylate copolymer) in an organic solvent or in water. Such a
pharmaceutically acceptable carrier generally further comprises an
auxiliary, an aromatic, a stabilizer or an antiseptic, each being
used when needed.
[0074] The dose of the compounds to be used in the present
invention, optical isomers thereof or pharmaceutically acceptable
salts thereof may be selected as appropriate on the basis of the
state, physique, diathesis, age and sex of a patient to be applied,
as well as the intended route of administration, the intended
dosage form, etc. In general, a dose of 10 to 1000 mg per kg body
weight is sufficient to achieve the object. The DHOD inhibitor of
the present invention is desirably formulated into tablets or
capsules, and any other dosage form suitable for oral
administration by being neutralized with an alkali and then
dissolved in water or by being mixed with a suspending agent, an
excipient or auxiliaries thereof, by way of example. More
specifically, the DHOD inhibitor of the present invention is
desirably formulated into enteric-coated tablets which prevent the
compounds from being digested in the stomach and thereby allow the
compounds to reach the intestinal tract without being digested. As
an excipient or auxiliaries thereof, lactose, various starches,
glucose, fructose, cellulose, methylcellulose, carboxymethyl
cellulose, magnesium stearate, lauryl sulfate, talc, vegetable
oils, lecithin or the like may be used for preparation. Moreover,
the concentration of an active ingredient(s) in the formulation is
generally 0.0001% to 100% by weight, preferably 0.001% to 10% by
weight, when expressed as a concentration in the formulation.
[0075] A kit for the DHOD inhibitor comprises one or two or more of
the above compounds represented by formula (I), optical isomers
thereof and pharmaceutically acceptable salts thereof, as well as
instructions for use.
[0076] The compounds of the present invention have a very wide
range of members, and accordingly there are many various synthesis
procedures. By way of example, the compounds of the present
invention may be prepared as shown below.
PREPARATION EXAMPLES
[0077] The compounds to be used in the present invention will be
further described in more detail by way of the following
illustrative examples. It should be noted that these examples are
not intended to limit the scope of the present invention.
1. Derivatives 215-15-COOEt, 215-15-COO.sup.IPr and 215-13-COOH
[Formula 1]
##STR00007##
[0078] Ethyl
12-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)dodecanate
(215-15-COOEt)
[0079] To a solution of acetic anhydride (12.5 ml, 132 mmol) in
CHCl.sub.3 (16 ml), 30% aqueous hydrogen peroxide (10 ml, 98 mmol)
was added at 0.degree. C. and stirred at the same temperature for 1
hour. Then, maleic anhydride (10.0 g, 102 mmol) in solid state was
added, followed by stirring for 2 hours while gradually returning
to room temperature. Upon confirmation of heat generation in the
reaction mixture, cyclododecanone (compound 1, 2.52 g, 13.8 mmol)
in solid state was added thereto and stirred at 35.degree. C. for
16 hours. After returning to room temperature, the reaction mixture
was further cooled to 0.degree. C. and filtered to remove the
precipitated maleic acid.
[0080] The filtrate was washed with H.sub.2O and further washed
with an aqueous solution prepared to contain 10% KOH and 10%
Na.sub.2SO.sub.3 and with saturated aqueous sodium chloride, and
then dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the residue was loaded onto silica gel column chromatography
(hexane:EtOAc=1:1) to give compound 2 as a crude product. The
resulting product was used for the subsequent reaction without
further purification.
[0081] To a solution of the resulting compound 2 (crude 2.70 g) in
EtOH (100 ml), sulfuric acid (0.5 ml) was added at room
temperature, followed by heating and stirring at 70.degree. C. for
17 hours. After the solvent was almost completely distilled off,
the residue was extracted with EtOAc. The organic layer was washed
with aqueous solutions of sat. NaHCO.sub.3 and sat. NaCl, and then
dried over Na.sub.2SO.sub.4. After the solvent was distilled off,
the residue was purified by silica gel column chromatography
(hexane:EtOAc=7:1.fwdarw.3:1) to give the corresponding ethyl ester
(compound 3) (1.85 g, 55% for 2 steps).
[0082] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 4.14 (2H, q, J=7.3
Hz, CO.sub.2CH.sub.2CH.sub.3), 3.64 (2H, t, J=6.4 Hz, CH.sub.2OH),
2.26 (2H, t, J=7.5 Hz, CH.sub.2CO.sub.2Et), 1.71 (1H, br, OH),
1.68-1.53 (4H, m, CH.sub.2CH.sub.2OH &
CH.sub.2CH.sub.2CO.sub.2Et), 1.28 {14H, m, (CH.sub.2).sub.7}, 1.26
(3H, t, J=7.3 Hz, CO.sub.2CH.sub.2CH.sub.3).
[0083] Under an argon stream, CHCl.sub.3 (30 ml) was mixed with
oxalyl chloride (1.16 ml, 13.5 mmol) at room temperature and then
cooled to -55.degree. C. After DMSO (1.90 ml, 26.8 mmol) was added
dropwise and stirred for 15 minutes, a solution of compound 3 (1.63
g, 6.67 mmol) in CHCl.sub.3 (15 ml) was added dropwise thereto and
further stirred for 3 hours. After addition of Et.sub.3N (5.6 ml,
40 mmol), the reaction mixture was stirred for 45 minutes while
elevating the temperature to 0.degree. C., and H.sub.2O was added
to stop the reaction. After the organic layer was separated and
collected, the aqueous layer was extracted with EtOAc. The combined
organic layers were washed with aqueous solutions of sat.
NH.sub.4Cl and sat. (saturated) NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=5:1)
and the resulting solid was further purified by recrystallization
(hexane:EtOAc=10:1) to give an aldehyde (compound 5) (1.53 g, 95%).
Mp. 60-61.degree. C.
[0084] .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta. 9.77 (1H, t, J=1.8
Hz, CHO), 4.12 (2H, q, J=7.1 Hz, CO.sub.2CH.sub.2CH.sub.3), 2.42
(2H, dt, J=1.8, 7.3 Hz, CH.sub.2CH.sub.2CHO), 2.28 (2H, t, J=7.6
Hz, CH.sub.2CO.sub.2Et), 1.65-1.58 (4H, m, CH.sub.2CH.sub.2CHO and
CH.sub.2CH.sub.2CO.sub.2Et), 1.28 {12H, br, (CH.sub.2).sub.6}, 1.25
(3H, t, J=7.1 Hz, CO.sub.2CH.sub.2CH.sub.3).
[0085] To a solution of 3-chloro-4,6-dihydroxy-2-methylbenzaldehyde
(hereinafter abbreviated as compound 112, 0.285 g, 1.527 mmol) in
MeOH (1.0 ml), CaCl.sub.2.2H.sub.2O (0.200 g, 1.360 mmol) was added
and then cooled to 0.degree. C. To this mixture, KOH (1.1 M in
MeOH, 2.3 ml, 2.5 mmol) was added and stirred for 5 minutes, and a
solution of compound 5 (0.447 g, 1.844 mmol) in MeOH (1.0 ml) was
further added dropwise thereto and stirred for 16 hours while
gradually returning to room temperature. After addition of a 0.1 M
aqueous KOH solution (10 ml), the reaction mixture was extracted
three times with EtOAc. The combined organic layers were washed
with an aqueous solution of sat. NaCl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=3:1)
to give the corresponding aldol adduct (0.145 g, 22%).
[0086] To a solution of the resulting secondary alcohol (0.075 g,
0.175 mmol) in AcOH (1.5 ml), H.sub.3PO.sub.4 (0.06 ml) was added
and stirred at 70.degree. C. for 6 hours. After returning to room
temperature, the reaction mixture was diluted with H.sub.2O and
EtOA. After the organic layer was separated and collected, the
aqueous layer was extracted twice with EtOAc. The combined organic
layers were washed with aqueous solutions of sat. NaHCO.sub.3 and
sat. NaCl, and then dried over Na.sub.2SO.sub.4. After the solvent
was distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=5:1) and the resulting solid was
further purified by recrystallization (hexane:EtOAc=10:1) to give
the corresponding olefin (0.048 g, 67%).
[0087] The resulting olefin (42 mg, 0.10 mmol) was dissolved in
EtOAc (5 ml) and cooled to 0.degree. C., followed by addition of a
catalytic amount of Pd--C. This mixture was stirred for 2 hours
under a hydrogen atmosphere. After Pd--C was filtered off, the
solvent was distilled off and the residue was purified by silica
gel column chromatography (hexane:EtOAc=4:1). The resulting solid
was further recrystallized from hexane to give the desired product
(19.5 mg, 47%). Mp. 59-60.degree. C.
[0088] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, s, Ar--OH), 4.12 (2H, q,
J=7.2 Hz, CO.sub.2CH.sub.2CH.sub.3), 2.66 (2H, t, J=7.7 Hz,
ArCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.28 (2H, t, J=7.3 Hz,
CH.sub.2CO.sub.2Et), 1.63-1.56 (2H, m, CH.sub.2), 1.54-1.49 (2H, m,
CH.sub.2), 1.38-1.24 {17H, m, (CH.sub.2).sub.8 &
CO.sub.2CH.sub.2CH.sub.2}. IR (KBr) 3348, 2930, 2853, 1736, 1610,
1452, 1416, 1377, 1327, 1279, 1240, 1167, 1128, 1020, 916, 860,
785, 708, 590 cm.sup.-1. HRMS (EI) calcd. For
C.sub.22H.sub.33ClO.sub.5: 412.2018. found 412.2032.
Isopropyl
12-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)dodecanate
(215-15-COO.sup.IPr)
[0089] Compound 2 (crude, 5.418 g) was refluxed in KOH (1.5 M in
MeOH, 40 ml, 60 mmol) for 3 hours. After returning to room
temperature, the reaction mixture was poured into H.sub.2O and
washed twice with EtOAc, and the aqueous layer was then acidified
with 2 M HCl and extracted twice with EtOAc. The combined organic
layers were washed with sat. aq. NaCl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the
precipitated crude crystals were recrystallized from a mixed
solvent of acetone:hexane=1:5 to give the corresponding carboxylic
acid (4.326 g, 72% for 2 steps). Mp. 82-83.degree. C.
[0090] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 3.65 (2H, t, J=6.6
Hz, CH.sub.2OH), 2.35 (2H, t, J=7.5 Hz, CH.sub.2CO.sub.2H),
1.67-1.53 (4H, m, CH.sub.2CH.sub.2OH and
CH.sub.2CH.sub.2CO.sub.2Et), 1.28 {16H, br, CH.sub.2OH, COOH &
(CH.sub.2).sub.7}.
[0091] To a solution of this carboxylic acid (0.803 g, 3.71 mmol)
in .sup.iPrOH (50 ml), H.sub.2SO.sub.4 (0.5 ml) was added at room
temperature and stirred at 70.degree. C. for 20 hours. After
returning to room temperature, the reaction mixture was evaporated
to distill off about half of the solvent, and then poured into
H.sub.2O. This mixture was extracted twice with EtOAc, and the
combined organic layers were washed with sat. aq. NaCO.sub.3 and
sat. aq. NaCl, and then dried over Na.sub.2SO.sub.4. After the
solvent was distilled off, the residue was purified by silica gel
column chromatography (hexane:EtOAc=4:1.fwdarw.1:1) to prepare the
corresponding isopropyl ester (compound 4) (0.680 g, 71%).
[0092] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.00 {2H, sep,
J=6.2 Hz, OCH(CH.sub.3).sub.2}, 3.64 (2H, t, J=5.9 Hz, CH.sub.2OH),
2.29 (2H, t, J=7.5 Hz, CH.sub.2CO.sub.2Et), 1.68-1.53 (4H, m,
CH.sub.2CH.sub.2OH and CHCH.sub.2CO.sub.2Et), 1.42 (1H, br, OH),
1.27 {14H, m, (CH.sub.2).sub.7}, 1.22 {6H, d, J=6.2 Hz,
OCH(CH.sub.3).sub.2}.
[0093] The same steps were then repeated to give the desired
product (3% yield from compound 4). Mp. 56.degree. C.
[0094] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.66 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, s, Ar--OH), 5.00 {1H, m,
CO.sub.2CH(CH.sub.3).sub.2}, 2.66 (2H, t, J=7.7 Hz, Ar--CH.sub.2),
2.61 (3H, s, Ar--CH.sub.3), 2.25 {2H, t, J=7.5 Hz, CH.sub.2CO.sub.2
.sup.iPr}, 1.65-1.57 (2H, m, CH.sub.2), 1.54-1.48 (2H, m,
CH.sub.2), 1.26 {14H, br, (CH.sub.2).sub.7}, 1.22 {6H, d, J=6.2 Hz,
CH(CH.sub.3).sub.2}. IR (KBr) 3287, 2922, 2845, 1703, 1616, 1456,
1421, 1377, 1279, 1248, 1196, 1105, 836, 631, 590 cm.sup.-1. HRMS
(EI) Found: 426.2186. Calcd. for C.sub.23H.sub.35ClO.sub.5:
426.2173.
12-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)dodecanoic acid
(215-13-COOH)
[0095] To a solution of 215-15-COOEt (101 mg, 0.246 mmol) in a
mixture of acetone (1.3 ml)/H.sub.2O (0.7 ml), NaOH (21 mg, 0.48
mmol) was added at room temperature and stirred for 12 hours. The
reaction mixture was diluted with EtOAc and then acidified with a 1
M aqueous HCl solution, followed by addition of sat. aq. NaCl to
separate and collect the organic layer. Then, the aqueous layer was
extracted twice with EtOAc, and the combined organic layers were
dried over Na.sub.2SO.sub.4. After the solvent was distilled off,
the residue was purified by silica gel column chromatography
(hexane:EtOAc=2:1) to give the desired product. Mp. 130-131.degree.
C.
[0096] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.66 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.34 (1H, br, Ar--OH), 2.66 (2H,
t, J=7.7 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.35 (2H,
t, J=7.3 Hz, CH.sub.2COOH), 1.65-1.46 (4H, m, CH.sub.2CH.sub.2COOH
& ArCH.sub.2CH.sub.2), 1.35 {14H, br, (CH.sub.2).sub.7}. IR
(KBr) 3360, 2920, 2855, 1715, 1612, 1472, 1420, 1283, 1246, 1180,
1126, 937, 853, 785, 588 cm.sup.-1. HRMS (EI) Found: 384.1712.
Calcd. for C.sub.20H.sub.29ClO.sub.5: 384.1704.
2. Compound 215-13-COOEt
[Formula 2]
##STR00008##
[0097] Ethyl
10-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)decanate
(215-13-COOEt)
[0098] To a solution of 1,8-octanediol (compound 7, 5.85 g, 40.0
mmol) in CHCl.sub.3 (100 ml), DHP (3.46 ml, 37.9 mmol) and a
catalytic amount of PPTS were added at room temperature under an
argon stream and then stirred for 16 hours. After the reaction
mixture was diluted with H.sub.2O and stirred for 5 minutes, the
organic layer was separated and collected, and the aqueous layer
was extracted with EtOAc. The combined organic layers were washed
with aqueous solutions of sat. NaHCO.sub.3 and sat. NaCl, and then
dried over Na.sub.2SO.sub.4. After the solvent was distilled off,
the residue was purified by silica gel column chromatography
(hexane:EtOAc=3:1.fwdarw.2:1) to give the corresponding THP ether
(4.95 g, 54%).
[0099] To a solution of oxalyl chloride (2.0 ml, 23 mmol) in
CHCl.sub.3 (50 ml), DMSO (2.8 ml, 40 mmol) was added dropwise at
-55.degree. C. After 15 minutes, a solution of the primary alcohol
(2.18 g, 9.46 mmol) in CHCl.sub.3 (20 ml) was added dropwise and
stirred for 2 hours. To this mixture, Et.sub.3N (8.0 ml, 58 mmol)
was added dropwise and then stirred for 45 minutes while elevating
the temperature to 0.degree. C. The reaction mixture was diluted
with H.sub.2O to separate and collect the organic layer, and the
aqueous layer was then extracted with EtOAc. The combined organic
layers were washed with sat. aq. NaCl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=5:1)
to give an aldehyde (compound 8) (1.95 g, 90%).
[0100] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 9.77 (1H, t, J=1.8
Hz, CHO), 4.57 (1H, dd, J=2.6, 4.8 Hz, OCHO), 3.90-3.84 (1H, m,
CH.sub.2O), 3.73 (1H, td, J=6.8, 9.6 Hz, CH.sub.2O), 3.53-3.48 (1H,
m, CH.sub.2O), 3.38 (1H, td, J=6.6, 9.5 Hz, CH.sub.2O), 2.42 (2H,
dt, J=1.8, 7.5 Hz, CH.sub.2CHO), 1.87-1.78 (1H, m, OCHCH.sub.2),
1.75-1.68 (1H, m, OCHCH.sub.2), 1.67-1.49 (8H, m, 4.times.CH2),
1.43-1.28 (6H, m, 3.times.CH.sub.2).
[0101] Then, to a suspension of NaH (50% purity, 0.378 g, 7.88
mmol) in THF (50 ml), diethyl phosphonoacetic acid diethyl ether
(1.45 ml, 7.25 mmol) was added at 0.degree. C. under an argon
stream and stirred for 1.5 hours. After this reaction mixture was
cooled to -60.degree. C., a solution of 8 (1.44 g, 6.31 mmol) in
THF (15 ml) was added dropwise thereto. The reaction mixture was
stirred at the same temperature for 30 minutes and then returned to
room temperature, followed by stirring for 18 hours. This mixture
was cooled again to 0.degree. C., and H.sub.2O was then added
thereto in small portions to decompose excess NaH. After H.sub.2O
was further added, the mixture was extracted twice with Et.sub.2O.
The combined organic layers were washed with sat. aq. NaCl and
dried over Na.sub.2SO.sub.4. After the solvent was distilled off,
the residue was purified by silica gel column chromatography
(hexane:EtOAc=7:1) to give the corresponding ethyl ester (compound
9) (1.62 g, 86%).
[0102] To a solution of the ester (compound 9) (1.15 g, 3.85 mmol)
in EtOH (30 ml), a catalytic amount of PPTS was added at room
temperature, followed by heating and stirring at 60.degree. C. for
2.5 hours. After the solvent was almost completely distilled off,
the residue was dissolved in EtOAc, and this solution was washed
sequentially with H.sub.2O, sat. aq. NaHCO.sub.3 and sat. aq. NaCl,
and then dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=7:1) to give the corresponding primary
alcohol (0.63 g, 76%).
[0103] .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta. 6.96 (1H, dt,
J=7.0, 15.6 Hz, CH.dbd.CHCO.sub.2Et), 5.81 (1H, dt, J=1.5, 15.6 Hz,
CH.dbd.CHCO.sub.2Et), 4.18 (2H, q, J=7.1 Hz,
CO.sub.2CH.sub.2CH.sub.3), 3.64 (2H, t, J=6.5 Hz,
CH.sub.2CH.sub.2OH), 2.19 (2H, ddt, J=1.4, 7.1, 7.6 Hz,
CH.sub.2CH.dbd.CH), 1.56 (2H, m, CH.sub.2CH.sub.2OH), 1.46 (2H, m,
CH.sub.2CH.sub.2CH.dbd.CH), 1.37-1.31 {7H, m, (CH.sub.2).sub.3
& OH}, 1.29 (3H, t, J=7.1 Hz, CO.sub.2CH.sub.2CH.sub.3).
[0104] Subsequently, the resulting primary alcohol was converted by
Swern oxidation into the corresponding aldehyde (10) (0.45 g,
72%).
[0105] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 9.77 (1H, s, CHO),
6.95 (1H, dt, J=7.0, 15.8 Hz, CH.dbd.CHCO.sub.2Et), 5.81 (1H, dt,
J=1.4, 15.8 Hz, CH.dbd.CHCO.sub.2Et), 4.19 (2H, q, J=7.2 Hz,
CO.sub.2CH.sub.2CH.sub.3), 2.43 (2H, dt, J=1.8, 7.3 Hz,
CH.sub.2CHO), 2.20 (2H, ddt, J=1.4, 7.0, 7.3 Hz,
CH.sub.2CH.dbd.CH), 1.66-1.60 (2H, m, CH.sub.2CH.sub.2CHO),
1.49-1.42 (2H, m CH.sub.2CH.sub.2CH.dbd.CH), 1.36-1.32 {4H, m
(CH.sub.2).sub.2}, 1.29 (3H, t, J=7.2 Hz,
CO.sub.2CH.sub.2CH.sub.3).
[0106] The same procedures as described above were then used to
give the desired product (2% for 3 steps). Mp. 45-46.degree. C.
[0107] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.67 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.39 (1H, s, Ar--OH), 4.12 (2H, q,
J=7.3 Hz, CO.sub.2CH.sub.2CH.sub.3), 2.66 (2H, t, J=7.7 Hz,
ArCH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.28 (2H, t, J=7.3 Hz,
CH.sub.2CO.sub.2Et), 1.63-1.56 (2H, m, CH.sub.2), 1.54-1.48 (2H, m,
CH.sub.2), 1.31-1.23 {13H, m, (CH.sub.2).sub.5 and
CO.sub.2CH.sub.2CH.sub.3}. IR (KBr) 3452, 2922, 2853, 1736, 1637,
1468, 1421, 1377, 1327, 1286, 1248, 1175, 1119, 1084, 1018, 920,
843, 802, 726, 586 cm.sup.-1. HRMS (EI) calcd. For
C.sub.20H.sub.29Cl O.sub.5: 384.1704. found 384.1687.
3. Compounds 200-12-COOMe, 215-12-COOMe, 215-13-COO.sup.zPr and
215-11-COOH
[Formula 3]
##STR00009##
[0108] (E)-Methyl
10-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-10-decenoate
(200-12-COOMe)
[0109] Commercially available methyl 10-hydroxydecanate (compound
11) was subjected to Swern oxidation to give an aldehyde (compound
12) (59% yield).
[0110] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 9.76 (1H, t, J=1.8
Hz, CHO), 3.67 (3H, s, CO.sub.2CH.sub.3), 2.42 (2H, dt, J=1.8, 7.3
Hz, CH.sub.2CHO), 2.30 (2H, t, J=7.5 Hz, CH.sub.2CO.sub.2CH.sub.3),
1.67-1.57 (4H, m, CH.sub.2CH.sub.2CHO &
CH.sub.2CH.sub.2CO.sub.2CH.sub.3), 1.31 {8H, br,
(CH.sub.2).sub.4}.
[0111] This compound 11 was also subjected to aldol reaction with
compound 112 and further dehydrated under acidic conditions to give
the desired product (36% for 2 steps). Mp. 71-72.degree. C.
[0112] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 13.05 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.65 (1H, dt, J=6.8, 16.2 Hz,
ArCH.dbd.CH), 6.63 (1H, s, Ar--OH), 6.50 (1H, d, J=16.2 Hz,
ArCH.dbd.CH), 3.67 (3H, s, COOCH.sub.3), 2.61 (3H, s,
Ar--CH.sub.3), 2.33-2.23 (4H, m, CH.dbd.CHCH2 & CH.sub.2COOMe),
1.67-1.59 (2H, m, CH.sub.2), 1.50-1.45 (2H, m, CH.sub.2), 1.34 {6H,
br (CH.sub.2).sub.3}. IR (KBr) 3375, 2928, 2853, 1728, 1605, 1452,
1408, 1366, 1315, 1286, 1232, 1136, 1107, 980, 845, 802, 615, 592
cm.sup.-1. HRMS (EI) Found: 368.1377. Calcd. for
C.sub.19H.sub.25O.sub.5Cl (M.sup.+), 368.1391. Anal. Found: C,
61.97; H, 6.86; Cl, 9.37%. Calcd. for C.sub.19H.sub.25O.sub.5Cl: C,
61.87; H, 6.83; Cl, 9.61%.
Methyl 10-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)decanate
(215-12-COOMe)
[0113] The compound 200-12-COOEt was catalytically reduced to give
the desired product (79% yield). Mp. 87-88.degree. C.
[0114] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.37 (1H, br, Ar--OH), 3.67 (3H,
s, COOCH.sub.3), 2.66 (2H, t, J=8.0 Hz, ArCH.sub.2), 2.60 (3H, s,
Ar--CH.sub.3), 2.30 (2H, t, J=7.7 Hz, CH.sub.2COOCH.sub.3),
1.65-1.57 (2H, m, CH.sub.2), 1.57-1.47 (2H, m, CH.sub.2), 1.28
{10H, br, (CH.sub.2).sub.5}. IR (KBr) 3358, 2928, 2853, 1736, 1611,
1421, 1250, 1171, 1132, 777, 590 cm.sup.-1. HRMS (EI) Found:
370.1533. Calcd. for C.sub.19H.sub.27ClO.sub.5: 370.1547. Anal.
Found: C, 61.41; H, 7.32; Cl, 9.43%. Calcd. for C, 61.53; H, 7.34;
Cl, 9.67%.
Isopropyl
10-(3-chloro-2,6-dihydroxy-5-formyl-4-methylphenyl)decanate
(215-13-COO.sup.IPr)
[0115] To a solution of the compound 215-12-COOMe (114 mg, 0.307
mmol) in 2-propanol (25 ml), H.sub.2SO.sub.4 (0.25 ml) was added
and refluxed for 18 hours. After returning to room temperature, the
reaction mixture was evaporated to distill off the solvent, and the
residue was extracted twice with EtOA. The combined organic layers
were washed with sat. aq. NaHCO.sub.3 and sat. aq. NaCl, and then
dried over anhydrous Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by being subjected to
silica gel column chromatography (hexane:EtOAc=7:1) and then
recrystallization (hexane:EtOAc=9:1) to give the desired product.
In addition, the mother liquor was concentrated, and the residue
was purified by silica gel column chromatography (hexane:EtOAc=5:1)
to further give the desired product (combined yield (83 mg, 68%)).
Mp. 49.degree. C.
[0116] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.66 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.37 (1H, s, Ar--OH), 5.00 {1H,
septet, J=6.2 Hz, CO.sub.2CH(CH.sub.3).sub.2}, 2.66 (2H, t, J=7.7
Hz, Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.25 {2H, t, J=7.5
Hz, CH.sub.2CO.sub.2 .sup.iPr}, 1.64-1.57 (2H, m, CH.sub.2),
1.54-1.48 (2H, m, CH.sub.2), 1.28 {10H, br, (CH.sub.2).sub.5}, 1.23
{6H, d, J=6.2 Hz, CH(CH3).sub.2}. IR (KBr) 3271, 2916, 2845, 1703,
1610, 1468, 1412, 1366, 1325, 1286, 1251, 1217, 1109, 826, 631, 590
cm.sup.-1. HRMS (EI) Found: 398.1841. Calcd. for
C.sub.21H.sub.31ClO.sub.5: 398.1860.
10-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)decanoic acid
(215-11-COOH)
[0117] The compound 215-12-COOMe was hydrolyzed in the same manner
as described above to give the desired product (89% yield). Mp.
154-156.degree. C.
[0118] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.66 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.34 (1H, br, Ar--OH), 2.66 (2H,
t, J=7.7 Hz, ArCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.35 (2H, t,
J=7.5 Hz, CH.sub.2COOH), 1.67-1.47 (4H, m, CH.sub.2CH.sub.2COOH
& ArCH.sub.2CH.sub.2), 1.35 {10H, br, (CH.sub.2).sub.5}. IR
(KBr) 3360, 2920, 2853, 1715, 1614, 1470, 1418, 1371, 1236, 1184,
1126, 934, 847, 773, 588 cm.sup.-1. HRMS (EI) Found: 356.1408.
Calcd. for C.sub.18H.sub.25ClO.sub.5: 356.1391.
4. Compounds 215-13-COOtBu, 501-16-G, 502-16-G and 500-15-G
[Formula 4]
##STR00010##
[0119] tert-Butyl
10-(3-chloro-2,6-dihydroxy-5-formyl-4-methylphenyl)decanate
(215-13-COOtBu)
[0120] To a suspension of the compound 215-11-COOH (144 mg, 0.403
mmol) in toluene (5 ml), TFAA (0.20 ml, 1.4 mmol) was added at
0.degree. C. and stirred for 30 minutes while returning to room
temperature. After the starting material was confirmed to be
completely dissolved, the solution was cooled again to 0.degree.
C., mixed with .sup.tBuOH (0.40 ml, 4.2 mmol) and stirred for 15
hours while returning to room temperature. The reaction mixture was
diluted with sat. aq. NaHCO.sub.3, stirred for 5 minutes and then
extracted twice with EtOAc. The combined organic layers were washed
with sat. aq. NaCl and dried over anhydrous Na.sub.2SO.sub.4. After
the solvent was distilled off, the residue was purified by silica
gel column chromatography (hexane:EtOAc=7:1.fwdarw.4:1) and further
purified by PTLC (hexane:EtOAc=7:1) to give the desired product (28
mg, 17%).
[0121] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.40 (1H, br, Ar--OH), 2.66 (2H,
t, J=7.5 Hz, Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.20 {2H,
t, J=7.5 Hz, CH.sub.2CO.sub.2.sup.tBu}, 1.62-1.48 (4H, m,
CH.sub.2CH.sub.2CO.sub.2.sup.tBu & ArCH.sub.2CH.sub.2), 1.44
{9H, s, (CH.sub.3).sub.3}, 1.29 {10H, br, (CH.sub.2).sub.5}. IR
(KBr) 3287, 2922, 2845, 1732, 1616, 1452, 1425, 1366, 1290, 1248,
1213, 1161, 1126, 934, 795, 716, 630, 590, 530 cm.sup.-1.
1,3-Dioxolane-2-oxo-4-methyl
10-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)decanate
(501-16-G)
[0122] To a solution of the compound 215-11-COOH (184 mg, 0.516
mmol) in THF (30 ml), 2,2-dimethyl-1,3-dioxolane-4-methanol (98%
purity, 0.25 ml, 2.0 mmol), DMAP (62 mg, 0.51 mmol) and DCC (130
mg, 0.630 mmol) were added at room temperature and stirred for 7
hours. After being diluted with phosphate buffer (pH 6.98) and
EtOAc, the reaction mixture was filtered through celite, and the
organic layer of the filtrate was separated and collected. After
the aqueous layer was extracted twice with EtOAc, the combined
organic layers were washed with sat. aq. NaCl and dried over
anhydrous Na.sub.2SO.sub.4. After the solvent was distilled off,
the residue was subjected to silica gel column chromatography
(hexane:EtOAc=2:1-1:1) and further purified by PTLC
(toluene:EtOAc=9:1). After the solvent was distilled off, the
resulting crude product was purified again by silica gel column
chromatography (hexane:EtOAc=2:1.fwdarw.3:2) to give the desired
product (78 mg, 33%). Mp. 70-72.degree. C.
[0123] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.13 (1H, s, Ar--CHO), 6.49 (1H, br, Ar--OH), 4.93 {1H,
m, CO.sub.2CH.sub.2CHOC(O)OCH.sub.2}, 4.56 {1H, dd, J=8.4, 8.8 Hz,
CO.sub.2CH.sub.2CHOC(O)OCH.sub.2}, 4.37 {1H, dd, J=3.3, 12.6 Hz,
CO.sub.2CH.sub.2CHOC(O)OCH.sub.2}, 4.31 {1H, dd, J=5.8, 8.8 Hz,
CO.sub.2CH.sub.2CHOC(O)OCH.sub.2}, 4.26 {1H, dd, J=4.2, 12.6 Hz,
CO.sub.2CH.sub.2CHOC(O)OCH.sub.2}, 2.66 (2H, t, J=7.7 Hz,
Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.37 {2H, t, J=7.5 Hz,
CH.sub.2CH.sub.2C(O)O}, 1.65-1.58 (2H, m, CH.sub.2), 1.55-1.48 (2H,
m, CH.sub.2), 1.29 {10H, br, (CH.sub.2).sub.5}. .sup.13C-NMR (100
MHz, CDCl.sub.3) .delta. 193.24, 173.27, 162.37, 156.26, 154.36,
137.27, 115.68, 113.41, 113.06, 73.75, 66.96, 62.78, 33.83, 29.41,
29.23, 29.18, 29.05, 28.94, 28.25, 24.66, 22.77, 14.40. IR (KBr)
3362, 2922, 2853, 1788, 1736, 1620, 1599, 1468, 1416, 1398, 1283,
1248, 1165, 1136, 1092, 1040, 878, 752, 586 cm.sup.-1. HRMS (EI)
Found: 456.1546. Calcd. for C.sub.22H.sub.29ClO.sub.8:
456.1551.
2,2-Dimethyl-1,3-dioxolane-4-methyl
10-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)decanate
(502-16-G)
[0124] Esterification was conducted in the same manner to give the
desired product (28% yield). Mp. 55-56.degree. C.
[0125] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.38 (1H, br, Ar--OH), 4.32 {1H,
m, CHOC(CH.sub.3).sub.2OCH.sub.2--}, 4.17 {1H, dd, J=4.8, 11.7 Hz,
C(O)OCH.sub.2CH}, 4.11-4.06 {2H, m, CHOC(CH.sub.3).sub.2OCH.sub.2--
& C(O)OCH.sub.2CH}, 3.74 {1H, dd, J=6.2, 8.4 Hz,
CHOC(CH.sub.3).sub.2OCH.sub.2}, 2.66 (2H, t, J=7.7 Hz,
Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.33 {2H, t, J=7.7 Hz,
CH.sub.2CH.sub.2C(O)O}, 1.65-1.58 (2H, m, CH.sub.2), 1.54-1.48 (2H,
m, CH.sub.2), 1.43 (3H, s, CH.sub.3), 1.39 (3H, s, CH.sub.3), 1.28
{10H, br, (CH.sub.2).sub.5}. .sup.13C-NMR (100 MHz, CDCl.sub.3)
.delta. 193.26, 173.69, 162.42, 156.20, 137.24, 115.74, 113.47,
113.04, 109.81, 73.60, 66.35, 64.50, 34.10, 29.47, 29.27, 29.25,
29.14, 29.03, 28.29, 26.67, 25.38, 24.82, 22.82, 14.44. IR (KBr)
3265, 2922, 2853, 1745, 1620, 1526, 1460, 1425, 1369, 1331, 1244,
1219, 1171, 1132, 1092, 1045, 1007, 980, 932, 851, 795, 712, 625,
596, 534 cm.sup.-1. HRMS (EI) Found: 470.2047. Calcd. for
C.sub.24H.sub.35ClO.sub.7: 470.2071.
1-Glyceryl
10-(3-chloro-2,6-dihydroxy-5-formyl-4-methylphenyl)decanate
(500-15-G)
[0126] To a solution of the compound 502-16-G (77 mg, 0.16 mmol) in
MeOH (5 ml), PPTS (10 mg, 40 .mu.mol) was added at room temperature
and stirred at 50.degree. C. for 20 hours. After returning to room
temperature, the reaction mixture was evaporated to distill off the
solvent and the residue was purified by silica gel column
chromatography (hexane:EtOAc=2:1.fwdarw.EtOAc only) to give the
desired product (11 mg, 16%). It should be noted that its methyl
ester (compound 215-12-CO.sub.2Me) was also obtained as a
by-product in an amount of 10 mg (17%).
[0127] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.64 (1H, s,
Ar--OH), 10.13 (1H, s, Ar--CHO), 6.62 (1H, br, Ar--OH), 4.21 {1H,
dd, J=4.8, 11.7 Hz, C(O)OCH.sub.2CH(OH) CH.sub.2OH}, 4.15 {1H, dd,
J=6.2, 11.7 Hz, C(O)OCH.sub.2CH(OH)CH.sub.2OH}, 3.94 {1H, m,
C(O)OCH.sub.2CH(OH)CH.sub.2OH}, 3.71 {1H, dd, J=3.6, 11.4 Hz,
C(O)OCH.sub.2CH(OH)CH.sub.2OH}, 3.61 {1H, dd, J=5.9, 11.4 Hz,
C(O)OCH.sub.2CH(OH)CH.sub.2OH}, 2.98 (1H, br, OH), 2.65 (2H, t,
J=7.5 Hz, Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.35 {2H, t,
J=7.7 Hz, CH.sub.2CH.sub.2C(O)O--}, 2.07 (1H, br, OH), 1.66-1.58
(2H, m, CH.sub.2), 1.55-1.49 (2H, m, CH.sub.2), 1.28 {1OH, br,
(CH.sub.2).sub.5}. IR (KBr) 3314, 2930, 2853, 1740, 1599, 1558,
1468, 1425, 1383, 1335, 1279, 1252, 1182, 1126, 1057, 928, 795,
743, 712, 625, 592, 534 cm.sup.-1. HRMS (EI) Found: 430.1783.
Calcd. for C.sub.21H.sub.31ClO.sub.7: 430.1758.
5. Compounds 215-11-COOEt, 215-9-COOH and 215-18-Anthra
[0128] [Formula 5]
##STR00011##
Ethyl 8-(3-chloro-5-formyl-2,6-dihydroxy-4-methyphenyl)octanoate
(215-11-COOEt)
[0129] To a solution of the aldehyde (compound 8, 1.950 g, 8.541
mmol) in MeCN (40 ml), a solution of NaH.sub.2PO.sub.4.2H.sub.2O
(3.312 g, 21.23 mmol) in H.sub.2O (10 ml) was added at -15.degree.
C. and stirred for 10 minutes. This mixture was mixed with
H.sub.2O.sub.2 (30% in H.sub.2O, 7.8 ml, 76 mmol) and, after 5
minutes, with NaClO.sub.2 (79% purity, 1.311 g, 11.45 mmol), and
then further stirred for 1 hour. The reaction mixture was diluted
with a 20% aqueous Na.sub.2SO.sub.3 solution, stirred for 10
minutes and then poured into 1 M HCl. This mixture was extracted
three times with EtOAc, and the combined organic layers were washed
with sat. aq. NaCl and dried over Na.sub.2SO.sub.4. After the
solvent was distilled off, the residue was purified by silica gel
column chromatography (hexane:EtOAc=4:1.fwdarw.2:1) to give a
carboxylic acid (compound 13) (0.850 g, 41%).
[0130] To a solution of this compound 13 (0.453 g, 1.984 mmol) in
EtOH (20 ml), H.sub.2SO.sub.4 (0.5 ml) wad added and stirred at
60.degree. C. for 15 hours. After the solvent was distilled off,
the residue was diluted with EtOAc. This dilution was washed with
sat. aq. NaHCO.sub.3 and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=2:1)
to give the corresponding ethyl ester (compound 14) (0.224 g,
60%).
[0131] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 4.12 (2H, q, J=7.0
Hz, OCH.sub.2CH.sub.3), 3.64 (2H, dd, J=6.6, 7.3 Hz, CH.sub.2OH),
2.29 (2H, t, J=7.7 Hz, CH.sub.2CO.sub.2Et), 1.66-1.53 (5H, m,
CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2CO.sub.2Et, and OH), 1.34 {6H,
m, (CH.sub.2).sub.3}, 1.26 (3H, t, J=7.0 Hz,
OCH.sub.2CH.sub.3).
[0132] The same procedures as described above were then used to
synthesize the desired product. 2% yield from compound 14. Mp
54-55.degree. C.
[0133] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.66 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.34 (1H, s, Ar--OH), 4.11 (2H, q,
J=7.3 Hz, CO.sub.2CH.sub.2CH.sub.3), 2.66 (2H, t, J=7.5 Hz,
Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.28 (2H, t, J=7.3 Hz,
CH.sub.2CO.sub.2Et) 1.65-1.49 (4H, m, ArCH.sub.2CH.sub.2 &
CH.sub.2CH.sub.2CO.sub.2Et), 1.34 {6H, br, (CH.sub.2).sub.3} 1.26
(3H, t, J=7.3 Hz, CO.sub.2CH.sub.2CH.sub.2). IR (KBr) 3321, 2930,
2847, 1728, 1612, 1421, 1285, 1244, 1140, 783, 590 cm.sup.-1. HRMS
(EI) Found: 356.1381. Calcd. for C.sub.18H.sub.25ClO.sub.5:
356.1391.
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)octanoic acid
(215-9-COOH)
[0134] The compound 215-11-COOEt was hydrolyzed in the same manner
as described above to give the desired product (66% yield). Mp.
149-150.degree. C.
[0135] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.66 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, br, Ar--OH), 2.66 (2H,
t, J=7.7 Hz, ArCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.35 (2H, t,
J=7.7 Hz, CH.sub.2COOH), 1.68-1.48 (4H, m, CH.sub.2CH.sub.2COOH
& ArCH.sub.2CH.sub.2), 1.35 {6H, br, (CH.sub.2).sub.3}. IR
(KBr) 3350, 2930, 2850, 1710, 1620, 1420, 1370, 1280, 1245, 1135,
1120, 940, 775, 590 cm.sup.-1. HRMS (EI) Found: 328.1057. Calcd.
for C.sub.16H.sub.21ClO.sub.5: 328.1078.
9-Anthryl
8-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)octanate
(215-18-Anthra)
[0136] 215-9-COOH was esterified in the same manner as described
above to give the desired product (53% yield). Mp. 150-151.degree.
C.
[0137] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.64 (1H, s,
Ar--OH), 10.13 (1H, s, Ar--CHO), 8.51 (1H, s, Ar--H), 8.33 (2H, d,
J=8.8 Hz, Ar--H), 8.03 (2H, d, J=8.4 Hz, Ar--H), 7.57 (2H, t, J=7.7
Hz, Ar--H), 7.49 (2H, t, J=7.4 Hz, Ar--H), 6.29 (1H, s, Ar--OH),
6.15 (2H, s, CO.sub.2CH.sub.2Ar), 2.62 (2H, t, J=7.3 Hz,
Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.32 {2H, t, J=7.5 Hz,
CH.sub.2CO.sub.2CH.sub.2Ar}, 1.62-1.55 (2H, m, CH.sub.2), 1.50-1.42
(2H, m, CH.sub.2), 1.27 {6H, br, (CH.sub.2).sub.3}. IR (KBr) 3356,
2916, 2853, 1717, 1634, 1468, 1421, 1391, 1373, 1296, 1252, 1182,
1126, 1094, 949, 889, 795, 733, 638, 590 cm.sup.-1. HRMS (EI)
Found: 518.1859. Calcd. for C.sub.31H.sub.31ClO.sub.5:
518.1860.
6. Compounds 217 and 224, Known Naturally Occurring Colletorin B
(Compound 216), Known Naturally Occurring Colletochlorin B, and
Known Naturally Occurring LL-Z1272.alpha. (Compound 280-12)
[0138] [Formula 6]
##STR00012## ##STR00013##
[0139] Typical Experimental Procedures for Introduction of an
Allyl-Based Side Chain into an Aromatic Ring Moiety
[0140] To a solution of a resorcinol derivative (1.0 eq.) in KOH
(1.0 M in MeOH, 1.5 eq.), a MeOH solution of the corresponding side
chain bromide (1.2 eq) and CaCl.sub.2.2H.sub.2O (0.75 eq.) were
added and stirred (8 to 24 hours) under cooling (-40.degree. C. to
0.degree. C.). The reaction mixture was diluted with EtOAc and
filtered through celite. The filtrate was then poured into a 0.1 M
aqueous KOH solution to separate and collect the organic layer.
After the aqueous layer was further extracted twice with EtOAc, the
combined organic layers were washed with sat. aq. NaCl and dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography or
recrystallization to give the corresponding alkylated product. It
should be noted that the aqueous layer was acidified with 2 M aq.
HCl and then extracted twice with EtOAc to collect the unreacted
resorcinol derivative.
Typical Experimental Procedures for Chlorination of an Aromatic
Ring Moiety
[0141] To an acetic acid solution of a resorcinol derivative (1.0
eq.), NCS (1.1 eq) was added at room temperature, followed by
heating (80.degree. C. to 100.degree. C.) and stirring (14 to 24
hours). After returning to room temperature, the reaction mixture
was poured into H.sub.2O and extracted with EtOAc. After the
aqueous layer was further extracted with EtOAc, the combined
organic layers were washed three times with sat. aq. NaHCO.sub.3
and once with sat. aq. NaCl, and then dried over Na.sub.2SO.sub.4.
After the solvent was distilled off, the residue was purified by
silica gel column chromatography or recrystallization to give the
corresponding chlorine-substituted product.
(E)-2,4-Dihydroxy-3-(3,7-dimethyl-2,6-octadienyl)benzaldehyde
(compound 217)
[0142] Mp 85.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
11.79 (1H, s, Ar--OH), 9.69 (1H, s, Ar--CHO), 7.32 (1H, d, J=8.6
Hz, Ar--H), 6.48 (1H, d, J=8.6 Hz, Ar--H), 6.21 (1H, s, Ar--OH),
5.27 (1H, t, J=7.0 Hz, ArCH.sub.2CH.dbd.C), 5.05 {1H, m,
CH.dbd.C(CH.sub.3).sub.2}, 3.45 (2H, d, J=7.0 Hz, ArCH.sub.2),
2.16-2.05 (4H, m, CH.sub.2CH.sub.2), 1.82 (3H, s CH.sub.3), 1.68
(3H, s CH.sub.3). IR (KBr) 3145, 2922, 1620, 1487, 1443, 1383,
1313, 1248, 1213, 1150, 1059, 787, 718, 642, 530 cm.sup.-1. Anal.
Found: C, 74.41; H, 8.14%. Calcd for C.sub.17H.sub.22O.sub.3: C,
74.42; H, 8.08%.
(E)-5-Chloro-2,4-dihydroxy-3-(3,7-dimethyl-2,6-octadienyl)benzaldehyde
(compound 224)
[0143] Mp 94-95.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3)
.delta. 11.53 (1H, s, Ar--OH), 9.67 (1H, s, Ar--CHO), 7.40 (1H, s,
Ar--H), 6.33 (1H, s, Ar--OH), 5.23 {1H, t, J=7.3 Hz,
ArCH.sub.2CH.dbd.C), 5.05 {1H, t, J=7.0 Hz,
CH.dbd.C(CH.sub.3).sub.2}, 3.44 (2H, d, J=7.3 Hz, ArCH.sub.2CH),
2.10-2.04 (2H, m, CH.sub.2), 2.02-1.98 (2H, m, CH.sub.2), 1.80 (3H,
s, CH.sub.3), 1.65 (3H, s, CH.sub.3), 1.57 (3H, s, CH.sub.3). IR
(KBr) 3231, 2916, 1628, 1576, 1464, 1425, 1387, 1331, 1275, 1240.
1202, 1157, 1088, 912, 876, 750, 715, 604 cm.sup.-1. HRMS (MI)
Found: 308.1173. Calcd for C.sub.17H.sub.21O.sub.3Cl: 308.1179.
(E)-2,4-Dihydroxy-3-(3,7-dimethyl-2,6-octadienyl)-6-methylbenzaldehvde
(compound 216, known naturally occurring Colletorin B)
[0144] Mp 120-121.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3)
.delta. 12.78 (1H, s, Ar--OH), 10.08 (1H, s, Ar--CHO), 6.21 (1H, s,
Ar--H), 6.15 (1H, s, Ar--OH), 5.26 (1H, t, J=7.1 Hz,
ArCH.sub.2CH.dbd.C), 5.04 {1H, t, J=6.8 Hz,
CH.dbd.C(CH.sub.3).sub.2}, 3.41 (2H, d, J=7.1 Hz, ArCH.sub.2CH),
2.50 (3H, s, Ar--CH.sub.3), 2.14-2.05 (4H, m, CH.sub.2CH.sub.2),
1.81 (3H, s, CH.sub.3), 1.68 (3H, s, CH.sub.3), 1.59 (3H, s,
CH.sub.3). IR (KBr) 3132, 2908, 1610, 1491, 1435, 1327, 1254, 1217,
1171, 1101, 1003, 829, 750, 644, 569 cm.sup.-1.
(E)-3-Chloro-4,6-dihydroxy-5-(3,7-dimethyl-2,6-octadienyl)-2-methylbenzald-
ehvde (known naturally occurring Colletochlorin B)
[0145] 44% yield. .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta. 12.70
(1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.42 (1H, s, Ar--OH), 5.22
(1H, t, J=6.9 Hz, ArCH.sub.2CH.dbd.C), 5.06 {1H, t, J=6.6 Hz,
CH.dbd.C(CH.sub.3).sub.2}, 3.40 (2H, d, J=6.9 Hz, ArCH.sub.2CH),
2.61 (3H, s, Ar--CH.sub.3), 2.08-2.03 (2H, m, CH.sub.2), 2.01-1.96
(2H, m, CH.sub.2), 1.78 (3H, s, CH.sub.3), 1.64 (3H, s, CH.sub.3),
1.56 (3H, s, CH.sub.3).
(E,E)-3-Chloro-4,6-dihydroxy-5-(3,7,11-trimethyl-2,6,10-dodecatienyl)-2-me-
thylbenzaldehyde (compound 280-12, known naturally occurring
LL-Z1272.alpha.)
[0146] Mp 72-73.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta.12.69 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.41 (1H, s,
Ar--OH), 5.22 (1H, t, J=7.3 Hz, ArCH.sub.2CH.dbd.C), 5.06 (2H, t,
J=7.0 Hz, 2.times.CH.dbd.C), 3.40 (2H, d, J=7.4 Hz, ArCH.sub.2CH),
2.60 (3H, s, Ar--CH.sub.3), 2.07 (2H, t, J=7.3 Hz, CH.sub.2), 1.99
(4H, t, J=7.3 Hz, 2.times.CH.sub.2), 1.92 (2H, t, J=7.5 Hz,
CH.sub.2), 1.79 (3H, s, CH.sub.3), 1.64 (3H, s, CH.sub.3), 1.58
(3H, s, CH.sub.3), 1.56 (3H, s, CH.sub.3). IR (KBr) 3256, 2967,
2913, 2853, 1613, 1452, 1424, 1373, 1281, 1229, 1163, 1109, 961,
905, 876, 786, 713, 633, 592, 569 cm.sup.-1.
[0147] [Formula 6-2]
##STR00014##
[0148] By applying the procedures described in literature
(Tetrahedron, 1988, 44, 41-48), compound 112 (0.93 g, 5.0 mmol) was
mixed with a 1 M KOH/MeOH solution (5 mL) and stirred for 12 hours.
The resulting precipitates were washed with MeOH (50 mL), collected
by filtration, and further azeotroped and dehydrated in toluene to
quantitatively obtain compound A. Then, to a solution of geranyl
bromide (43 mg, 0.2 mmol) in toluene (2 mL), compound A (72 mg,
0.32 mmol) was added and heated under reflux for 18 hours. After
completion of the reaction, a 1 M aqueous HCl solution (5 mL) was
added to separate and collect the organic layer, and the aqueous
layer was extracted with EtOAc. The combined organic layers were
washed with saturated aqueous sodium chloride and then dried over
Na.sub.2SO.sub.4. After distilling off EtOAc, the resulting product
was purified by silica gel column chromatography
(hexane/AcOEt=20/1) to give known naturally occurring
Colletochlorin B (44 mg, 68% yield).
7. Compounds 161, 157, 146 and 152
[0149] [Formula 7]
##STR00015## ##STR00016##
Methyl (E)-3-(3,7-dimethyl-2,6-octadienyl)-2,4-dihydroxybenzoate
(compound 161)
[0150] Mp 62.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
11.31 (1H, s, Ar--OH), 7.63 (1H, d, J=8.6 Hz, Ar--H), 6.37 (1H, d,
J=8.6 Hz, Ar--H), 5.93 (1H, s, Ar--OH), 5.27 (1H, t, J=7.0 Hz,
ArCH.sub.2CH.dbd.C), 5.05 {1H, m, CH.dbd.C(CH.sub.3).sub.2}, 3.91
(1H, s, CO.sub.2CH.sub.3), 3.46 (2H, d, J=7.0 Hz, ArCH.sub.2),
2.14-2.04 (4H, m, CH.sub.2CH.sub.2), 1.82 (3H, s CH.sub.3), 1.67
(3H, s CH.sub.3), 1.59 (3H, s CH.sub.3). IR (KBr) 3462, 2916, 1645,
1498, 1439, 1387, 1344, 1296, 1201, 1147, 1049, 783, 731, 631, 561
cm.sup.-1. Anal. Found: C, 70.74; H, 7.70%. Calcd for
C.sub.18H.sub.24O.sub.4: C, 71.03; H, 7.95%.
Methyl 5-chloro-2,4-dihydroxybenzoate (compound 20)
[0151] 39% yield. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 10.84
(1H, s, Ar--OH), 7.83 (1H, s, Ar--H), 6.62 (1H, s, Ar--H), 5.92
(1H, br, Ar--OH), 3.93 (3H, s, CO.sub.2CH.sub.3).
Methyl
(E)-5-chloro-3-(3,7-dimethyl-2,6-octadienyl)-2,4-dihydroxybenzoate
(compound 157)
[0152] Mp 71.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
11.11 (1H, s, Ar--OH), 7.72 (1H, s, Ar--H), 6.10 (1H, s, Ar--OH),
5.23 (1H, t, J=7.2 Hz, ArCH.sub.2CH.dbd.C), 5.06 {1H, m,
CH.dbd.C(CH.sub.3).sub.2}, 3.92 (3H, s, CO.sub.2CH.sub.3), 3.43
(2H, d, J=7.2 Hz, Ar--CH.sub.2), 2.10-2.00 (2H, m, CH.sub.2),
2.01-1.95 (2H, m, CH.sub.2), 1.80 (3H, s, CH.sub.3), 1.65 (3H, s,
CH.sub.3), 1.57 (3H, s, CH.sub.3). HRMS (EI) Found: 338.1277.
Calcd. for C.sub.18H.sub.23O.sub.4Cl: M.sup.+, 338.1285.
Methyl 2,4-dihydroxy-6-methylbenzoate (compound 21)
[0153] This compound was prepared from the corresponding
benzaldehyde (compound 18) through the steps of oxidation and
esterification (52% from 18) (For details of the experimental
operation, refer to compound 113 described below).
[0154] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 11.78 (1H, s,
Ar--OH), 6.28 (1H, d, J=2.6 Hz, Ar--H), 6.23 (1H, d, J=2.6 Hz,
Ar--H), 5.25 (1H, br, Ar--OH), 3.93 (3H, s, CO.sub.2CH.sub.3), 2.49
(3H, s, Ar--CH.sub.3).
Methyl
(E)-3-(3,7-dimethyl-2,6-octadienyl)-2,4-dihydroxy-6-methylbenzoate
(compound 146)
[0155] Mp 46-47.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.12 (1H, s, Ar--OH), 6.23 (1H, s, Ar--H), 5.84 (1H, s,
Ar--OH), 5.23 (1H, t, J=7.1 Hz, ArCH.sub.2CH.dbd.C), 5.06 {1H, m,
CH.dbd.C(CH.sub.3).sub.2}, 3.92 (3H, s, CO.sub.2CH.sub.3), 3.43
(2H, d, J=7.0 Hz, Ar--CH.sub.2), 2.15-2.04 (4H, m,
CH.sub.2CH.sub.2), 1.81 (3H, s, CH.sub.3), 1.67 (3H, s, CH.sub.3),
1.59 (3H, s, CH.sub.3). IR (KBr) 3391, 2922, 2853, 1651, 1620,
1499, 1447, 1412, 1383, 1321, 1273, 1200, 1157, 1092, 1011, 984,
920, 878, 833, 812, 746, 718, 625, 604, 579 cm.sup.-1.
Methyl 3-chloro-4,6-dihydroxy-2-methylbenzoate (113)
[0156] To a solution of compound 112 (0.505 g, 2.706 mmol) in DMSO
(10 ml), H.sub.2O (5 ml) was added and cooled to 0.degree. C. This
mixture was then mixed with NaH.sub.2PO.sub.4.2H.sub.2O (1.113 g,
7.134 mmol) and, after 5 minutes, with NaClO.sub.2 (79% purity,
0.719 g, 6.28 mmol), each being in solid state, and then stirred
for 15 hours while gradually returning to room temperature. After
the reaction mixture was diluted with EtOAc, sat. aq. NaHCO.sub.3
was added to separate and collect the organic layer, to which sat.
aq. NaHCO.sub.3 was then added again for fractionation. The
combined aqueous layers were acidified with 2 M aq. HCl and
extracted three times with EtOAc. The combined organic layers were
washed with sat. aq. NaCl and dried over Na.sub.2SO.sub.4. After
the solvent was distilled off, the residue was loaded onto silica
gel column chromatography (hexane:EtOAc=2:1.fwdarw.1:2) and then
recrystallized from a mixed solvent of hexane:EtOAc=3:1 to give the
corresponding carboxylic acid (0.410 g, 76%).
[0157] To a solution of Ph.sub.3P (0.560 g, 2.14 mmol) in THF (4
ml), MeOH (0.085 ml, 2.1 mmol) was added at room temperature under
an Ar atmosphere and cooled to 0.degree. C. This mixture was mixed
with DEAD (40% in toluene, 0.5 ml, 2.1 mmol) and stirred for 1
hour, and then mixed with the carboxylic acid (0.339 g, 1.67 mmol)
in solid state and further stirred at 0.degree. C. for 1.5 hours.
After the reaction mixture was diluted with H.sub.2O and EtOAc and
stirred for 5 minutes, the organic layer was separated and
collected, and the aqueous layer was extracted twice with EtOAc.
The combined organic layers were washed twice with sat. aq.
NaHCO.sub.3 and once with sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. The solvent was distilled off, and the residue
was loaded onto silica gel column chromatography (hexane:EtOAc=2:1)
and then recrystallized from a mixed solvent of hexane:EtOAc=10:1
to give the desired product. In addition, the mother liquor was
concentrated and then purified by silica gel column chromatography
(hexane:EtOAc=7:1) to further give the desired product (combined
yield, 0.286 g, 79%).
[0158] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 11.42 (1H, s,
Ar--OH), 6.54 (1H, s, Ar--H), 6.06 (1H, s, Ar--OH), 3.95 (3H, s,
CO.sub.2CH.sub.3), 2.63 (3H, s, Ar--H).
Methyl
(E)-3-chloro-4,6-dihydroxy-5-(3,7-dimethyl-2,6-octadienyl)-2-methylbenzoat-
e (compound 152)
[0159] .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta. 11.65 (1H, s,
Ar--OH), 6.20 (1H, s, Ar--OH), 5.23 (1H, t, J=7.1 Hz,
ArCH.sub.2CH.dbd.C), 5.06 {1H, t, J=6.9 Hz,
CH.dbd.C(CH.sub.3).sub.2}, 3.94 (3H, s, CO.sub.2CH.sub.3), 3.44
(2H, d, J=7.1 Hz, ArCH.sub.2CH), 2.59 (3H, s, Ar--CH.sub.3),
2.09-2.03 (2H, m, CH.sub.2), 2.00-1.96 (2H, m, CH.sub.2), 1.79 (3H,
s, CH.sub.3), 1.65 (3H, s, CH.sub.3), 1.57 (3H, s, CH.sub.3). IR
(KBr) 3508, 2935, 1655, 1603, 1464, 1439, 1415, 1383, 1313, 1292,
1258. 1202, 1196, 1161, 1088, 978, 799, 700 cm.sup.-1. HRMS (MI)
Found: m/z, 338.1277. Calcd for C.sub.18H.sub.23O.sub.4Cl: M.sup.+,
338.1285.
8. Compounds 184, 177, 183, 173 and 282-12
[0160] [Formula 8]
##STR00017##
(E)-3-(3,7-Dimethyl-2,6-octadienyl)-2,4-dihydroxyacetophenone
(compound 184)
[0161] Mp 134-135.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 13.13 (1H, s, Ar--OH), 7.54 (1H, d, J=8.8 Hz, Ar--H), 6.39
(1H, d, J=8.8 Hz, Ar--H), 6.11 (1H, s, Ar--OH), 5.27 (1H, t, J=7.0
Hz, ArCH.sub.2CH.dbd.C), 5.05 {1H, m,
CH.sub.2CH.dbd.C(CH.sub.3).sub.2}, 3.46 (2H, d, J=7.0 Hz,
ArCH.sub.2), 2.57 (3H, s, CH.sub.3C.dbd.O), 2.15-2.05 (4H, m,
CH.sub.2CH.sub.2), 1.82 (3H, s, CH.sub.3), 1.68 (3H, s, CH.sub.3),
1.59 (3H, s, CH.sub.3). IR (KBr) 3161, 2964, 2916, 1624, 1589,
1499, 1456, 1379, 1317, 1279, 1223, 1163, 1055, 791, 721, 613, 567
cm.sup.-1.
5-Chloro-2,4-dihydroxyacetophenone (compound 23)
[0162] 66% yield. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.48
(1H, s, Ar--OH), 7.71 (1H, s, Ar--H), 6.60 (1H, s, Ar--H), 6.16
(1H, s, Ar--OH), 2.57 (3H, s, ArCOCH.sub.3).
(E)-5-Chloro-3-(3,7-dimethyl-2,6-octadienyl)-2,4-dihydroxyacetophenone
(compound 177)
[0163] Mp 109-110.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3)
.delta. 12.83 (1H, s, Ar--OH), 7.60 (1H, s, Ar--H), 6.21 (1H, s,
Ar--OH), 5.23 (1H, t, J=7.1 Hz, ArCH.sub.2CH.dbd.C), 5.05 {1H, t,
J=7.7 Hz, CH.dbd.C(CH.sub.3).sub.2}, 3.43 (2H, d, J=7.1 Hz,
ArCH.sub.2), 2.56 (3H, s, CH.sub.3C.dbd.O), 2.09-2.04 (2H, m,
CH.sub.2), 2.00-1.97 (2H, m, CH.sub.2), 1.79 (3H, s, CH.sub.3),
1.65 (3H, s, CH.sub.3), 1.57 (3H, s, CH.sub.3). IR (KBr) 3271,
2921, 1628, 1469, 1425, 1373, 1300, 1240, 1209, 1163, 1062, 907,
787 cm.sup.-1. HRMS (MI) Found: m/z, 322.1353. Calcd for
C.sub.18H.sub.23O.sub.3 Cl: M.sup.+, 322.1336.
3-Chloro-4,6-dihydroxy-2-methylacetophenone (compound 111)
[0164] To a solution of orcinol (1.269 g, 10.22 mmol) in AcOH (4.0
ml, 70 mmol), BF.sub.3.OEt.sub.2 (2.6 ml, 21 mmol) was added at
room temperature, followed by heating and stirring at 80.degree. C.
for 18 hours. After returning to room temperature, the reaction
mixture was diluted with EtOAc and poured into H.sub.2O. After the
organic layer was separated and collected, the aqueous layer was
extracted with EtOAc. The combined organic layers were washed three
times with sat. aq. NaHCO.sub.3 and once with sat. aq. NaCl, and
then dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the precipitated crude crystals were recrystallized from a
mixed solvent of hexane:EtOAc=1:3 to give a C-acetylated product
(compound 25). The mother liquor was concentrated and subjected to
silica gel column chromatography (hexane:EtOAc=3:2) to collect only
fractions containing compound 25, which were then purified by being
recrystallized again from the same solvent (combined yield
65%).
[0165] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 13.44 (1H, s,
Ar--OH), 6.26 (1H, d, J=2.6 Hz, Ar--H), 6.24 (1H, d, J=2.6 Hz
Ar--H), 5.43 (1H, s, Ar--OH), 2.63 (3H, s, Ar--CH.sub.3), 2.56 (3H,
s, ArCOCH.sub.3).
[0166] Compound 25 was chlorinated with NCS in AcOH to give the
desired product (refer to the typical procedures, 65% yield).
[0167] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.37 (1H, s,
Ar--OH), 6.52 (1H, s, Ar--H), 6.09 (1H, s, Ar--OH), 2.63 (6H, br,
Ar--CH.sub.3 & ArCOCH.sub.3).
(E)-3-(3,7-Dimethyl-2,6-octadienyl)-2,4-dihydroxy-6-methylacetophenone
(compound 183)
[0168] Mp 102.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta.
13.91 (1H, s, Ar--OH), 6.23 (1H, s, Ar--H), 5.98 (1H, s, Ar--OH),
5.27 (1H, t, J=6.8 Hz, ArCH.sub.2CH.dbd.C), 5.05 {1H, t, J=6.2 Hz,
CH.dbd.C(CH.sub.3).sub.2}, 3.43 (2H, d, J=7.1 Hz, Ar--CH.sub.2),
2.62 (3H, s, Ar--CH.sub.3), 2.53 (3H, s, CH.sub.3C.dbd.O),
2.14-2.04 (4H, m, CH.sub.2CH.sub.2), 1.84 (3H, s, CH.sub.3), 1.68
(3H, s, CH.sub.3), 1.59 (3H, s, CH.sub.3). IR (KBr) 3175, 2964,
2922, 1568, 1439, 1362, 1258, 1223, 1171, 1094, 1011, 986, 829,
791, 608, 575 cm.sup.-1. Anal. found: C, 75.22; H, 8.69%. Calcd.
for C.sub.19H.sub.26O.sub.3: C, 75.46; H, 8.67%.
(E)-3-Chloro-4,6-dihydroxy-5-(3,7-dimethyl-2,6-octadienyl)-2-methylacetoph-
enone (compound 173)
[0169] Mp 57-58.degree. C.; .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.56 (1H, s, Ar--OH), 6.25 (1H, s, Ar--OH), 5.23 (1H, t,
J=7.1 Hz, ArCH.sub.2CH.dbd.C), 5.06 {1H, t, J=6.7 Hz,
CH.dbd.C(CH.sub.3).sub.2}, 3.41 (2H, d, J=7.0 Hz, Ar--CH.sub.2),
2.61 (3H, s, Ar--CH.sub.3), 2.58 (3H, s, CH.sub.3C.dbd.O),
2.10-2.03 (2H, m, CH.sub.2), 2.01-1.95 (2H, m, CH.sub.2), 1.79 (3H,
s, CH.sub.3), 1.65 (3H, s, CH.sub.3), 1.57 (3H, s, CH.sub.3). IR
(KBr) 3460, 2922, 2866, 1595, 1468, 1421, 1381, 1360, 1275, 1236,
1209, 1175, 1094, 993, 916, 826, 785, 638, 621, 600 cm.sup.-1.
Anal. found: C, 67.80; H, 7.59%. Calcd. for
C.sub.19H.sub.25ClO.sub.3: C, 67.75; H, 7.48%. (Cl was impossible
to measure because of too small amount of the sample).
(E,E)-3-Chloro-4,6-dihydroxy-5-(3,7,11-trimethyl-2,6,10-dodecatienyl)-2-me-
thylacetophenone (compound 282-12)
[0170] Mp 92-93.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.55 (1H, s, Ar--OH), 6.23 (1H, s, Ar--OH), 5.23 (1H, t,
J=7.2 Hz, ArCH.sub.2CH.dbd.C), 5.06 (2H, t, J=6.6 Hz,
2.times.CH.dbd.C), 3.41 (2H, d, J=7.4 Hz, Ar--CH.sub.2), 2.60 (3H,
s, Ar--CH.sub.3), 2.58 (3H, s, Ar--COCH.sub.3), 2.07 (2H, t, J=7.3
Hz, CH.sub.2), 2.01-1.96 (4H, m, 2.times.CH.sub.2), 1.93 (2H, t,
J=7.5 Hz, CH.sub.2), 1.79 (3H, s, CH.sub.3), 1.67 (3H, s,
CH.sub.3), 1.58 (3H, s, CH.sub.3), 1.57 (3H, s, CH.sub.3). IR (KBr)
3362, 2970, 2926, 2864, 1601, 1468, 1412, 1375, 1360, 1277, 1242,
1198, 1148, 1092, 1018, 991, 924, 887, 766, 617, 598, 556
cm.sup.-1. Anal. Found: C, 70.90; H, 8.16; Cl, 8.77%. Calcd for
C.sub.24H.sub.33ClO.sub.3: C, 71.18; H, 8.21; Cl, 8.75%. 9.
Compounds 200-11-OPiv, 215-11-OPiv, 200-12-OPiv, 215-12-OPiv,
200-13-OPiv, 215-13-OPiv, 200-12-OCO.sup.IPr, 215-12-OCO.sup.IPr,
215-13-OCO.sup.IPr, 215-12-OCOEt, 200-13-OCOEt and 215-13-OCOEt
[0171] [Formula 9]
##STR00018##
7-Oxoheptyl pivalate (compound 27-1, R=.sup.tBu)
[0172] To a solution of 1,7-heptanediol (compound 26-1, 0.28 ml,
2.0 mmol) in CH.sub.3Cl (2 ml), Piv-Cl (0.12 ml, 1.0 mmol) and
pyridine (0.03 ml, 0.4 mmol) were added at 0.degree. C. and stirred
for 1 day. After the reaction mixture was diluted with H.sub.2O to
separate and collect the organic layer, the aqueous layer was
extracted with EtOAc. The combined organic layers were washed with
sat. aq. NaCl and dried over Na.sub.2SO.sub.4. After the solvent
was distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=3:1) to give 7-hydroxyheptyl pivalate
(147 mg, 68%).
[0173] To a solution of 7-hydroxyheptyl pivalate (552 mg, 2.55
mmol) in CH.sub.3Cl (5.1 ml), NMO (597 mg, 5.11 mmol), MS-4A (1.290
g) and TPAP (44 mg, 0.13 mmol) were added at room temperature and
stirred for 3 hours. After the reaction mixture was diluted with
sat. aq. NH.sub.4Cl to separate and collect the organic layer, the
aqueous layer was extracted with CH.sub.3Cl. The combined organic
layers were extracted with CH.sub.3Cl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=7:1)
to give the desired side chain precursor compound 27-1 (217 mg,
40%).
[0174] .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta. 9.77 (1H, t, J=1.7
Hz, CHO), 4.05 (2H, t, J=6.5 Hz, CH.sub.2OPiv), 2.44 (2H, dt,
J=1.8, 7.3 Hz, CH.sub.2CHO), 1.68-1.61 (4H, m, CH.sub.2CH.sub.2CHO
& CH.sub.2CH.sub.2OPiv), 1.39-1.35 (4H, m, CH.sub.2CH.sub.2),
1.19 {9H, s, C(CH.sub.3).sub.3}. IR (neat) 2941, 2860, 1728, 1477,
1286, 1159 cm.sup.-1.
(E)-7-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-6-heptenyl
pivalate (compound 200-11-OPiv)
[0175] To a solution of the side chain precursor 27-1 (162 mg, 0.75
mmol) in MeOH (1.3 ml), compound 112 (118 mg, 0.63 mmol) and
CaCl.sub.2 2H.sub.2O (63 mg, 0.44 mmol) were added and cooled to
0.degree. C. To this mixture, KOH (1.0 M in MeOH, 0.9 ml, 0.9 mmol)
was added and stirred at the same temperature for 1 day. After
addition of 1 M aq. HCl, the reaction mixture was extracted three
times with EtOAc. The combined organic layers were washed with sat.
aq. NaCl and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was subjected to silica gel column
chromatography (hexane:EtOAc=10:1) to give an aldol product (126
mg). The resulting product was used for the subsequent reaction
without further purification.
[0176] Namely, the whole product was dissolved in AcOH (1.8 ml),
and H.sub.3PO.sub.4 (85% purity, 0.2 ml) was added thereto at room
temperature, followed by refluxing for 2 hours. After returning to
room temperature, the reaction mixture was diluted with sat. aq.
NaCl and extracted twice with EtOAc. The combined organic layers
were dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the residue was purified by silica gel column chromatography
(hexane:EtOAc=10:1) to give the desired product (104 mg, 43% for 2
steps).
[0177] Mp 57-58.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3)
.delta. 13.06 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.66 (1H,
dt, J=6.9, 16.3 Hz, ArCH.dbd.CH), 6.58 (1H, s, Ar--OH), 6.54 (1H,
d, J=16.3 Hz, ArCH.dbd.CH), 4.06 (2H, t, J=6.7 Hz, CH.sub.2OPiv),
2.62 (3H, s, Ar--CH.sub.3), 2.28 (2H, q, J=7.1 Hz,
CH.dbd.CHCH.sub.2), 1.69-1.64 (2H, m, CH.sub.2), 1.54-1.50 (2H, m,
CH.sub.2), 1.46-1.41 (2H, m, CH.sub.2), 1.19 {9H, s,
C(CH.sub.3).sub.3}. IR (neat) 3387, 2930, 2885, 1726, 1634, 1462,
1426, 1375, 1285, 1256, 1161, 1028, 980, 816, 754 cm.sup.-1. Anal.
Found: C, 62.71; H, 7.05; Cl, 9.25%. Calcd for
C.sub.20H.sub.27O.sub.5Cl: C, 62.74; H, 7.11; Cl, 9.26%.
7-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)heptyl pivalate
(compound 215-11-OPiv)
[0178] To a solution of 200-11-OPiv (70 mg, 0.18 mmol) in EtOH (2
ml), a catalytic amount of Pd--C was added at 0.degree. C. and
stirred for 80 minutes under a H.sub.2 atmosphere. The reaction
mixture was filtered through silica gel, and the filtrate was
concentrated and then purified by PTLC (hexane:EtOAc=3:1) to give
the desired product (34 mg, 49%).
[0179] Mp 63-64.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3)
.delta. 12.65 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.31 (1H,
br, Ar--OH), 4.04 (2H, t, J=6.6 Hz, CH.sub.2OPiv), 2.67 (2H, t,
J=7.7 Hz, ArCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 1.64-1.59 (2H,
m, CH.sub.2), 1.56-1.50 (2H, m, CH.sub.2), 1.36 {6H, br,
(CH.sub.2).sub.3}, 1.19 {9H, s, C(CH.sub.3).sub.3}. IR (KBr) 3435,
2920, 2848, 1730, 1637, 1458, 1425, 1366, 1277, 1161, 1048, 848,
800, 760 cm.sup.-1. Anal. Found: C, 62.19; H, 7.57%. Calcd. for
C.sub.20H.sub.29O.sub.5Cl: C, 62.41; H, 7.59%.
[0180] Compounds differing in their side chain length and/or
terminal acyl group were also synthesized in the same manner.
(E)-8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-7-octenyl
pivalate (compound 200-12-OPiv)
[0181] Mp 57-58.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 13.07 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.51-6.69
(2H, m, CH.dbd.CH), 4.06 (2H, t, J=7.0 Hz, CH.sub.2OPiv), 2.62 (3H,
s, Ar--CH.sub.3), 2.27 (2H, q, J=6.6 Hz, CH.dbd.CHCH.sub.2),
1.64-1.52 (4H, m, 2.times.CH.sub.2), 1.39 (4H, br,
2.times.CH.sub.2), 1.20 {9H, s, C(CH.sub.3).sub.3}. IR (KBr) 3244,
2937, 1718, 1616, 1414, 1288, 1232, 978, 795, 596 cm.sup.-1.
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)octyl pivalate
(compound 215-12-OPiv)
[0182] Mp 70-71.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.66 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.34 (1H,
br, Ar--OH), 4.04 (2H, t, J=6.4 Hz, CH.sub.2OPiv), 2.66 (2H, t,
J=7.2 Hz, ArCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 1.65-1.58 (2H,
m, CH.sub.2), 1.55-1.48 (2H, m, CH.sub.2), 1.35 {8H, m,
(CH.sub.2).sub.4}, 1.20 {9H, s, C(CH.sub.3).sub.3}. IR (KBr) 3350,
2930, 2858, 1724, 1612, 1421, 1362, 1248, 1159, 800, 714, 590
cm.sup.-1. HRMS (EI) Found: 398.1890. Calcd. for
C.sub.21H.sub.31ClO.sub.5: 398.1860.
(E)-9-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-8-nonenyl
pivalate (compound 200-13-OPiv)
[0183] Mp 69-70.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 13.06 (1H, s, Ar--OH), 10.15 (1H, s, ArCHO), 6.65 (1H, dt,
J=6.8, 16.0 Hz, ArCH.dbd.CH.sub.2), 6.61 (1H, br, Ar--OH), 6.52
(1H, d, J=16.0 Hz, ArCH.dbd.CH.sub.2), 4.05 (2H, t, J=6.8 Hz,
CH.sub.2OPiv), 2.62 (3H, s, Ar--CH.sub.3), 2.27 (2H, q, J=6.8 Hz,
CH.dbd.CH.sub.2CH.sub.2), 1.67-1.58 (2H, m, CH.sub.2), 1.53-1.45
(2H, m, CH.sub.2), 1.36 {6H, br, (CH.sub.2).sub.3}, 1.20 {9H, s,
C(CH.sub.3).sub.3}. IR (KBr) 2943, 2860, 1724, 1628, 1460, 1391,
1377, 1286, 1161, 1028, 976, 941, 885, 808, 716, 590 cm.sup.-1.
HRMS (EI) Found: 410.1849. Calcd. for C.sub.22H.sub.31ClO.sub.5:
410.1860.
9-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)nonyl pivalate
(compound 215-13-OPiv)
[0184] Mp 62.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
12.66 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, br,
Ar--OH), 4.04 (2H, t, J=6.6 Hz, CH.sub.2OPiv), 2.66 (2H, t, J=7.9
Hz, ArCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 1.64-1.57 (2H, m,
CH.sub.2), 1.54-1.48 (2H, m, CH.sub.2), 1.30 {10H, br,
(CH.sub.2).sub.5}, 1.19 {9H, s, C(CH.sub.3).sub.3}. IR (KBr) 3377,
2916, 2853, 1732, 1614, 1481, 1421, 1366, 1283, 1240, 1145, 1126,
1032, 843, 785, 621, 586 cm.sup.-1. HRMS (EI) Found: 412.2043.
Calcd. for C.sub.22H.sub.33ClO.sub.5: 412.2017.
(E)-8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-7-octenyl
isobutylate (compound 200-12-OCO.sup.IPr)
[0185] Mp 73.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
13.06 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.64 (1H, dt, J=6.8,
16.1 Hz, ArCH.dbd.CH.sub.2), 6.60 (1H, br, Ar--OH), 6.53 (1H, d,
J=16.1 Hz, ArCH.dbd.CH.sub.2), 4.06 {2H, t, J=6.8 Hz,
CH.sub.2OC(O).sup.iPr}, 2.62 (3H, s, Ar--CH.sub.3), 2.58-2.51 {1H,
m, CH(CH.sub.3).sub.2}, 2.27 (2H, q, J=6.8 Hz,
CH.dbd.CH.sub.2CH.sub.2), 1.68-1.60 (2H, m, CH.sub.2), 1.53-1.47
(2H, m, CH.sub.2), 1.42-1.35 {4H, m, (CH.sub.2).sub.2}, 1.16 {6H,
d, J=7.0 Hz, CH(CH.sub.3).sub.2}. IR (KBr) 3206, 2972, 2928, 2855,
1732, 1618, 1456, 1414, 1283, 1204, 1163, 1132, 978, 793, 592
cm.sup.-1. Anal. Found: C, 63.03; H, 7.16; Cl, 9.22%. Calcd. for
C.sub.20H.sub.27ClO.sub.5: C, 62.74; H, 7.11; Cl, 9.26%.
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)octyl isobutylate
(compound 215-12-OCO.sup.IPr)
[0186] Mp 65.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
12.65 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, br,
Ar--OH), 4.05 {2H, t, J=6.8 Hz, CH.sub.2OC(O).sup.iPr}, 2.66 (2H,
t, J=7.7 Hz, Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.57-2.50
{1H, m, CH(CH.sub.3).sub.2}, 1.65-1.58 (2H, m, CH.sub.2), 1.54-1.48
(2H, m, CH.sub.2), 1.33 {8H, br, (CH.sub.2).sub.4}, 1.16 {6H, d,
J=7.0 Hz, CH(CH.sub.3).sub.2}. IR (KBr) 3335, 2930, 2853, 2363,
1728, 1628, 1464, 1421, 1240, 1136, 791, 586. Anal. Found: C,
62.59; H, 7.62; Cl, 9.01%. Calcd. for C.sub.20H.sub.29ClO.sub.5: C,
62.41; H, 7.59; Cl, 9.21%.
9-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)nonyl isobutylate
(compound 215-13-OCO.sup.IPr)
[0187] Mp 55-56.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.66 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, s,
Ar--OH), 4.05 {2H, t, J=6.8 Hz, CH.sub.2OC(O).sup.iPr}, 2.66 (2H,
t, J=7.7 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.58-2.51
{1H, m, CH(CH.sub.3).sub.2}, 1.65-1.58 (2H, m, CH.sub.2), 1.54-1.48
(2H, m, CH.sub.2), 1.33 {10H, br, (CH.sub.2).sub.5}, 1.16 {6H, d,
J=7.0 Hz, CH(CH.sub.3).sub.2}. IR (KBr) 3364, 2964, 2930, 2860,
1736, 1620, 1470, 1418, 1373, 1283, 1240, 1198, 1153, 1124, 787,
592 cm.sup.-1. Anal. Found: C, 63.41; H, 7.82; Cl, 8.71%. Calcd for
C.sub.21H.sub.31ClO.sub.5: C, 63.23; H, 7.83; Cl, 8.89%.
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)octyl propionate
(compound 215-12-OCOEt)
[0188] Mp 63-64.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.65 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.33 (1H,
br, Ar--OH), 4.06 {2H, t, J=6.4 Hz, CH.sub.2OC(O)Et}, 2.67 (2H, t,
J=7.7 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.32 {2H, q,
J=7.5 Hz, C(O)CH.sub.2CH.sub.3}, 1.67-1.48 (4H, m,
2.times.CH.sub.2), 1.33 {8H, br, (CH.sub.2).sub.4}, 1.14 {3H, t,
J=7.5 Hz, C(O)CH.sub.2CH.sub.3}. IR (KBr) 3335, 2935, 2839, 1729,
1632, 1470, 1418, 1369, 1286, 1261, 1213, 1128, 1088, 812, 627, 590
cm.sup.-1. HRMS (EI) Found: 370.1546. Calcd. for
C.sub.19H.sub.27ClO.sub.5: 370.1547.
(E)-9-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-8-nonenyl
propionate (compound 200-13-OCOEt)
[0189] Mp 72-73.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 13.05 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.65 (1H,
dt, J=6.8, 16.1 Hz, ArCH.dbd.CH.sub.2), 6.60 (1H, br, Ar--OH), 6.53
(1H, d, J=16.1 Hz, ArCH.dbd.CH.sub.2), 4.07 {2H, t, J=6.8 Hz,
CH.sub.2OC(O)Et}, 2.62 (3H, s, Ar--CH.sub.3), 2.32 {2H, q, J=7.5
Hz, C(O)CH.sub.2CH.sub.3}, 2.27 (2H, q, J=6.8 Hz,
CH.dbd.CH.sub.2CH.sub.2), 1.66-1.58 (2H, m, CH.sub.2), 1.52-1.46
(2H, m, CH.sub.2), 1.36 {6H, br, (CH.sub.2).sub.3}, 1.14 (3H, t,
J=7.5 Hz, CH.sub.2CH.sub.3). IR (KBr) 3385, 2916, 2847, 1728, 1624,
1582, 1456, 1425, 1352, 1261, 1194, 1132, 1111, 1084, 964, 829,
791, 683, 592 cm.sup.-1.
9-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)nonyl propionate
(compound 215-13-OCOEt)
[0190] Mp 69-70.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.66 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, s,
Ar--OH), 4.06 {2H, t, J=6.9 Hz, CH.sub.2OC(O)Et}, 2.66 (2H, t,
J=7.7 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.31 {2H, q,
J=7.7 Hz, C(O)CH.sub.2CH.sub.3}, 1.67-1.48 (4H, m,
2.times.CH.sub.2), 1.30 {10H, br, (CH.sub.2).sub.5}, 1.14 {3H, t,
J=7.7 Hz, C(O)CH.sub.2CH.sub.3}. IR (KBr) 3352, 2926, 2853, 1742,
1614, 1421, 1369, 1285, 1238, 1184, 1124, 1082, 783, 627, 586
cm.sup.4. Anal. Found: C, 62.40; H, 7.45; Cl, 9.09%. Calcd for
C.sub.20H.sub.29ClO.sub.5: C, 62.41; H, 7.59; Cl, 9.21%.
10. Compounds 143-12-OPiv, 178-11-OPiv, 172-11-OPiv and
193-11-Opiv
[0191] [Formula 10]
##STR00019##
8-(3-Chloro-2,6-dihydroxy-5-methoxycarbonyl-4-methylphenyl)octyl
pivalate (compound 143-12-OPiv)
[0192] In accordance with the same procedures as described in
Scheme 9 above, the desired product was synthesized from the
aromatic ring starting material in ester form (113).
[0193] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 11.63 (1H, s,
Ar--OH), 6.14 (1H, br, Ar--OH), 4.04 (2H, t, J=6.6 Hz,
CH.sub.2OPiv), 3.94 (3H, s, CO.sub.2CH.sub.3), 2.68 (2H, t, J=7.7
Hz, ArCH.sub.2), 2.59 (3H, s, Ar--CH.sub.3), 1.65-1.49 (4H, m,
ArCH.sub.2CH.sub.2 & CH.sub.2CH.sub.2O Piv), 1.33 (8H, br,
(CH.sub.2).sub.4), 1.19 (9H, s, C(CH.sub.3).sub.3).
7-(3-Acetyl-5-chloro-2,6-dihydroxyphenyl)heptyl pivalate (compound
178-11-OPiv)
[0194] In accordance with the same procedures as described in
Scheme 9 above, the desired product was synthesized from the
aromatic ring starting material in ketone form (23).
[0195] Mp 48.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
12.78 (1H, s, Ar--OH), 7.59 (1H, s, Ar--H), 6.12 (1H, br, Ar--OH),
4.04 (2H, t, J=6.6 Hz, CH.sub.2OPiv), 2.69 (2H, t, J=7.5 Hz,
Ar--CH.sub.2), 2.55 (3H, s, CH.sub.3C.dbd.O), 1.66-1.58 (2H, m,
CH.sub.2), 1.56-1.48 (2H, m, CH.sub.2), 1.36 {6H, br,
(CH.sub.2).sub.3}, 1.19 {9H, s, C(CH.sub.3).sub.3}. IR (KBr) 3300,
2930, 2852, 1728, 1616, 1474, 1418, 1373, 1339, 1286, 1150, 1119,
1045, 968, 872, 787, 623, 586 cm.sup.-1. HRMS (EI) Found: 384.1705.
Calcd. for C.sub.20H.sub.29ClO.sub.5: 384.1704.
7-(3-Acetyl-5-chloro-2,6-dihydroxy-4-methylphenyl)heptyl pivalate
(compound 172-11-OPiv)
[0196] In accordance with the same procedures as described in
Scheme 9 above, the desired product was synthesized from the
aromatic ring starting material in ketone form (111).
[0197] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.64 (1H, s,
Ar--OH), 6.15 (1H, s, Ar--OH), 4.04 (2H, t, J=6.6 Hz,
CH.sub.2OPiv), 2.67 (2H, t, J=7.7 Hz, Ar--CH.sub.2), 2.61 (3H, s,
Ar--CH.sub.3), 2.59 (3H, s, CH.sub.3C.dbd.O), 1.64-1.57 (2H, m,
CH.sub.2), 1.55-1.48 (2H, m, CH.sub.2), 1.36 (6H, br,
(CH.sub.2).sub.3), 1.19 (9H, s, C(CH.sub.3).sub.3). IR (KBr) 3412,
2943, 2866, 1720, 1607, 1464, 1416, 1366, 1273, 1161, 1115, 1074,
1036, 984, 860, 770, 596 cm.sup.-1. HRMS (EI) Found: 398.1870.
Calcd. for C.sub.21H.sub.31ClO.sub.5: 398.1860.
4-Chloro-6-cyano-5-methylresorcinol diacetate (compound 28)
[0198] To a solution of AcONa (0.648 g, 7.90 mmol) in AcOH (10 ml),
NH.sub.2OH.HCl (0.589 g, 8.47 mmol) and compound 112 (1.308 g, 7.01
mmol) were added at room temperature and stirred for 7 hours. The
reaction mixture was diluted with EtOAc and H.sub.2O to separate
and collect the organic layer, and the aqueous layer was then
extracted with EtOAc. The combined organic layers were washed with
sat. aq. NaHCO.sub.3 and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. The solvent was distilled off and the resulting
corresponding oxime (1.400 g) was used in crude state for the
subsequent reaction without purification.
[0199] Namely, the whole product was dissolved in Ac.sub.2O (30
ml), and this solution was stirred at 130.degree. C. for 12 hours.
After returning to room temperature, the reaction mixture was
diluted with Et.sub.2O and H.sub.2O to separate and collect the
organic layer, and the aqueous layer was then extracted with
Et.sub.2O. The combined organic layers were washed twice with sat.
aq. NaHCO.sub.3 and once with sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the
precipitated crude crystals were recrystallized from a mixed
solvent of MeOH and H.sub.2O (4:1) to give aromatic ring starting
material compound 28. In addition, the mother liquor was
concentrated, and the residue was purified by silica gel column
chromatography (hexane:EtOAc=2:1) to also give compound 28 (1.388 g
in total, 74% yield for 2 steps).
[0200] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.06 (1H, s,
Ar--H), 2.64 (3H, s, Ar--CH.sub.3), 2.39 (3H, s, OCOCH.sub.3), 2.37
(3H, s, OCOCH.sub.3). .sup.13C-NMR (100 MHz, CDCl.sub.3) 167.9,
167.5, 151.2, 150.7, 142.7, 125.7, 116.4, 113.6, 106.8, 20.8, 20.6,
19.4.
7-(3-Chloro-5-cyano-2,6-dihydroxy-4-methylphenyl)heptyl pivalate
(compound 193-11-OPiv)
[0201] In accordance with the same procedures as described in
Scheme 9 above, the desired product was synthesized from the
aromatic ring starting material in nitrile form (28).
[0202] Mp 67-68.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 6.21 (1H, br, Ar--OH), 6.17 (1H, s, Ar--OH), 4.05 (2H, t,
J=6.6 Hz, CH.sub.2OPiv), 2.66 (2H, t, J=7.7 Hz, ArCH.sub.2), 2.51
(3H, s, Ar--CH.sub.3), 1.66-1.58 (2H, m, CH.sub.2), 1.56-1.48 (2H,
m, CH.sub.2), 1.35 {6H, br, (CH.sub.2).sub.3}, 1.20 {9H, s,
C(CH.sub.3).sub.3}. .sup.13C-NMR (100 MHz, CDCl.sub.3) 178.8,
156.3, 154.1, 137.2, 115.8, 115.3, 113.4, 93.9, 64.4, 38.8, 29.3,
28.9, 28.6, 28.3, 27.2, 25.8, 23.7, 18.9. IR (KBr) 3383, 2926,
2853, 2232, 1715, 1593, 1468, 1416, 1366, 1325, 1286, 1244, 1171,
1119, 1057, 1036, 980, 847, 799, 690, 627, 590 cm.sup.-1.
11. Compounds 215-11-OAc and 215-9-OH
[0203] [Formula 11]
##STR00020##
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)octyl acetate
(compound 215-11-OAc)
[0204] When an aldol product, which had been prepared in the same
manner as described above from aromatic ring starting material 112
and aldehyde 8, was refluxed in acetic acid in the presence of
phosphoric acid, cleavage of the THP group and the subsequent
acetylation occurred to give the desired product.
[0205] Mp. 68.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
12.65 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, br,
Ar--OH), 4.05 (2H, t, J=6.8 Hz, CH.sub.2OPiv), 2.66 (2H, t, J=7.7
Hz, ArCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.04 (3H, s,
OC(O)CH.sub.3), 1.65-1.50 (4H, m, 2.times.CH.sub.2), 1.34 (8H, br,
(CH.sub.2).sub.4). IR (KBr) 3321, 2930, 2853, 1728, 1624, 1464,
1258, 1128, 1051, 797, 596 cm.sup.-1. HRMS (EI) Found: 356.1393.
Calcd. for C.sub.18H.sub.25ClO.sub.5: 356.1391.
5-Chloro-2,4-dihydroxy-3-(8-hydoroxyoctyl)-6-methylbenzaldehyde
(compound 215-9-OH)
[0206] The compound 215-11-OAc was hydrolyzed in the same manner as
described above to give the desired product.
[0207] Mp 129-130.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.66 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.33 (1H, s,
Ar--OH), 3.64 (2H, t, J=6.2 Hz, CH.sub.2OH), 2.67 (2H, t, J=7.3 Hz,
Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 1.64-1.47 (4H, m,
CH.sub.2CH.sub.2OH & ArCH.sub.2CH.sub.2), 1.34 (8H, br,
(CH.sub.2).sub.4). IR (KBr) 3539, 2924, 1627, 1421, 1296, 1257,
1132, 1016, 812 cm.sup.-1. HRMS (EI) Found: 314.1265. Calcd. for
C.sub.16H.sub.23ClO.sub.4: 314.1285.
12. Compounds ascofuranone, 214 (acetyl AF), 209 (demethyl AF), 249
and 250
[0208] [Formula 12]
##STR00021##
dl-5-Chloro-2,4-dihydroxy-6-methyl-3-[(2E,6E)-3-methyl-7-(3,3-dimethyl-4--
oxo-2-oxacyclopentyl)-2,6-octadienyl]benzaldehyde (Ascofuranone;
AF)
[0209] To a solution of geranyl acetate (compound 29, 7.7 ml, 36
mmol) in EtOH (20 ml), SeO.sub.2 (4.34 g, 37.9 mmol) was added at
room temperature and refluxed for 1 hour. After returning to room
temperature, the reaction mixture was filtered through celite. The
filtrate was concentrated and then subjected to silica gel column
chromatography (hexane:EtOAc=1:1) to collect fractions containing
an alcohol (compound 30) and an aldehyde (compound 31). After the
solvent was distilled off, the residue was dissolved in Et.sub.2O
(100 ml), to which MnO.sub.2 (85% purity, 22.5 g, 220 mmol) was
then added and stirred for 15 hours. After the reaction mixture was
filtered through celite, the filtrate was washed with sat. aq. NaCl
and dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the residue was purified by silica gel column chromatography
(hexane:EtOAc=4:1) to give the aldehyde (compound 31) (2.142 g,
28%).
[0210] To a solution of 2-methyl-3-buty2-ol (185 mg, 2.20 mmol) in
THF (14 ml), BuLi (1.58 M in hexane, 2.7 ml, 4.3 mmol) was added at
-20.degree. C. under an Ar stream and stirred for 2 hours. After
the reaction mixture was cooled to -50.degree. C., 31 (505 mg, 2.40
mmol) in THF (18 ml) was added dropwise thereto. After stirring at
the same temperature for 9 hours, sat. aq. NH.sub.4Cl (5 ml) was
added to stop the reaction. The reaction mixture was extracted with
EtOAc, and the organic layer was washed with sat. aq. NaCl and
dried over Na.sub.2SO.sub.4. After the solvent was distilled off,
the residue was purified by silica gel column chromatography
(hexane:EtOAc=2:1) to give a diol (compound 32) (479 mg, 68%).
[0211] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.54 (1H, t, J=7.0
Hz, AcOCH.sub.2CH.dbd.C), 5.33 {1H, t, J=7.1 Hz,
CH.dbd.C(CH.sub.3)CH(OH)}, 4.76 {1H, d, J=5.1 Hz,
CH.dbd.C(CH.sub.3)CH(OH)}, 4.59 (2H, d, J=7.0 Hz,
AcOCH.sub.2CH.dbd.C), 2.20-2.16 (2H, m, CH.sub.2), 2.12-2.09 (2H,
m, CH.sub.2), 2.06 (3H, s, CH.sub.3C.dbd.O), 1.97 {1H, d, J=5.1 Hz,
CH.dbd.C(CH.sub.3)CH(OH)}, 1.74 (3H, s, CH.sub.3), 1.71 (3H, s,
CH.sub.3), 1.61 {1H, s, C(OH)(CH.sub.3).sub.2}, 1.53 {6H, s,
C(OH)(CH.sub.3).sub.2}. IR (neat) 3382, 2978, 2922, 1734, 1711,
1663, 1443, 1362, 1236, 1167, 1024, 951, 864, 712, 610, 554
cm.sup.-1.
[0212] To a solution of compound 32 (1.058 g, 3.594 mmol) in
CHCl.sub.3 (2.8 ml), pyridine (1.06 ml, 13.1 mmol), DMAP (88 mg,
0.72 mmol) and Piv-Cl (0.97 ml, 7.9 mmol) were added at 0.degree.
C. under an Ar stream and stirred at the same temperature for 8
hours. The reaction mixture was diluted with H.sub.2O to separate
and collect the organic layer. The aqueous layer was extracted with
EtOAc, and the combined organic layers were washed with sat. aq.
NaCl and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=7:2) to give a pivalate (compound 33)
(1.322 g, 97%).
[0213] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.77 (1H, s,
CHOPiv), 5.62 {1H, t, J=7.0 Hz, CH.dbd.C(CH.sub.3)CHOPiv}, 5.35
(1H, t, J=7.3 Hz, AcOCH.sub.2CH.dbd.C), 4.59 (2H, d, J=7.3 Hz,
AcOCH.sub.2CH.dbd.C), 2.22-2.16 (2H, m, CH.sub.2), 2.12-2.08 (2H,
m, CH.sub.2), 2.06 (3H, s, CH.sub.3C.dbd.O), 1.71 (3H, s,
CH.sub.3), 1.69 (3H, s, CH.sub.3), 1.62 {1H, br,
C(OH)(CH.sub.3).sub.2}, 1.51 {6H, s, C(OH)(CH.sub.3).sub.2}. 1.19
{9H, s, C(CH.sub.3).sub.3}. IR (neat) 3460, 2978, 2922, 2866, 1732,
1666, 1481, 1456, 1366, 1265, 1234, 1144, 1028, 955, 932, 864, 785,
708, 608, 561 cm.sup.-1.
[0214] To a solution of compound 33 (937 mg, 2.48 mmol) in toluene
(25 ml), AgBF.sub.4 (38 mg, 0.20 mmol) was added at room
temperature under an Ar stream and stirred at 80.degree. C. for 4
hours under light-shielded conditions. After returning to room
temperature, the reaction mixture was diluted with H.sub.2O and
extracted with CHCl.sub.3. The combined organic layers were washed
with sat. aq. NaCl and dried over Na.sub.2SO.sub.4. After the
solvent was distilled off, the residue was purified by silica gel
column chromatography (hexane:BuOAc=20:1) to give the corresponding
cyclic product (compound 34) (589 mg, 63%).
[0215] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.58 (1H, d, J=1.5
Hz, CH.dbd.CHOPiv), 5.47 (1H, t, J=6.8 Hz,
CH.sub.2CH.sub.2CH.dbd.C), 5.34 (1H, dt, J=1.1, 7.0 Hz,
AcOCH.sub.2CH.dbd.C), 5.14 (1H, d, J=0.8 Hz, CH.dbd.CHOPiv), 4.58
(2H, d, J=7.0 Hz, AcOCH.sub.2CH.dbd.C), 2.20-2.15 (2H, m,
CH.sub.2), 2.10-2.05 (2H, m, CH.sub.2), 2.06 (3H, s,
CH.sub.3C.dbd.O), 1.70 (3H, s, CH.sub.3), 1.60 (3H, s, CH.sub.3),
1.37 {3H, s, C(CH.sub.3).sub.2}, 1.33 {3H, s, C(CH.sub.3).sub.2},
1.28 {9H, s, C(CH.sub.3).sub.3}. IR (neat) 2978, 2943, 2860, 1763,
1736, 1655, 1481, 1460, 1366, 1331, 1275, 1234, 1146, 1105, 1028,
955, 876, 837, 760, 604, 586 cm.sup.-1.
[0216] To a solution of compound 34 (810 mg, 2.14 mmol) in MeOH (63
ml), NaOMe (1 M in MeOH, 0.63 ml, 0.63 mmol) was added at room
temperature and stirred for 3 hours. The reaction mixture was
diluted with H.sub.2O and extracted with Et.sub.2O. The combined
organic layers were washed with sat. aq. NaCl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=4:1)
to give the corresponding primary alcohol (compound 35) (498 mg,
92%).
[0217] To a solution of known compound (H. Saimoto et al, Bull.
Chem. Soc. Jpn., 1999, 72, 279-284) 35 (448 mg, 1.78 mmol) in
Et.sub.2O (10 ml), CBr.sub.4 (1.482 g, 4.469 mmol) and
(.sup.nC.sub.8H.sub.17).sub.3P (1.642 g, 4.430 mmol) were added at
0.degree. C. under an Ar stream and stirred at the same temperature
for 4 hours. After the solvent was distilled off, the residue was
purified by silica gel column chromatography (hexane/EtOAc=20:1) to
give the corresponding bromide (538 mg, 96%).
[0218] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.54 (2H, m,
2.times.CH.dbd.C), 4.57 {1H, dd, J=6.4, 10.2 Hz, C(O)CH.sub.2CH},
4.02 (2H, d, J=8.4 Hz, BrCH.sub.2CH.dbd.C), 2.53 {1H, dd, J=6.4,
18.2 Hz, C(O)CH.sub.2CH}, 2.45 {1H, dd, J=10.2, 18.2 Hz,
C(O)CH.sub.2CH}, 2.24-2.17 (2H, m, CH.sub.2), 2.15-2.09 (2H, m,
CH.sub.2), 1.74 (3H, s, CH.sub.3), 1.67 (3H, s, CH.sub.3), 1.31
{3H, s, C(CH.sub.3).sub.2}, 1.24 {3H, s, C(CH.sub.3).sub.2}. IR
(neat) 2965, 2901, 2860, 1757, 1659, 1460, 1377, 1356, 1342, 1310,
1202, 1170, 1111, 1001, 856, 675 cm.sup.-1.
[0219] To a solution of this bromide (136 mg, 0.431 mmol) in MeOH
(0.5 ml), compound 112 (67 mg, 0.36 mmol) and CaCl.sub.2 2H.sub.2O
(37 mg, 0.25 mmol) were added and cooled to 0.degree. C. To this
mixture, KOH (1 M in MeOH, 0.76 ml, 0.76 mmol) was added and
stirred at the same temperature for 8 hours. The reaction mixture
was diluted with sat. aq. NaCl and then extracted with EtOAc. After
the combined organic layers were dried over Na.sub.2SO.sub.4, the
solvent was distilled off and the residue was purified by PTLC
(hexane:THF=5:1 for 1st run, hexane:EtOAc=5:1 for 2nd run) and
recrystallization (hexane/EtOAc) to give the desired product
dl-ascofuranone (52 mg, 34%).
[0220] Mp 88-90.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3)
.delta. 2.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.43 (1H, s,
Ar--OH), 5.51 (1H, t, J=6.9 Hz, CH.dbd.C), 5.21 (1H, d, J=7.1 Hz,
ArCH.sub.2CH.dbd.C), 4.52 {1H, dd, J=6.3, 10.1 Hz, C(O)CH.sub.2CH},
3.39 (2H, d, J=7.1 Hz, ArCH.sub.2CH.dbd.C), 2.61 (3H, s,
Ar--CH.sub.3), 2.42 {1H, dd, J=6.3, 18.2 Hz, C(O)CH.sub.2CH}, 2.35
{1H, dd, J=10.1, 18.2 Hz, C(O)CH.sub.2CH}, 2.18-2.14 (2H, m,
CH.sub.2), 2.06-2.02 (2H, m, CH.sub.2), 1.79 (3H, s, CH.sub.3),
1.63 (3H, s, CH.sub.3), 1.28 {3H, s, C(CH.sub.3).sub.2}, 1.22 {3H,
s, C(CH.sub.3).sub.2}. IR (KBr) 3327, 2985, 2922, 2874, 1740, 1634,
1582, 1460, 1418, 1371, 1325, 1304, 1283, 1248, 1203, 1171, 1111,
1059, 1011, 907, 824, 712, 631, 592, 523 cm.sup.-1.
5-Chloro-2,4-dihydroxy-6-methyl-3-[(2E,6E)-7-(5,5-dimethyl-4-oxotetrahydro-
furan-2-yl)-3,7-dimethyl-2,6-heptadienyl]acetophenone (compound
214; Acetyl AF)
[0221] A bromide was prepared from the same known compound 35 as
used above, and then reacted in the same manner with the aromatic
ring starting material in ketone form (111) to give the desired
product.
[0222] .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta. 12.64 (1H, s,
Ar--OH), 6.26 (1H, s, Ar--OH), 5.50 (1H, t, J=7.0 Hz,
ArCH.sub.2CH.dbd.C), 5.21 (1H, t, J=6.8 Hz, CH.dbd.C), 4.52 {1H,
dd, J=6.4, 10.0 Hz, CHCH.sub.2C.dbd.O}, 3.40 (2H, d, J=7.0 Hz,
ArCH.sub.2CH), 2.61 {3H, s, ArC(O)CH.sub.3}, 2.59 (3H, s,
ArCH.sub.3), 2.40 (1H, dd, J=6.4, 18.3 Hz, CHCH.sub.2C.dbd.O), 2.34
(1H, dd, J=10.0, 18.3 Hz, CHCH.sub.2C.dbd.O), 2.19-2.13 (2H, m,
CH.sub.2), 2.07-2.01 (2H, m, CH.sub.2), 1.79 (3H, s, CH.sub.3),
1.62 (3H, s, CH.sub.3), 1.28 (3H, s, CH.sub.3), 1.22 (3H, s,
CH.sub.3).
5-Chloro-2,4-dihydroxy-3-[(2E,6E)-7-(5,5-dimethyl-4-oxotetrahydrofuran-2-y-
l)-3,7-dimethyl-2,6-heptadienyl]benzaldehyde (compound 209;
Demethyl AF)
[0223] A bromide was prepared from the same known compound 35 as
used above, and then reacted in the same manner with
5-chloro-2,4-dihydroxybenzaldehyde to give the desired product.
[0224] Mp 70-72.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 11.54 (1H, s, Ar--OH), 9.67 (1H, s, CHO), 7.40 (1H, s,
Ar--H), 6.39 (1H, s, Ar--OH), 5.51 (1H, t, J=6.8 Hz,
CH.sub.2CH.sub.2CH.dbd.C), 5.22 (1H, t, J=7.1 Hz,
ArCH.sub.2CH.dbd.C), 4.53 {1H, dd, J=6.2, 9.9 Hz, C(O)CH.sub.2CH},
3.42 (2H, d, J=7.1 Hz, ArCH.sub.2CH.dbd.C), 2.46 {1H, dd, J=6.2,
18.0 Hz, C(O)CH.sub.2CH}, 2.38 {1H, dd, J=9.9, 18.0 Hz,
C(O)CH.sub.2CH}, 2.20-2.14 (2H, m, CH.sub.2), 2.08-2.02 (2H, m,
CH.sub.2), 1.79 (3H, s, CH.sub.3), 1.63 (3H, s, CH.sub.3), 1.29
(3H, s, CH.sub.3), 1.23 (3H, s, CH.sub.3). IR (KBr) 3327, 2986,
2921, 2853, 1753, 1649, 1620, 1473, 1433, 137, 1331, 1290, 1252,
1205, 1167, 1111, 1084, 993, 916, 876, 820, 743, 610, 561, 523
cm.sup.-1. HRMS (EI) Found: 406.1537. Calcd. for
C.sub.22H.sub.27ClO.sub.5: 406.1547.
3-Chloro-4,6-dihydroxy-2-methyl-5-[(E)-7-(5,5-dimethyl-4-oxo-tetrahydrofur-
an-2-yl)-1-heptenyl]benzaldehyde (compound 249)
[0225] Aldehyde 8 was converted into furanone 36 in the same manner
as described in literature (H. Saimoto et al., Bull. Chem. Soc.
Jpn., 1995, 68, 2727-2734).
[0226] .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta. 4.57 (1H, dd,
J=2.8, 4.2 Hz, OCHO), 4.20-4.14 (1H, m, CH.sub.2CHCH.sub.2C.dbd.O),
3.89-3.85 (1H, m, CH.sub.2O), 3.73 (1H, dt, J=6.9, 9.4 Hz,
CH.sub.2O), 3.52-3.48 (1H, m, CH.sub.2O), 3.38 (1H, dt, J=6.7, 9.6
Hz, CH.sub.2O), 2.55 (1H, dd, J=5.8, 18.1 Hz, CH.sub.2C.dbd.O),
2.20 (1H, dd, J=10.1, 18.1 Hz, CH.sub.2C.dbd.O), 1.86-1.80 (1H, m,
CH.sub.2CHO), 1.77-1.69 (2H, m), 1.64-1.51 (7H, m), 1.48-1.42 (1H,
m), 1.35 (7H, br), 1.28 (3H, s, CH.sub.3), 1.20 (3H, s, CH.sub.3).
IR (neat) 2922, 2854, 1757, 1462, 1443, 1369, 1350, 1177, 1119,
1070, 1032, 988, 905, 872, 814, 731 cm.sup.-1.
[0227] To a solution of compound 36 (5.935 g, 19.00 mmol) in EtOH
(100 ml), PPTS (1.933 g, 7.692 mmol) was added and stirred for 4
hours. After returning to room temperature, the reaction mixture
was evaporated to distill off about half of the solvent, and then
poured into saturated aqueous sodium chloride. This mixture was
extracted twice with EtOAc, and the combined organic layers were
dried over Na.sub.2SO.sub.4. After the solvent was distilled off,
the residue was purified by silica gel column chromatography
(hexane:EtOAc=4:1) to give the corresponding primary alcohol (4.007
g, 92%).
[0228] To a solution of oxalyl chloride (98% purity, 0.35 ml, 4.1
mmol) in CHCl.sub.3 (5 ml), a solution of DMSO (0.57 ml, 8.0 mmol)
in CHCl.sub.3 (2.5 ml) was added dropwise at -60.degree. C. After
stirring at the same temperature for 50 minutes, a solution of the
primary alcohol (235 mg, 1.03 mmol) in CHCl.sub.3 (2 ml) was added
and then further stirred for 2 hours. To this mixture, Et.sub.3N
(2.2 ml, 16 mmol) was added and further stirred for 40 minutes.
After the reaction mixture was diluted with sat. aq. NH.sub.4Cl to
separate and collect the organic layer, the aqueous layer was
extracted with CHCl.sub.3. After the combined organic layers were
dried over Na.sub.2SO.sub.4, the solvent was distilled off and the
residue was purified by silica gel column chromatography
(hexane:EtOAc=5:1) to give aldehyde 37 (203 mg, 87%).
[0229] .sup.1H-NMR (500 MHz, CDCl.sub.3) .delta. 9.60 (1H, t, J=1.7
Hz, CHO), 4.01 (1H, m, CH.sub.2CHCO), 2.39 (1H, dd, J=5.7 Hz, 17.8
Hz, CH.sub.2C.dbd.O), 2.27 (2H, dt, J=1.6 Hz, 7.4 Hz, CH.sub.2CHO),
2.04 (1H, dd, J=10.1 Hz, 17.8 Hz, CH.sub.2C.dbd.O), 1.62-1.52 (1H,
m, CH.sub.2CHCH.sub.2C.dbd.O), 1.51-1.42 (3H, m), 1.35-1.26 (1H,
m), 1.20 (5H, br), 1.09 (3H, s, CH.sub.3), 1.03 (3H, s, CH.sub.3).
IR (neat) 2932, 2860, 2721, 1755, 1724, 1462, 1375, 1360, 1177,
1113, 1011, 83, 702, 534 cm.sup.-1. HRMS (EI)) Found: 226.1569.
Calcd. for C.sub.13H.sub.22O.sub.3: M.sup.+ 226.1569.
[0230] In accordance with the same procedures as described above,
an aldol product was prepared from compound 112 and compound 37,
and this product was dehydrated in the presence of H.sub.3PO.sub.4
to give the desired product 249 (6% for 2 steps).
[0231] Mp 99-100.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3)
.delta. 13.07 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.66 (1H,
dt, J=6.9, 16.3 Hz, ArCH.dbd.CH), 6.59 (1H, s, Ar--OH), 6.53 (1H,
d, J=16.3 Hz, ArCH.dbd.CH), 4.18 (1H, m, CHCH.sub.2C.dbd.O), 2.62
(3H, s, Ar--CH.sub.3), 2.57 (1H, dd, J=5.7, 17.9 Hz,
CHCH.sub.2C.dbd.O), 2.28 (2H, q, J=6.9 Hz, CH.dbd.CHCH.sub.2), 2.21
(1H, dd, J=10.1, 17.9 Hz, CHCH.sub.2C.dbd.O), 1.80-1.74 (1H, m,
CH.sub.2CHCH.sub.2C.dbd.O), 1.66-1.60 (1H, m,
CH.sub.2CHCH.sub.2C.dbd.O), 1.55-1.48 (2H, m, CH.sub.2), 1.44-1.35
{4H, m, (CH.sub.2).sub.2}, 1.27 (3H, s, CHa), 1.20 (3H, s,
CH.sub.3). IR (neat) 3400, 2930, 2858, 1755, 1634, 1462, 1418,
1375, 1285, 1256, 1175, 1113, 978, 910, 733, 675, 592 cm.sup.-1.
HRMS (EI) Found: 394.1552. Calcd. for C.sub.21H.sub.27O.sub.5 Cl:
M.sup.+ 394.1547.
5-Chloro-2,4-dihydroxy-6-methyl-3-[7-(3,3-dimethyl-4-oxo-2-oxacyclopentyl)-
heptyl]benzaldehyde (compound 250)
[0232] In accordance with the same procedures as described above,
compound 249 was subjected to catalytic reduction reaction to give
the desired product (98% yield).
[0233] Mp 70-71.degree. C. .sup.1H-NMR (500 MHz, CDCl.sub.3)
.delta.12.66 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.32 (1H, br,
Ar--OH), 4.16 (1H, m, CHCH.sub.2C.dbd.O), 2.66 (2H, t, J=7.7 Hz,
ArCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.55 (1H, dd, J=5.8, 18.1
Hz, CHCH.sub.2C.dbd.O), 2.20 (1H, dd, J=10.1, 18.1 Hz,
CHCH.sub.2C.dbd.O), 1.78-1.71 (1H, m, CH.sub.2CHCH.sub.2C.dbd.O),
1.63-1.56 (2H, m, CH), 1.55-1.49 (2H, m, CH), 1.47-1.40 (1H, m,
CH.sub.2CHCH.sub.2C.dbd.O), 1.34 {6H, m, (CH.sub.2).sub.3}, 1.28
(3H, s, CH.sub.3), 1.20 (3H, s, CH.sub.3).
[0234] HRMS (EI) Found: 396.1690. Calcd. for
C.sub.21H.sub.29ClO.sub.5: 396.1704.
13. Compounds 275-10-COOMe, 276-9, 277-11-OAc, 286-11-OAc, 277-9-OH
and 286-9-OH
[Formula 13]
##STR00022##
[0235] Methyl (2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dienoate
(compound 39)
[0236] To a solution of aldehyde 31 (2.226 g, 10.59 mmol) in MeOH
(50 ml), K.sub.2CO.sub.3 (0.802 g, 5.803 mmol) in crushed state was
added at room temperature and stirred for 4 hours. The reaction
mixture was diluted with H.sub.2O and extracted twice with EtOAc
and once with Et.sub.2O. The combined organic layers were washed
with sat. aq. NH.sub.4Cl and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography
(hexane:EtOAc=2:1.fwdarw.1:2) to give the corresponding primary
alcohol (1.266 g, 71%).
[0237] To a solution of this primary alcohol (1.266 g, 7.525 mmol)
in CHCl.sub.3 (40 ml), Et.sub.3N (3.1 ml, 22 mmol), DMAP (cat.
amount) and TBS--Cl (50% in toluene, 8.0 ml, 23 mmol) were added at
0.degree. C. and stirred at the same temperature for 2.5 hours.
After the reaction mixture was diluted with sat. aq. NH.sub.4Cl to
separate and collect the organic layer, the aqueous layer was
extracted once with EtOAc and twice with Et.sub.2O. The combined
organic layers were washed with sat. aq. NaCl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was subjected to silica gel column chromatography
(hexane:EtOAc=7:1) to give the corresponding silyl ether 38 (2.126
g, 100%).
[0238] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 9.37 (1H, s, CHO),
6.46 (1H, t, J=7.1 Hz, CH.dbd.CCHO), 5.34 (1H, t, J=6.2 Hz,
TBSOCH.sub.2CH.dbd.C), 4.19 (2H, d, J=6.2 Hz, TBSOCH.sub.2CH), 2.47
(2H, q, J=7.3 Hz, CH.sub.2), 2.19 (2H, t, J=7.3 Hz, CH.sub.2), 1.74
(3H, s, CH.sub.3), 1.65 (3H, s, CH.sub.3), 0.89 (9H, s,
C(CH.sub.3).sub.3), 0.06 (6H, s, Si(CH.sub.3).sub.2).
[0239] To a solution of silyl ether 38 (0.772 g, 2.733 mmol) in a
mixture of .sup.tBuOH (20 ml)/H.sub.2O (5 ml),
NaH.sub.2PO.sub.4.2H.sub.2O (1.067 g, 6.839 mmol) and
2-methyl-2-butene (3.0 ml, 28 mmol) were added at room temperature
and cooled to 0.degree. C. To this mixture, NaClO.sub.2 (79%
purity, 0.627 g, 5.48 mmol) was added and stirred for 15 hours
while returning to room temperature. The reaction mixture was
diluted with EtOAc and washed with sat. aq. NaCl, and the organic
layer was dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was used directly for the subsequent
reaction without purification. Namely, to a solution of Ph.sub.3P
(0.868 g, 3.309 mmol) in THF (10 ml), MeOH (0.13 ml, 3.2 mmol) was
added at room temperature and cooled to 0.degree. C. After DEAD
(40% in toluene, 1.35 ml, 2.96 mmol) was added dropwise and stirred
for 30 minutes, a solution of the crude carboxylic acid (0.787 g)
in THF (10 ml) was added dropwise and stirred for 4 hours while
returning to room temperature. After the reaction mixture was
diluted with H.sub.2O to separate and collect the organic layer,
the aqueous layer was extracted with EtOAc. The combined organic
layers were washed with sat. aq. NaCl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=3:1)
to give the corresponding methyl ester (0.535 g, 63% for 2
steps).
[0240] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 6.74 (1H, t, J=7.3
Hz, CH.dbd.CCO.sub.2Me), 5.33 (1H, t, J=6.2 Hz,
TBSOCH.sub.2CH.dbd.C), 4.21 (2H, d, J=6.2 Hz, TBSOCH.sub.2CH), 3.73
(3H, s, CO.sub.2CH.sub.3), 2.30 (2H, q, J=7.5 Hz, CH.sub.2), 2.13
(2H, t, J=7.5 Hz, CH.sub.2), 1.84 (3H, s, CH.sub.3), 1.64 (3H, s,
CH.sub.3), 0.91 (9H, s, C(CH.sub.3).sub.3), 0.07 (6H, s,
Si(CH.sub.3).sub.2).
[0241] The whole product (0.535 g, 1.712 mmol) was dissolved in THF
(20 ml) and cooled to 0.degree. C., followed by addition of TBAF
(1.0 M in THF, 2.0 ml, 2.0 mmol) and stirring for 15 hours while
returning to room temperature. After the reaction mixture was
diluted with H.sub.2O to separate and collect the organic layer,
the aqueous layer was extracted twice with EtOAc. The combined
organic layers were washed with sat. aq. NaCl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=2:1)
to give the desired side chain precursor 39 (0.245 g, 72%).
[0242] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 6.73 (1H, t, J=7.3
Hz, CH.dbd.CCO.sub.2Me), 5.44 (1H, t, J=7.0 Hz,
HOCH.sub.2CH.dbd.C), 4.21 (2H, d, J=6.6 Hz, HOCH.sub.2CH), 3.73
(3H, s, CO.sub.2CH.sub.3), 2.31 (2H, q, J=7.3 Hz, CH.sub.2), 2.15
(2H, t, J=7.7 Hz, CH.sub.2), 1.84 (3H, s, CH.sub.3), 1.69 (3H, s,
CH.sub.3), 1.45 (1H, br, OH).
Methyl
(2E,6E)-8-(3-chloro-5-formyl-2,6-dihydroxy-4-methyl)phenyl-2,6-dimethyl-2,-
6-octa dienoate (compound 275-10-COOMe)
[0243] To a solution of primary alcohol 39 (0.245 g, 1.236 mmol) in
Et.sub.2O (20 ml), CBr.sub.4 (1.250 g, 3.769 mmol) and
(C.sub.8H.sub.17).sub.3P (1.65 ml, 3.07 mmol) were added at
0.degree. C. and stirred at 0.degree. C. to 10.degree. C. for 5
hours. After the solvent was distilled off, the residue was
subjected to silica gel column chromatography (hexane:EtOAc=4:1) to
give the corresponding bromide. The resulting product was used for
the subsequent reaction without further purification.
[0244] Namely, to a solution of compound 112 (0.711 g, 3.810 mmol)
in KOH (1.0 M in MeOH, 5.7 ml, 5.7 mmol), CaCl.sub.2.2H.sub.2O
(0.419 g, 2.85 mmol) and the whole bromide obtained above dissolved
in MeOH (8.5 ml) were added at 0.degree. C. and stirred for 19
hours while returning to room temperature. After the reaction
mixture was diluted with EtOAc and filtered through celite, the
filtrate was washed with 0.1 M aq. KOH and sat. aq. NaCl, and then
dried over Na.sub.2SO.sub.4. After the solvent was distilled off,
the residue was subjected to silica gel column chromatography
(hexane:EtOAc=3:1) and the precipitated crude crystals were then
recrystallized from a mixed solvent of hexane:toluene=10:1 to give
the desired product 275-10-COOMe (0.115 g, 25% yield from compound
39).
[0245] Mp 103-105.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.14 (1H, s, CHO), 6.71 (1H. t,
J=7.4 Hz, CH.dbd.C), 6.47 (1H, s, Ar--OH), 5.24 (1H. t, J=7.0 Hz,
CH.dbd.C), 3.71 (3H, s, COOCH.sub.3), 3.39 (2H, d, J=7.0 Hz,
Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.29-2.23 (2H, m,
CH.sub.2), 2.11-2.08 (2H, m, CH.sub.2), 1.80 (3H, s, CH.sub.3),
1.79 (3H, s, CH.sub.3). IR (KBr) 3369, 2957, 2908, 1715, 1624,
1526, 1456, 1433, 1377, 1279, 1240, 1212, 1161, 1128, 962, 907,
808, 787, 712, 627, 596, 569, 527 cm.sup.-1.
(3E,7E)-9-Hydroxv-3,7-dimethylnona-3,7-diene-2-one (compound
41)
[0246] To a solution of aldehyde 38 (1.600 g, 5.664 mmol) in THF
(50 ml), MeLi (1.0 M in Et.sub.2O, 11.5 ml, 11.5 mmol) was added at
-85.degree. C. and stirred for 2 hours while elevating the
temperature to -50.degree. C. To this mixture, H.sub.2O was added
to stop the reaction. After the organic layer was separated and
collected, the aqueous layer was extracted with Et.sub.2O. The
combined organic layers were washed with sat. aq. NaCl and dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography
(hexane:EtOAc=4:1) to give the corresponding secondary alcohol 40
(1.212 g, 72%).
[0247] To a solution of this secondary alcohol (0.570 g, 1.91 mmol)
in toluene (40 ml), MnO.sub.2 (85% purity, 2.05 g, 20.0 mmol) was
added and stirred vigorously for 18 hours. MnO.sub.2 (2.60 g, 25.4
mmol) was further added and stirring was continued for an
additional 1 day. After the reaction mixture was filtered through
silica gel and the filtrate was concentrated, the residue was
purified by silica gel column chromatography (hexane:EtOAc=8:1) to
give the corresponding ketone. Moreover, 96 mg of the starting
material was collected and oxidized again with MnO.sub.2 (1.20 g,
11.7 mmol) in toluene (10 ml), followed by the same purification
procedures to give the ketone (0.444 g, 87% yield).
[0248] The whole product (0.444 g, 1.497 mmol) was dissolved in THF
(20 ml) and cooled to 0.degree. C., followed by addition of TBAF
(1.0 M in THF, 1.8 ml, 1.8 mmol) and stirring for 2.5 hours while
returning to room temperature. After the reaction mixture was
diluted with H.sub.2O to separate and collect the organic layer,
the aqueous layer was extracted twice with EtOAc. The combined
organic layers were washed with saturated aqueous sodium chloride
and dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the residue was purified by silica gel column chromatography
(hexane:EtOAc=2:1.fwdarw.1:1) to give the desired product 41 (0.222
g, 81%).
[0249] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 6.61 {1H, t, J=6.4
Hz, CH.dbd.C(CH.sub.3)C.dbd.O}, 5.45 (1H, t, J=7.0 Hz,
HOCH.sub.2CH.dbd.C), 4.21 (2H, d, J=7.0 Hz, HOCH.sub.2CH), 2.38
(2H, q, J=7.3 Hz, CH.sub.2), 2.30 (3H, s, COCH.sub.3), 2.19 (2H, t,
J=7.7 Hz, CH.sub.2), 1.77 (3H, s, CH.sub.3), 1.71 (3H, s,
CH.sub.3).
(2E,6E)-3-Chloro-4,6-dihydroxy-2-methyl-5-[(2E,6E)-(3,7-dimethyl-8-oxo-2,6-
-nona dienyl)benzaldehyde (compound 276-9)
[0250] In accordance with the same procedures as described above,
the desired product was obtained from alcohol 41.
[0251] Mp 119-120.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.14 (1H, s, CHO), 6.54 (1H. t,
J=7.2 Hz, CH.dbd.C), 6.39 (1H, s, Ar--OH), 5.26 (1H. t, J=7.3 Hz,
CH.dbd.C), 3.40 (2H, d, J=7.3 Hz, Ar--CH.sub.2), 2.61 (3H, s,
Ar--CH.sub.3), 2.34 (2H, m, CH.sub.2), 2.19 {3H, s, C(O)CH.sub.3},
2.14 (2H, m, CH.sub.2), 1.81 (3H, s, CH.sub.3), 1.72 (3H, s,
CH.sub.3). IR (KBr) 3356, 2920, 2840, 1663, 1620, 1520, 1460, 1425,
1366, 1279, 1236, 1196, 1161, 1111, 962, 903, 812, 787, 708, 631,
592, 569, 527 cm.sup.-1. Anal. Found: C, 65.05; H, 6.61; Cl,
10.11%. Calcd for C.sub.19H.sub.23ClO.sub.4: C, 64.91; H, 6.52; Cl,
10.09%.
(3E,7E)-9-Hydroxv-3,7-dimethylnona-3,7-dien-2-vl acetate (compound
42)
[0252] To a solution of secondary alcohol 40 (0.682 g, 2.28 mmol)
in pyridine (12 ml), Ac.sub.2O (6 ml) was added at room temperature
and stirred for 2.5 hours. The reaction mixture was poured into
H.sub.2O and extracted twice with Et.sub.2O and once with EtOAc.
The combined organic layers were washed with 1 M aq. HCl and sat.
aq. NaCl, and then dried over Na.sub.2SO.sub.4. After the solvent
was distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=4:1) to give the corresponding acetate
(0.585 g, 75%).
[0253] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.42 (1H, t, J=7.0
Hz, CH.dbd.C(CH.sub.3)CHOAc), 5.30 (1H, t, J=6.2 Hz,
TBSOCH.sub.2CH.dbd.C), 5.24 (1H, q, J=6.6 Hz,
CH.dbd.C(CH.sub.3)CHOAc), 4.18 (2H, d, J=6.2 Hz, TBSOCH.sub.2CH),
2.13 (2H, q, J=6.6 Hz, CH.sub.2), 2.03 (3H, s, COCH.sub.3), 2.03
(2H, t, J=7.3 Hz, CH.sub.2), 1.62 (6H, s, 2.times.CH.sub.3), 1.28
(3H, d, J=6.6 Hz, CH(OAc)CH.sub.3), 0.90 (9H, s,
C(CH.sub.3).sub.3), 0.07 (6H, s, Si(CH.sub.3).sub.2).
[0254] The whole product (0.585 g, 1.718 mmol) was dissolved in THF
(20 ml) and cooled to 0.degree. C., followed by addition of TBAF
(1.0 M in THF, 2.0 ml, 2.0 mmol) and stirring for 17 hours while
returning to room temperature. After the reaction mixture was
diluted with H.sub.2O to separate and collect the organic layer,
the aqueous layer was extracted twice with EtOAc. The combined
organic layers were washed with saturated aqueous sodium chloride
and dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the residue was purified by silica gel column chromatography
(hexane:EtOAc=2:1) to give the desired product 42 (0.340 g,
87%).
[0255] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.39 (2H, m,
2.times.CH.dbd.C), 5.22 (1H, q, J=6.6 Hz, CHOAc), 4.21 (2H, d,
J=6.2 Hz, HOCH.sub.2CH), 2.19-2.13 (2H, m, CH.sub.2), 2.09-2.05
(2H, m, CH.sub.2), 2.03 (3H, s, COCH.sub.3), 1.66 (3H, s,
CH.sub.3), 1.61 (3H, s, CH.sub.3), 1.28 (3H, d, J=6.6 Hz,
CHCOCH.sub.3).
(3E,7E)-9-(3-Chloro-5-formyl-2,6-dihydroxy-4-methyl)phenyl-3,7-dimethyl-3,-
7-non adien-2-vl acetate (compound 277-11-OAc)
[0256] In accordance with the same procedures as described above,
the desired product was obtained from alcohol 42.
[0257] Mp 101-102.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.14 (1H, s, CHO), 6.56 (1H, s,
Ar--OH), 5.36 (1H. t, J=7.3 Hz, CH.dbd.C), 5.20 {2H. m,
CH(OAc)CH.sub.3 & CH.dbd.C}, 3.39 (2H, d, J=7.3 Hz,
Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.10 (2H, m, CH.sub.2),
2.02 {3H, s, OC(O)CH.sub.3}, 2.03-2.00 (2H, m, CH.sub.2), 1.77 (3H,
s, CH.sub.3), 1.58 (3H, s, CH.sub.3), 1.22 {3H, d, J=6.6 Hz,
CH(OAc)CH.sub.3}. IR (KBr) 3356, 2986, 2916, 1711, 1624, 1456,
1422, 1377, 1283, 1254, 1157, 1115, 1080, 1024, 959, 910, 841, 808,
708, 631, 583, 544, 523 cm.sup.-1. Anal. Found: C, 63.85; H, 6.91;
Cl, 8.95%. Calcd for C.sub.21H.sub.27ClO.sub.5: C, 63.87; H, 6.89;
Cl, 8.98%.
(3E,7E)-9-(5-Acetyl-3-chloro-2,6-dihydroxy-4-methyl)phenyl-3,7-dimethyl-3,-
7-nona dien-2-vl acetate (compound 286-11-OAc)
[0258] Mp 89-91.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.57 (1H, s, Ar--OH), 6.35 (1H, s, Ar--OH), 5.37 (2H, t,
J=6.8 Hz, CH.dbd.C), 5.24-5.17 (2H, m, CH.dbd.C & CHOAc), 3.40
(2H, d, J=6.84 Hz, ArCH.sub.2), 2.61 (3H, s, ArCH.sub.3), 2.58 (3H,
s, ArCOCH.sub.3), 2.07-2.04 (2H, m, CH.sub.2), 2.03-1.99 (2H, s,
Ch.sub.2), 2.02 (3H, s, COCH.sub.3), 1.78 (3H, s, CH.sub.3), 1.58
(3H, s, CH.sub.3), 1.22 (3H, d, J=6.4 Hz, CHOAc). IR (KBr) 3354,
2978, 2920, 1717, 1611, 1589, 1414, 1379, 1362, 1279, 1258, 1155,
1140, 1096, 1024, 953, 922, 891, 866, 845, 870, 642, 619
cm.sup.-1.
3-Chloro-4,6-dihydroxy-2-methyl-5-[(2E,6E)-(8-hydroxy-3,7-dimethyl-2,6-non-
adienyl)benzaldehyde (compound 277-9-OH)
[0259] To a solution of the compound 277-11-OAc (73 mg, 0.185 mmol)
in MeOH (10 ml), K.sub.2CO.sub.3 (45 mg, 0.33 mmol) was added at
room temperature and stirred for 19 hours. After the reaction
mixture was diluted with sat. aq. NH.sub.4Cl and EtOAc to separate
and collect the organic layer, the aqueous layer was extracted
twice with EtOAc. The combined organic layers were washed with sat.
aq. NaCl and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (toluene:EtOAc=10:1) to give the desired product (11
mg, 17%).
[0260] Mp 105-107.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.71 (1H, s, Ar--OH), 10.14 (1H, s, CHO), 6.61 (1H, s,
Ar--OH), 5.32 (1H. t, J=6.6 Hz, CH.dbd.C), 5.21 (1H. t, J=7.0 Hz,
CH.dbd.C), 4.17 (1H, m, CHOH), 3.40 (2H, d, J=7.0 Hz,
Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.16-2.08 (2H, m,
CH.sub.2), 2.07-2.03 (2H, m, CH.sub.2), 1.78 (3H, s, CH.sub.3),
1.59 (3H, s, CH.sub.3), 1.48 (1H, br, OH), 1.20 {3H, d, J=6.2 Hz,
CH(OH)CH.sub.3}. IR (KBr) 3341, 2970, 2916, 1616, 1456, 1421, 1377,
1279, 1234, 1165, 1111, 1080, 966, 907, 865, 785, 716, 635, 579
cm.sup.-1.
(2E,6E)-3-Chloro-4,6-dihydroxy-2-methyl-5-(8-hydroxy-3',7'-dimethyl-2',6'--
nonadi enyl)acetophenone (compound 286-9-OH)
[0261] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.58 (1H, s,
Ar--OH), 6.40 (1H, s, Ar--OH), 5.31 (1H. t, J=6.9 Hz, CH.dbd.C),
5.22 (1H. t, J=7.0 Hz, CH.dbd.C), 4.17 (1H, m, CHOH), 3.41 (2H, d,
J=7.0 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.58 (3H, s,
CH.sub.3C.dbd.O), 2.17-2.08 (2H, m, CH.sub.2), 2.07-2.02 (2H, m,
CH.sub.2), 1.78 (3H, s, CH.sub.3), 1.59 (3H, s, CH.sub.3), 1.49
(1H, br, OH), 1.20 {3H, d, J=6.6 Hz, CH(OH)CH.sub.3}. IR (KBr)
3345, 2972, 2920, 1596, 1410, 1377, 1361, 1287, 1261, 1209, 1159,
1099, 1078, 1049, 986, 949, 922, 885, 862, 843, 772, 604
cm.sup.-1.
14. Compounds 273-12 and 271-12
[0262] [Formula 14]
##STR00023##
3-Chloro-4,6-dihydroxy-2-methyl-5-[(2E,6E,8E)-3,7,11,11-tetramethyl-10-ox-
o-2,6,8-dodecatrienyl]benzaldehyde (compound 273-12)
[0263] To a solution of HMDS (0.8 ml, 3.8 mmol) in THF (20 ml),
BuLi (1.58 M in hexane, 2.4 ml, 3.8 mmol) was added dropwise at
-50.degree. C. and stirred for 10 minutes. To this mixture,
pinacolone (0.44 ml, 3.5 mmol) was added and stirred for 2 hours
while elevating the temperature to -20.degree. C. After the
reaction mixture was cooled to -80.degree. C., a solution of
compound 31 (0.625 g, 3.184 mmol) in THF (5 ml) was added dropwise
thereto and stirred at the same temperature for 1 hour and then
stirred for 15 hours while returning to room temperature. After the
reaction mixture was diluted with H.sub.2O to separate and collect
the organic layer, the aqueous layer was extracted twice with
Et.sub.2O. The combined organic layers were washed with sat. aq.
NaCl and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=7:1) to give the corresponding
.alpha.,.beta.-unsaturated ketone (compound 43) (0.333 g, 36%).
[0264] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.31 (1H, d,
J=15.4 Hz, CH.dbd.CHC.dbd.O), 6.47 (1H, d, J=15.4 Hz,
CH.dbd.CHC.dbd.O), 5.92 (1H, t, J=7.0 Hz, AcOCH.sub.2CH.dbd.C),
5.36 (1H, t, J=6.6 Hz, CH.dbd.C(CH.sub.3)CH.dbd.CH), 4.59 (2H, d,
J=7.0 Hz, AcOCH.sub.2CH.dbd.C), 2.38-2.32 (2H, m, CH.sub.2),
2.17-2.13 (2H, m, CH.sub.2), 2.06 (3H, s, CH.sub.3C.dbd.O), 1.81
(3H, s, CH.sub.3), 1.68 (3H, s, CH.sub.3), 1.18 (9H, s,
C(CH3).sub.3).
[0265] To a solution of compound 43 (0.333 g, 1.14 mmol) in a
mixture of MeOH (18 ml)/CHCl.sub.3 (2 ml), guanidine hydrochloride
(0.120 g, 1.26 mmol) and NaOMe (0.015 g, 0.28 mmol) were added at
room temperature and stirred for 6 hours. After the solvent was
distilled off, the residue was extracted with EtOAc. This organic
layer was washed with sat. aq. NaCl and then dried over
Na.sub.2SO.sub.4. The solvent was distilled off and the residue was
purified by silica gel column chromatography (hexane:EtOAc=7:1) to
give the corresponding primary alcohol 44 (0.218 g, 76%).
[0266] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.31 (1H, d,
J=15.4 Hz, CH.dbd.CHC.dbd.O), 6.47 (1H, d, J=15.4 Hz,
CH.dbd.CHC.dbd.O), 5.93 (1H, t, J=7.3 Hz, HOCH.sub.2CH.dbd.C), 5.43
(1H, t, J=6.8 Hz, CH.dbd.C(CH.sub.3)CH.dbd.CH), 4.16 (2H, d, J=7.0
Hz, HOCH.sub.2CH.dbd.C), 2.38-2.32 (2H, m, CH.sub.2), 2.15-2.11
(2H, m, CH.sub.2), 1.81 (3H, s, CH.sub.3), 1.69 (3H, s, CH.sub.3),
1.18 (9H, s, C(CH.sub.3).sub.3).
[0267] To a solution of compound 44 (0.218 g, 0.871 mmol) in
CHCl.sub.3 (10 ml), CBr.sub.4 (0.647 mmol, 1.95 mmol) and
(CsH.sub.17).sub.3P (0.86 ml, 1.93 mmol) were added at 0.degree. C.
and stirred for 2 hours. After the solvent was distilled off, the
residue was subjected to silica gel column chromatography
(hexane:EtOAc=2:1) to give a bromide (compound 45).
[0268] The whole product was dissolved in MeOH (2.1 ml) and added
at 0.degree. C. to a solution of compound 112 (0.190 g, 1.02 mmol)
in KOH (1 M in MeOH, 1.4 ml, 1.4 mmol). CaCl.sub.2.2H.sub.2O (0.107
g, 0.73 mmol) was further added and the mixture was stirred for 20
hours while returning to room temperature. After the reaction
mixture was filtered, the filtrate was diluted with EtOAc and
washed with 0.1 M aq. KOH and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was subjected to silica gel column chromatography
(hexane:EtOAc=3:1). The solvent was distilled off and the resulting
crude crystals were purified by recrystallization
(hexane:EtOAc=10:1) to give the desired product. The mother liquor
was concentrated, and the residue was purified by silica gel column
chromatography (hexane:EtOAc=3:1) to further give the desired
product (70 mg in total, 19% from compound 44).
[0269] Mp. 108-110.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.14 (1H, s, CHO), 7.23 {1H, d,
J=15.4 Hz, CH.dbd.CHC(O)}, 6.43 (1H, d, J=15.4 Hz, CH.dbd.CHC(O)),
6.40 (1H, s, Ar--OH), 5.37 (1H. t, J=7.0 Hz, CH.dbd.C), 5.21 (1H.
t, J=6.6 Hz, CH.dbd.C), 3.39 (2H, d, J=7.0 Hz, Ar--CH.sub.2), 2.61
(3H, s, Ar--CH.sub.3), 2.30 (2H, m, CH.sub.2), 2.08 (2H, m,
CH.sub.2), 1.79 (3H, s, CH.sub.3), 1.77 (3H, s, CH.sub.3), 1.17
(9H, s, C(CH.sub.3).sub.3). IR (KBr) 3194, 2964, 2916, 1672, 1599,
1460, 1421, 1394, 1369, 1275, 1236, 1205, 1165, 1115, 1074, 980,
910, 806, 764, 715, 631, 586 cm.sup.-1.
3-Chloro-4,6-dihydroxy-2-methyl-5-[(2E,6E)-(8-methoxv-3,7,11,11-tetramethy-
l-10-oxo-2,6-dodecadienyl)benzaldehyde (compound 271-12)
[0270] To a solution of HMDS (1.6 ml, 7.6 mmol) in THF (25 ml),
BuLi (1.58 M in hexane, 5.0 ml, 7.9 mmol) was added dropwise at
-50.degree. C. and stirred for 15 minutes. To this mixture,
pinacolone (0.96 ml, 7.7 mmol) was added and stirred for 1 hour
while elevating the temperature to -20.degree. C. After the
reaction mixture was cooled to -80.degree. C., a solution of
compound 31 (1.069 g, 5.084 mmol) in THF (10 ml) was added dropwise
thereto and stirred for 6 hours while elevating the temperature to
-50.degree. C. After the reaction mixture was diluted with H.sub.2O
to separate and collect the organic layer, the aqueous layer was
extracted twice with EtOAc. The combined organic layers were washed
with saturated aqueous sodium chloride and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=3:1)
to give the corresponding aldol product (1.047 g, 66%).
[0271] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.44 (1H, t, J=6.4
Hz, AcOCH.sub.2CH.dbd.C), 5.34 (1H, t, J=7.1 Hz,
CH.dbd.C(CH.sub.3)CH(OH)), 4.59 (2H, d, J=7.3 Hz,
AcOCH.sub.2CH.dbd.C), 4.42 (1H, t, J=5.9 Hz, CH(OH)), 3.22 (1H, br,
CH(OH)), 2.68 (2H, d, J=6.0 Hz, CH.sub.2C.dbd.O), 2.18-2.12 (2H, m,
CH.sub.2), 2.11-2.07 (2H, m, CH.sub.2), 2.06 (3H, s,
CH.sub.3C.dbd.O), 1.71 (3H, s, CH.sub.3), 1.64 (3H, s, CH.sub.3),
1.15 (9H, s, C(CH.sub.3).sub.3).
[0272] To a solution of the resulting aldol adduct (0.504 g, 1.624
mmol) in MeCN (5 ml), Mel (1.5 ml, 24 mmol) and Ag.sub.2O (0.609 g,
2.63 mmol) were added at room temperature under an Ar atmosphere
and refluxed for 1 day. After returning to room temperature, the
reaction mixture was diluted with EtOAc and then filtered. The
filtrate was washed with water, and the organic layer was dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography
(hexane:EtOAc=4:1) to give the corresponding methyl ether 46 (0.258
g, 49%).
[0273] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.33 (1H, t, J=6.3
Hz, CH.dbd.C), 5.29 (1H, t, J=7.0 Hz, CH.dbd.C), 4.51 (2H, d, J=7.3
Hz, AcOCH.sub.2CH.dbd.C), 3.97 (1H, dd, J=4.4, 8.0 Hz,
CHOCH.sub.3), 3.07 (3H, s, OCH.sub.3), 2.80 (1H, d, J=8.0, 16.9 Hz,
CH.sub.2C.dbd.O), 2.33 (1H, d, J=4.4, 16.9 Hz, CH.sub.2C.dbd.O),
2.16-2.01 (4H, m, CH.sub.2CH.sub.2), 1.99 (3H, s, CH.sub.3C.dbd.O),
1.63 (3H, s, CH.sub.3), 1.48 (3H, s, CH.sub.3), 1.05 (9H, s,
C(CH.sub.3).sub.3).
[0274] It should be noted that retro-aldol occurred as a side
reaction and thereby aldehyde 31 was collected.
[0275] To a solution of compound 46 (0.306 g, 0.943 mmol) in MeOH
(4.5 ml)/CHCl.sub.3 (0.5 ml), a guanidine solution (which was
prepared from a solution of guanidine hydrochloride (0.103 g, 1.08
mmol) in MeOH (9.0 ml) by addition of CHCl.sub.3 (1.0 ml) and NaOMe
(12 mg, 0.23 mmol) and then stirring for 10 minutes) was added
dropwise at room temperature under an Ar stream and stirred for 6
hours. After the solvent was distilled off, the residue was diluted
with EtOAc and washed with saturated aqueous sodium chloride, and
then dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the residue was subjected to silica gel column chromatography
(hexane:EtOAc=2:1) to give a mixture (213 mg) of primary alcohol 47
and compound 44 free from the methoxy group, which was used for the
subsequent reaction without further purification.
[0276] Namely, the whole mixture was dissolved in Et.sub.2O (20 ml)
and cooled to 0.degree. C., followed by addition of CBr.sub.4 (563
mg, 1.70 mmol) and (C.sub.8H.sub.17).sub.3P (0.75 ml, 1.7 mmol) and
stirring at the same temperature for 2 hours. The reaction mixture
was diluted with H.sub.2O and then extracted twice with Et.sub.2O.
The combined organic layers were washed with saturated aqueous
sodium chloride and dried over Na.sub.2SO.sub.4. The residue was
subjected to silica gel column chromatography (hexane:EtOAc=2:1) to
give a fraction containing bromides (compound 48 and compound
45).
[0277] Compound 112 (387 mg, 2.07 mmol) was mixed with KOH (1.0 M
in MeOH, 3.2 ml, 3.2 mmol) and cooled to -10.degree. C. To this
mixture, CaCl.sub.2 2H.sub.2O (221 mg, 1.50 mmol) and a solution of
the above bromide mixture in MeOH (5 ml) were added and stirred at
the same temperature for 1 day. After the reaction mixture was
diluted with EtOAc and 0.1 M aq. KOH to separate and collect the
organic layer, the aqueous layer was extracted with EtOAc. The
combined organic layers were washed with saturated aqueous sodium
chloride and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane/EtOAc=4:1) and PTLC (hexane/EtOAc=7:1) to
give the desired product (compound 271-12) and a by-product
(compound 273-12) in amounts of 10 mg (2% from compound 46) and 12
mg (3% from compound 46), respectively.
[0278] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.69 (1H, s,
Ar--OH), 10.14 (1H, s, CHO), 6.56 (1H, s, Ar--OH), 5.37 (1H. t,
J=6.6 Hz, CH.dbd.C), 5.23 (1H. t, J=7.0 Hz, CH.dbd.C), 3.99 (1H,
dd, J=4.4, 8.1 Hz, C(O)CH.sub.2CHOMe), 3.39 (2H, d, J=7.0 Hz,
Ar--CH.sub.2), 3.08 (3H, s, OCH.sub.3), 2.85 (1H, dd, J=4.4, 16.6
Hz, C(O)CH.sub.2CHOMe), 2.61 (3H, s, Ar--CH.sub.3), 2.39 (1H, dd,
J=8.1, 16.6 Hz, C(O)CH.sub.2CHOMe), 2.19-2.08 (2H, m, CH.sub.2),
2.05-2.01 (2H, m, CH.sub.2), 1.78 (3H, s, CH.sub.3), 1.52 (3H, s,
CH.sub.3), 1.11 (9H, s, C(CH.sub.3).sub.3).
15. Compounds 234-12-OPiv, 175-12-OPiv and 235-12-Opiv
[0279] [Formula 15]
##STR00024##
(2E,6E)-8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-2,6-dimethyl-2-
,6-octadienyl pivalate (compound 234-12-OPiv)
[0280] To a solution of geranyl acetate (compound 29, 1.0 ml, 4.7
mmol) in EtOH (20 ml), SeO.sub.2 (602 mg, 5.43 mmol) was added at
room temperature and refluxed for 1 hour. After returning to room
temperature, the reaction mixture was filtered through celite. The
filtrate was concentrated and mixed with EtOH (20 ml), followed by
cooling to 0.degree. C. To this mixture, NaBH.sub.4 (58 mg, 1.5
mmol) was added and stirred for 1 hour. After addition of 2 M aq.
HCl (2 ml), the reaction mixture was stirred for 5 minutes and then
poured into H.sub.2O (30 ml). After extraction with EtOAc, the
combined organic layers were washed with sat. aq. NaCl and dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was subjected to silica gel column chromatography
(hexane:EtOAc=2:1) to give a primary alcohol (compound 30) as a
crude product (1.517 g).
[0281] To this crude product, CHCl.sub.3 (10 ml) was added and
cooled to 0.degree. C., followed by addition of Et.sub.3N (0.5 ml,
3.6 mmol), DMAP (18 mg, 0.15 mmol) and Piv-Cl (0.46 ml, 3.8 mmol)
in this order. The mixture was stirred for 16 hours while returning
to room temperature. After addition of H.sub.2O (20 ml), the
reaction mixture was extracted with EtOAc, and the combined organic
layers were washed sequentially with sat. aq. NH.sub.4Cl, sat. aq.
NaHCO.sub.3 and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=4:1)
to give diester 49 (389 mg, 28% for 2 steps).
[0282] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.41 (1H, t, J=7.0
Hz, CH.dbd.C), 5.35 (1H, t, J=7.1 Hz, CH.dbd.C), 4.59 (2H, d, J=7.0
Hz, AcOCH.sub.2), 4.44 (2H, s, CH.sub.2OPiv), 2.21-2.15 (2H, m,
CH.sub.2), 2.11-2.07 (2H, m, CH.sub.2), 1.71 (3H, s, CH.sub.3),
1.64 (3H, s, CH.sub.3), 1.20 (9H, s, C(CH.sub.3).sub.3).
[0283] To a solution of diester 49 (411 mg, 1.39 mmol) in a mixture
of MeOH (4.5 ml)/CHCl.sub.3 (0.5 ml), a guanidine solution (which
was prepared from a solution of guanidine hydrochloride (0.146 g,
1.528 mmol) in MeOH (13.5 ml) by addition of CHCl.sub.3 (1.5 ml)
and NaOMe (17 mg, 0.32 mmol) and then stirring for 10 minutes) was
added dropwise at room temperature under an Ar stream and stirred
for 3 hours. After the solvent was distilled off, the residue was
diluted with EtOAc and washed sequentially with saturated aqueous
NH.sub.4Cl and saturated aqueous sodium chloride, and then dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography
(hexane:EtOAc=3:1.fwdarw.2:1) to give primary alcohol 50 (316 mg,
90%).
[0284] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.47-5.34 (2H, m,
2.times.CH.dbd.C), 4.44 (2H, s, CH.sub.2OPiv), 4.15 (2H, d, J=6.6
Hz, CH.sub.2OH), 2.23-2.13 (2H, m, CH.sub.2), 2.11-2.03 (2H, m,
CH.sub.2), 1.67 (3H, s, CH.sub.3), 1.64 (3H, s, CH.sub.3), 1.42
(1H, br, CH.sub.2OH), 1.21 (9H, s, C(CH.sub.3).sub.3).
[0285] To a solution of primary alcohol 50 (316 mg, 1.24 mmol) in
Et.sub.2O (10 ml), CBr.sub.4 (856 mg, 2.58 mmol) and
(C.sub.8H.sub.17).sub.3P (1.1 ml, 2.5 mmol) were added at 0.degree.
C. under an Ar stream and stirred at the same temperature for 40
minutes. After the solvent was distilled off, the residue was
subjected to silica gel column chromatography (hexane:EtOAc=10:1)
to give bromide 51.
[0286] Compound 112 (928 mg, 4.97 mmol) was mixed with KOH (0.99 M
in MeOH, 7.0 ml, 6.9 mmol) and cooled to 0.degree. C. To this
mixture, CaCl.sub.2 2H.sub.2O (506 mg, 3.44 mmol) in crushed state
and a solution of compound 51 (crude, 1.055 g) in MeOH (10 ml) were
added and stirred at -5.degree. C. for 18 hours. After the solvent
was distilled off, the residue was diluted with EtOAc (30 ml) and
0.1 M aq. KOH (30 ml), and then filtered through celite. The
filtrate was extracted with EtOAc (2.times.20 ml), and the combined
organic layers were washed with saturated aqueous sodium chloride
(20 ml) and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane/EtOAc=5:1) and the resulting solids were
further purified by recrystallization (hexane) to give the desired
product 234-12-OPiv (213 mg, 41%).
[0287] Mp 60.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.54 (1H, s,
Ar--OH), 5.38 (1H. t, J=6.8 Hz, CH.dbd.C), 5.22 (1H. t, J=6.8 Hz,
CH.dbd.C), 4.40 (2H, s, CH.sub.2OPiv), 3.39 (2H, d, J=6.8 Hz,
Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.16-2.11 (2H, m,
CH.sub.2), 2.04-2.00 (2H, m, CH.sub.2), 1.78 (3H, s, CH.sub.3),
1.61 (3H, s, CH.sub.3), 1.20 {9H, s, C(CH.sub.3).sub.3}.
.sup.13C-NMR (100 MHz, CDCl.sub.3) .delta.193.3, 178.4, 162.2,
156.4, 137.7, 136.2, 130.3, 128.4, 121.2, 114.4, 113.6, 113.3,
69.9, 39.1, 38.9, 27.2, 26.1, 22.0, 16.1, 14.4, 13.8. IR (KBr)
3244, 2978, 2922, 1728, 1616, 1485, 1450, 1421, 1369, 1279, 1234,
1157, 1105, 1032, 959, 910, 876, 770, 718, 635, 604, 575, 536
cm.sup.-1. Anal. Found: C, 65.07; H, 7.32; Cl, 8.44%. Calcd for
C.sub.23H.sub.31ClO.sub.5: C, 65.32; H, 7.39; Cl, 8.38%.
(2E,6E)-8-(5-Acetyl-3-chloro-2,6-dihydroxy-4-methylphenyl)-2,6-dimethyl-2,-
6-octa dienyl pivalate (compound 175-12-OPiv)
[0288] Compound 111 was used as an aromatic ring starting material
and synthesis was conducted in the same manner to give the desired
product.
[0289] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.62 (1H, s,
Ar--OH), 6.31 (1H, s, Ar--OH), 5.38 (1H. t, J=6.8 Hz, CH.dbd.C),
5.23 (1H. t, J=6.2 Hz, CH.dbd.C), 4.39 (2H, s, CH.sub.2OPiv), 3.40
(2H, d, J=7.3 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3), 2.59
(3H, s, CH.sub.3C.dbd.O), 2.17-2.10 (2H, m, CH.sub.2), 2.06-1.98
(2H, m, CH.sub.2), 1.79 (3H, s, CH.sub.3), 1.60 (3H, s, CH.sub.3),
1.19 {9H, s, C(CH.sub.3).sub.3}. IR (KBr) 3412, 2978, 2922, 1728,
1610, 1464, 1416, 1360, 1279, 1157, 1094, 1036, 984, 951, 841, 768,
600 cm.sup.-1. HRMS (EI) Found: 436.2024. Calcd. for
C.sub.24H.sub.33ClO.sub.5: 436.2017.
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-2,6-dimethloctyl
pivalate (compound 235-12-OPiv)
[0290] The compound 234-12-OPiv was reduced in the same manner as
used in Scheme 1 to give the desired product.
[0291] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.61 (1H, s,
Ar--OH), 10.10 (1H, s, Ar--CHO), 6.50 (1H, d, J=12.1 Hz, Ar--OH),
3.98-3.93 (1H, m, CH.sub.2OPiv), 3.87-3.82 (1H, m, CH.sub.2OPiv),
2.66-2.59 (2H, m, Ar--CH.sub.2), 2.56 (3H, s, Ar--CH.sub.3),
1.80-1.70 (2H, m, CH.sub.2), 1.53-1.41 (2H, m), 1.36-1.27 (4H, br,
CH.sub.2CH.sub.2), 1.23-1.17 (2H, m), 1.17 {9H, s,
C(CH.sub.3).sub.3}, 0.91 (3H, d, J=7.0 Hz, CH(CH.sub.3), 0.90 (3H,
d, J=7.0 Hz, CHCH.sub.3). .sup.13C-NMR (100 MHz, CDCl.sub.3)
.delta. 193.19, 178.75, 162.31, 156.22, 137.20, 115.6, 113.45,
113.86, 69.18, 38.83, 36.79, 35.21, 33.74, 32.77, 32.61, 27.19,
23.89, 20.43, 19.61, 16.99, 14.39. IR (neat) 3395, 2961, 2932,
2872, 1724, 1717, 1634, 1462, 1422, 1375, 1290, 1248, 1167, 1034,
980, 800, 710, 592 cm.sup.-1. HRMS (EI) Found: 426.2144. Calcd. for
C.sub.23H.sub.35ClO.sub.5: 426.2173.
16. Compounds 264-11-OPiv and 265-11-Opiv
[0292] [Formula 16]
##STR00025##
(5E)-7-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-5-methl-5-hept
enyl pivalate (compound 264-11-OPiv)
[0293] To a solution of 6-valerolactone (compound 52, 3.0 ml, 32
mmol) in THF (50 ml), MeLi (1.04 M in Et.sub.2O, 33 ml, 34 mmol)
was added dropwise at -80.degree. C. under an Ar atmosphere and
stirred for 4 hours while elevating the temperature to -65.degree.
C. The reaction was stopped by addition of H.sub.2O, followed by
stirring at room temperature for 5 minutes. The organic layer was
then separated and collected, and the aqueous layer was extracted
twice with EtOAc. The combined organic layers were washed with
saturated aqueous sodium chloride and dried over Na.sub.2SO.sub.4.
After the solvent was distilled off, the residue was purified by
silica gel column chromatography (EtOAc) to give
7-hydroxy-2-hexanone (2.545 g, 68%).
[0294] To a solution of this ketone (2.545 g, 21.91 mmol) in
CHCl.sub.3 (70 ml), Et.sub.3N (6.1 ml, 44 mmol), DMAP (cat. amount)
and TBS--Cl (50% in toluene, 4.5 ml, 27 mmol) were added at
0.degree. C. and stirred for 13 hours while returning to room
temperature. The reaction mixture was diluted with H.sub.2O and
stirred for 5 minutes. The organic layer was then separated and
collected, and the aqueous layer was extracted twice with EtOAc.
The combined organic layers were washed with saturated aqueous
NH.sub.4Cl and saturated aqueous sodium chloride, and then dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography
(hexane:EtOAc=5:1) to give the corresponding silyl ether 53 (4.385
g, 87%).
[0295] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 3.57 (2H, t, J=6.6
Hz, CH.sub.2OTBS), 2.41 (2H, t, J=7.3 Hz, C(O)CH.sub.2CH.sub.2),
2.09 (3H, s, CH.sub.3C.dbd.O), 1.62-1.55 (2H, m, CH.sub.2),
1.51-1.43 (2H, m, CH.sub.2), 0.85 (9H, s, C(CH.sub.3).sub.3), 0.01
(6H, s, Si(CH.sub.3).sub.2).
[0296] To a suspension of NaH (60% in oil, 146 mg, 3.65 mmol) in
THF (20 ml), triethyl phosphonoacetate (0.7 ml, 3.2 mmol) was added
at 0.degree. C. under an Ar atmosphere and stirred for 1.5 hours
while returning to room temperature. The mixture was cooled to
-65.degree. C., and a solution of compound 53 (676 mg, 2.93 mmol)
in THF (10 ml) was added dropwise thereto and stirred for 16 hours
while returning to room temperature. The reaction was stopped by
addition of H.sub.2O, followed by stirring for 5 minutes. The
organic layer was then separated and collected, and the aqueous
layer was extracted twice with Et.sub.2O. The combined organic
layers were washed with saturated aqueous NH.sub.4Cl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography
(hexane:EtOAc=10:1) to give the corresponding unsaturated ester as
an (E)-isomer and as a mixture of (E)- and (Z)-isomers (total 0.336
g, 38%).
[0297] (E)-isomer: .sup.1H-NMR (400 MHz, CDCl.sub.3) 85.66 (1H, d,
J=1.1 Hz, C.dbd.CHCO.sub.2Et), 4.14 (2H, q, J=7.3 Hz,
CO.sub.2CH.sub.2CH.sub.3), 3.61 (2H, t, J=5.9 Hz, CH.sub.2OTBS),
2.17-2.13 (2H, m, CH.dbd.C(CH.sub.3)CH.sub.2), 2.15 (3H, d, J=1.1
Hz, CH.dbd.C(CH.sub.3)CH.sub.2), 1.55-1.51 (4H, m,
(CH.sub.2).sub.2), 1.28 (3H, t, J=7.3 Hz,
CO.sub.2CH.sub.2CH.sub.3), 0.89 (9H, s, C(CH.sub.3).sub.3), 0.05
(6H, s, Si(CH.sub.3).sub.2).
[0298] To a solution of the (E)-isomer of the unsaturated ester
(1.441 g, 4.795 mmol) in toluene (50 ml), DIBAL (1.0 M in hexane,
25 ml, 25 mmol) was added dropwise at -80.degree. C. under an Ar
atmosphere and stirred at -65.degree. C. for 2.5 hours. To the
reaction mixture, EtOAc was added slowly and then H.sub.2O and 2 M
aq. HCl were further added, followed by stirring for 15 minutes
while returning to room temperature. After this mixture was
filtered through celite, the organic layer of the filtrate was
separated and collected, and the aqueous layer was further
extracted twice with EtOAc. The combined organic layers were washed
with sat. aq. NaHCO.sub.3 and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was loaded onto silica gel column chromatography (hexane:EtOAc=1:1)
to give the corresponding allyl alcohol (1.458 g) as a crude
product.
[0299] The whole product was dissolved in pyridine (12 ml), and
Ac.sub.2O (6 ml) was added thereto at room temperature and stirred
for 5 hours. The reaction mixture was diluted with EtOAc, to which
H.sub.2O and 2 M aq. HCl were then added and stirred for 5 minutes.
After the organic layer was separated and collected, the aqueous
layer was extracted twice with EtOAc, and the combined organic
layers were washed with sat. aq. NaHCO.sub.3 and sat. aq. NaCl, and
then dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the residue was purified by silica gel column chromatography
(hexane:EtOAc=7:1) to give the corresponding acetate 54 (1.259 g,
87% for 2 steps).
[0300] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.34 (1H, dt,
J=1.1, 7.0 Hz, C.dbd.CH), 4.57 (2H, d, J=7.0 Hz, CH.sub.2OAc), 3.61
(2H, t, J=6.0 Hz, CH.sub.2OTBS), 2.13-2.05 (5H, m, CH.sub.3OC.dbd.O
& CH.dbd.C(CH.sub.3)CH.sub.2), 1.69 (3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.53-1.43 (4H, m, CH.sub.2CH.sub.2),
0.89 (9H, s, C(CH.sub.3).sub.3), 0.05 (6H, s,
Si(CH.sub.3).sub.2).
[0301] To a solution of compound 54 (1.26 g, 4.19 mmol) in THF (30
ml), TBAF (1.0 M in THF, 5.0 ml, 5.0 mmol) was added at 0.degree.
C. and stirred for 6 hours while returning to room temperature.
After TBAF (0.5 ml, 0.5 mmol) were further added and stirred for 2
hours, the reaction mixture was diluted with H.sub.2O to stop the
reaction. This mixture was extracted with EtOAc, and the combined
organic layers were washed with sat. aq. NaHCO.sub.3 and sat. aq.
NaCl, and then dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=2:1.fwdarw.1:1) to give the
corresponding primary alcohol (0.741 g, 95%).
[0302] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.35 (1H, dt,
J=1.1, 7.0 Hz, C.dbd.CH), 4.58 (2H, d, J=7.0 Hz, CH.sub.2Ac), 3.65
(2H, t, J=6.2 Hz, CH.sub.2OH), 2.08-2.05 (5H, m, CH.sub.3OC.dbd.O
& CH.dbd.C(CH.sub.3)CH.sub.2), 1.70 (3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.59-1.46 (4H, m,
CH.sub.2CH.sub.2).
[0303] To a solution of this primary alcohol (0.741 g, 3.98 mmol)
in CHCl.sub.3 (30 ml), Et.sub.3N (0.65 ml, 4.7 mmol), DMAP (cat.
amount) and Piv-Cl (0.55 ml, 4.5 mmol) were added at 0.degree. C.
and stirred at room temperature for 16 hours. After the reaction
mixture was diluted with H.sub.2O and stirred for 5 minutes, the
organic layer was separated and collected, and the aqueous layer
was extracted twice with EtOAc. The combined organic layers were
washed with saturated aqueous NaHCO.sub.3 and saturated aqueous
sodium chloride, and then dried over Na.sub.2SO.sub.4. After the
solvent was distilled off, the residue was purified by silica gel
column chromatography (hexane:EtOAc=5:1.fwdarw.1:1) to give
pivalate 55 (0.471 g, 44%).
[0304] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.35 (1H, t, J=7.1
Hz, C.dbd.CH), 4.58 (2H, d, J=7.0 Hz, CH.sub.2OAc), 4.06 (2H, t,
J=6.4 Hz, CH.sub.2OPiv), 2.09-2.03 (5H, m, CH.sub.3OC.dbd.O &
CH.dbd.C(CH.sub.3)CH.sub.2), 1.69 (3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.63-1.57 (2H, m, CH.sub.2), 1.53-1.46
(2H, m, CH.sub.2), 1.20 (9H, s, C(CH.sub.3).sub.3).
[0305] It should be noted that the unreacted starting material was
collected (0.392 g, 53%).
[0306] To a mixed solvent of MeOH (13.5 ml) and CHCl.sub.3 (1.5
ml), guanidine hydrochloride (0.184 g, 1.926 mmol) and NaOMe (0.024
g, 0.44 mmol) were added at room temperature under an Ar atmosphere
and stirred for 10 minutes. This solution was added dropwise to a
solution of compound 55 (0.471 g, 1.74 mmol) in a mixture of MeOH
(4.5 ml) and CHCl.sub.3 (0.5 ml), followed by stirring at room
temperature for 5 hours. After the solvent was distilled off, the
residue was diluted with EtOAc and H.sub.2O to separate and collect
the organic layer. The aqueous layer was further extracted with
EtOAc, and the combined organic layers were washed with sat. aq.
NaHCO.sub.3 and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=2:1)
to give the corresponding allyl alcohol (0.376 g, 95%).
[0307] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 5.42 (1H, ddt,
J=1.5, 2.6, 7.0 Hz, C.dbd.CH), 4.16 (2H, d, J=6.6 Hz, CH.sub.2OH),
4.06 (2H, t, J=6.2 Hz, CH.sub.2OPiv), 2.05 (2H, t, J=7.3 Hz,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.67 (3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.63-1.58 (2H, m, CH.sub.2), 1.53-1.46
(2H, m, CH.sub.2), 1.28 (1H, br, OH), 1.19 (9H, s,
C(CH.sub.3).sub.3).
[0308] To a solution of this allyl alcohol (0.376 g, 1.65 mmol) in
CHCl.sub.3 (20 ml), Ph.sub.3P (0.952 g, 3.63 mmol) and CBr.sub.4
(1.205 g, 3.633 mmol) were added at 0.degree. C. and stirred for 1
hour. After the solvent was distilled off, the residue was
subjected to silica gel column chromatography (hexane:EtOAc=2:1) to
give the corresponding bromide. The resulting product was used for
the subsequent reaction without further purification.
[0309] Namely, to a solution of compound 112 (1.358 g, 7.278 mmol)
in MeOH (10 ml), KOH (1.0 M in MeOH, 11.0 ml, 11.0 mmol) was added
and cooled to 0.degree. C. To this mixture, the bromide (crude,
0.736 g) in MeOH (10 ml) and CaCl.sub.2.2H.sub.2O (0.749 g, 5.09
mmol) were added and stirred at room temperature for 1 day. After
the reaction mixture was filtered through celite, the filtrate was
concentrated and the residue was diluted with EtOAc and 0.1 M aq.
KOH. The organic layer was separated and collected, and the aqueous
layer was extracted twice with Et.sub.2O and once with EtOAc. The
combined organic layers were washed with sat. aq. NaCl and dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography
(hexane:EtOAc=4:1) and further recrystallized twice from hexane to
give the desired product (0.188 g, 28%).
[0310] Mp 74-75.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.42 (1H, s,
Ar--OH), 5.22 (1H. dt, J=1.5, 7.3 Hz, CH.dbd.C), 4.03 (2H, t, J=6.4
Hz, CH.sub.2OPiv), 3.40 (2H, d, J=7.3 Hz, Ar--CH.sub.2), 2.61 (3H,
s, Ar--CH.sub.3), 2.00 (2H, t, J=7.5 Hz,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.77 (3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.58-1.53 (2H, m, CH.sub.2), 1.49-1.43
(2H, m, CH.sub.2), 1.18 (9H, s, C(CH.sub.3).sub.3). IR (KBr) 3188,
2964, 2874, 1728, 1607, 1477, 1456, 1421, 1377, 1283, 1231, 1161,
1111, 1031, 910, 868, 770, 712, 631, 592 cm.sup.-1. Anal. Found: C,
63.53; H, 7.41; Cl, 8.72%. Calcd for C.sub.21H.sub.29ClO.sub.5: C,
63.55; H, 7.36; Cl, 8.93%.
[0311] It should be noted that the aqueous layer was acidified with
2 M hydrochloric acid and then extracted with EtOAc to thereby
collect the unreacted compound 112.
7-(3-Chloro-2,6-dihydroxy-5-formyl-4-methylphenyl)-5-methylheptyl
pivalate (compound 265-11-OPiv)
[0312] To a solution of the compound 264-11-OPiv (0.130 g, 0.328
mmol) in EtOAc (10 ml), Pd--C(cat. amount) was added at 0.degree.
C. and stirred for 5 hours under a H.sub.2 atmosphere. After Pd--C
was filtered off, the solvent was distilled off and the residue was
purified by silica gel column chromatography (hexane:EtOAc=7:1) to
give the desired product (0.108 g, 83%).
[0313] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.35 (1H, br, Ar--OH), 4.05 (2H,
t, J=6.6 Hz, CH.sub.2OPiv), 2.70-2.63 (2H, m, Ar--CH.sub.2), 2.60
(3H, s, Ar--CH.sub.3), 1.64-1.57 (2H, m, CH.sub.2), 1.55-1.30 (5H,
m, CHCH.sub.3 & CH.sub.2CH.sub.2), 1.23-1.17 (2H, m, CH.sub.2),
1.19 (9H, s, C(CH.sub.3).sub.3), 0.95 (3H, d, J=6.2 Hz,
CH(CH.sub.3)CH.sub.2). IR (KBr) 3391, 2957, 2874, 1720, 1628, 1481,
1468, 1421, 1373, 1292, 1248, 1165, 1126, 1094, 1036, 972, 937,
802, 708, 631, 590, 523 cm.sup.-1.
[0314] HRMS (EI) Found: 398.1865. Calcd. for
C.sub.21H.sub.31ClO.sub.5: 398.1860.
17. Compounds 264-8, 265-8, (Z)-264-8, 268-8, 270-8 and 269-8
[0315] [Formula 17]
##STR00026##
(E)-3-Chloro-4,6-dihydroxy-2-methyl-5-(3-methyl-2-octenyl)benzaldehyde
(compound 264-8)
[0316] To a suspension of NaH (60% in oil, 0.511 g, 12.8 mmol) in
THF (20 ml), triethyl phosphonoacetate (2.4 ml, 11 mmol) was added
at 0.degree. C. and stirred for 1.5 hours while returning to room
temperature. This mixture was cooled to -65.degree. C., and
2-hetanone (compound 56, 1.3 ml, 9.3 mmol) was then added dropwise
thereto and stirred for 1 day while returning to room temperature.
The reaction was quenched by addition of H.sub.2O, followed by
stirring for 5 minutes. The organic layer was then separated and
collected, and the aqueous layer was extracted once with Et.sub.2O
and once with EtOAc. The combined organic layers were washed with
sat. aq. NH.sub.4Cl and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography
(hexane:EtOAc=30:1) to give unsaturated ester 57 as an (E)-isomer,
a (Z)-isomer and a mixture thereof (total 1.102 g, 64%).
[0317] (E)-isomer: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 5.66
(1H, dd, J=1.6, 2.4 Hz, C.dbd.CHCO.sub.2Et), 4.14 (2H, q, J=7.0 Hz,
CO.sub.2CH.sub.2CH.sub.3), 2.15-2.10 (5H, m,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.51-1.43 (2H, m,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 1.33-1.23 (7H, m,
CO.sub.2CH.sub.2CH.sub.3 &
CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 0.89 {3H, t, J=7.0 Hz,
(CH.sub.2).sub.4CH.sub.3}. (Z)-isomer: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 5.64 (1H, d, J=1.4 Hz, C.dbd.CHCO.sub.2Et),
4.14 (2H, q, J=7.3 Hz, CO.sub.2CH.sub.2CH.sub.3), 2.61 (2H, t,
J=7.8 Hz, CH.dbd.C(CH.sub.3)CH.sub.2), 1.88 (3H, d, J=1.4 Hz,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.50-1.42 {2H, m,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3}, 1.34-1.23 (7H, m,
CO.sub.2CH.sub.2CH.sub.3 &
CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 0.89 (3H, t, J=7.3 Hz,
(CH.sub.2).sub.4CH.sub.3).
[0318] To a solution of compound (E)-57 (1.030 g, 5.589 mmol) in
toluene (70 ml), DIBAL (1.0 M in hexane, 30 ml, 30 mmol) was added
dropwise at -85.degree. C. under an Ar atmosphere and stirred at
-65.degree. C. for 2 hours. To the reaction mixture, 1 M aq. HCl
was added slowly and stirred for 10 minutes while returning to room
temperature. The organic layer was then separated and collected,
followed by extraction twice with EtOAc. The combined organic
layers were washed with sat. aq. NaCl and dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=1:1)
to give allyl alcohol (E)-58 (0.738 g, 64%).
[0319] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.40 (1H, dt,
J=1.1, 7.0 Hz, CH.dbd.C), 4.15 (2H, d, J=7.0 Hz, CH.sub.2OH), 2.01
(2H, t, J=7.7 Hz, CH.dbd.C(CH.sub.3)CH.sub.2), 1.67 (3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.45-1.38 (2H, m,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 1.36-1.21 (5H, m,
CH.sub.2OH & CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 0.89
(3H, t, J=7.0 Hz, (CH.sub.2).sub.4CH.sub.3).
[0320] To a solution of allyl alcohol (E)-58 (0.738 g, 5.19 mmol)
in CHCl.sub.3 (30 ml), Ph.sub.3P (3.067 g, 11.69 mmol) and
CBr.sub.4 (3.788 g, 11.42 mmol) were added at 0.degree. C. and
stirred for 1 hour. The reaction mixture was diluted with H.sub.2O
to separate and collect the organic layer, followed by extraction
twice with EtOAc. The combined organic layers were washed with
saturated aqueous sodium chloride and dried over Na.sub.2SO.sub.4.
After the solvent was distilled off, the residue was purified by
silica gel column chromatography (hexane:EtOAc=4:1) to give the
corresponding bromide (1.20 g). The resulting product was used for
the subsequent reaction without further purification.
[0321] Namely, to a solution of compound 112 (2.121 g, 11.37 mmol)
in MeOH (4.0 ml), KOH (0.99 M in MeOH, 16.0 ml, 15.8 mmol) was
added and cooled to 0.degree. C. To this mixture,
CaCl.sub.2.2H.sub.2O (1.176 g, 7.999 mmol) and a solution of the
bromide (crude, 1.20 g) in MeOH (10 ml) were added and stirred at
room temperature for 15 hours. After the reaction mixture was
filtered through celite, the filtrate was concentrated and the
residue was diluted with EtOAc and then poured into 0.1 M aq. KOH.
The organic layer was separated and collected, and the aqueous
layer was extracted with Et.sub.2O and EtOAc. The combined organic
layers were washed with saturated aqueous sodium chloride and dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography
(hexane:EtOAc=2:1) and further recrystallized twice from a mixed
solvent of hexane and CHCl.sub.3 (5:1) to give the desired product
264-8 (0.371 g, 23%).
[0322] Mp 99-101.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.42 (1H, s,
Ar--OH), 5.21 (1H. tq, J=1.1, 7.0 Hz, CH.dbd.C), 3.40 (2H, d, J=7.0
Hz, Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 1.96 {2H, t, J=7.5
Hz, CH.dbd.C(CH.sub.3)CH.sub.2}, 1.78 {3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2}, 1.41-1.34 {2H, m,
CH.sub.2(CH.sub.2).sub.2CH.sub.2CH.sub.3}, 1.31-1.18 {4H, m,
CH.sub.2(CH.sub.2).sub.2CH.sub.2CH.sub.3}, 0.86 {3H, t, J=7.1 Hz,
CH.sub.2(CH.sub.2).sub.3CH.sub.3}. IR (KBr) 3341, 2922, 2860, 1620,
1525, 1464, 1421, 1373, 1330, 1279, 1234, 1165, 1111, 955, 907,
876, 787, 715, 625, 592, 561 cm.sup.-1. Anal. Found: C, 65.43; H,
7.44; Cl, 11.43%. Calcd for C.sub.17H.sub.23ClO.sub.3: C, 65.69; H,
7.46; Cl, 11.41%.
[0323] It should be noted that the aqueous layer was acidified with
2 M aq. HCl and then extracted with EtOAc to thereby collect the
unreacted compound 112.
3-Chloro-4,6-dihydroxy-2-methyl-5-(3-methyloctyl)benzaldehyde
(compound 265-8)
[0324] To a solution of the compound 264-8 (0.185 g, 0.595 mmol) in
EtOH (10 ml), Pd--C(cat. amount) was added at 0.degree. C. and
stirred under a H.sub.2 atmosphere at 0.degree. C. for 2 hours and
at room temperature for 3 hours. After Pd--C was filtered off, the
solvent was distilled off and the residue was purified by silica
gel column chromatography (hexane:EtOAc=12:1) and further
recrystallized twice from hexane to give the desired product 265-8
(0.071 g, 38%).
[0325] Mp 65-67.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.65 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.30 (1H, s,
Ar--OH), 2.69-2.64 (2H, m, Ar--CH.sub.2), 2.60 (3H, s,
Ar--CH.sub.3), 1.53-1.41 (2H, m, CH.sub.2), 1.38-1.20 {8H, m,
(CH.sub.2).sub.4}, 1.19-1.10 (1H, m, CHCH.sub.3), 0.95 {3H, d,
J=6.6 Hz, CH(CH.sub.3)CH.sub.2}, 0.88 {3H, t, J=7.0 Hz,
CH.sub.2(CH.sub.2).sub.3CH.sub.3}. IR (KBr) 3258, 2922, 2860, 1603,
1464, 1418, 1373, 1290, 1240, 1128, 924, 799, 764, 708, 631, 592,
530 cm.sup.-1. HRMS (EI) Found: 312.1479. Calcd for
C.sub.17H.sub.25ClO.sub.3: 312.1492.
(Z)-3-Chloro-4,6-dihydroxy-2-methyl-5-(3-methyl-2-octenyl)benzaldehyde
(compound (Z)-264-8)
[0326] The desired product was obtained in the same manner,
starting from compound (Z)-57.
[0327] Mp 157-158.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.42 (1H,
br, Ar--OH), 5.23 (1H. t, J=7.3 Hz, CH.dbd.C), 3.40 (2H, d, J=7.3
Hz, Ar--CH.sub.2), 2.60 (3H, s, Ar--CH.sub.3), 2.21 (2H, t, J=7.5
Hz, CH.dbd.C(CH.sub.3)CH.sub.2), 1.68 (3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2), 1.47-1.39 (2H, m,
CH.sub.2(CH.sub.2).sub.2CH.sub.2CH.sub.3), 1.37-1.30 (4H, m,
CH.sub.2(CH.sub.2).sub.2CH.sub.2CH.sub.3), 0.91 (3H, t, J=6.8 Hz,
CH.sub.2(CH.sub.2).sub.3CH.sub.3). IR (KBr) 3279, 2964, 2916, 2860,
1616, 1516, 1452, 1421, 1373, 1334, 1279, 1231, 1192, 1157, 1109,
959, 899, 868, 787, 718, 621, 592, 527 cm.sup.-1. HRMS (EI) Found:
310.1337. Calcd for C.sub.17H.sub.23ClO.sub.3: 310.1336.
(E/Z)-3-Chloro-4,6-dihydroxy-2-methyl-5-(3-methyl-2-octenyl)acetophenone
(compound 268-8)
[0328] The desired product was obtained in the same manner,
starting from the alcohol (compound 58, as an (E)/(Z) mixture).
[0329] (E): (Z)=5:1. Mp 42-46.degree. C. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 12.55 {1/6H, s, Ar--OH, (Z)}, 12.53 {5/6H, s,
Ar--OH, (E)}, 6.25 (1H, s, Ar--OH), 5.21 (1H. t, J=6.8 Hz,
CH.dbd.C), 3.41 (2H, d, J=6.8 Hz, Ar--CH.sub.2), 2.60 (3H, s,
Ar--CH.sub.3), 2.58 (3H, s, CH.sub.3C.dbd.O), 2.21 {1/3H, t, J=7.5
Hz, CH.dbd.C(CH.sub.3)CH.sub.2, (Z)}, 1.96 {5/3H, t, J=7.7 Hz,
CH.dbd.C(CH.sub.3)CH.sub.2, (E)}, 1.77 {5/2H, s,
CH.dbd.C(CH.sub.3)CH.sub.2, (E)}, 1.68 {1/2H, s,
CH.dbd.C(CH.sub.3)CH.sub.2, (Z)}, 1.41-1.18 {6H, m,
CH.sub.2(CH.sub.2).sub.3CH.sub.3}, 0.91 (1/2H, t, J=7.0 Hz,
CH.sub.2(CH.sub.2).sub.3CH.sub.3, (Z)), 0.86 {5/2H, t, J=7.1 Hz,
CH.sub.2(CH.sub.2).sub.3CH.sub.3, (E)}.
(E)-3-Chloro-6-hydroxy-2-methyl-(3-methyl-2-octenoxy)acetophenone
(compound 270-8)
[0330] This compound was obtained as a by-product of the compound
268-8.
[0331] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 6.38 (1H, s, Ar--H), 5.46 (1H. t, J=6.2 Hz, CH.dbd.C),
4.63 (2H, d, J=6.2 Hz, ArOCH.sub.2), 2.61 (3H, s, Ar--CH.sub.3),
2.57 (3H, s, CH.sub.3C.dbd.O), 2.06 {2H, t, J=7.5 Hz,
CH.dbd.C(CH.sub.3)CH.sub.2}, 1.73 {3H, s,
CH.dbd.C(CH.sub.3)CH.sub.2}, 1.43 {2H, m,
(CH.sub.2).sub.3CH.sub.2CH.sub.3}, 1.34-1.23 {4H, m,
CH.sub.2(CH.sub.2).sub.2CH.sub.2CH.sub.3}, 0.88 {3H, t, J=7.0 Hz,
CH.sub.2(CH.sub.2).sub.3CH.sub.3}. IR (KBr) 2978, 2916, 1607, 1460,
1408, 1360, 1273, 1249, 1202, 1094, 1040, 1011, 824, 752, 638, 625
cm.sup.-1.
3-Chloro-4,6-dihydroxy-2-methyl-5-(3-methyloctyl)acetophenone
(compound 269-8)
[0332] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 12.53 (1H, s,
Ar--OH), 6.08 (1H, s, Ar--OH), 2.64-2.56 (2H, m, Ar--CH.sub.2),
2.53 (3H, s, Ar--CH.sub.3), 2.51 (3H, s, CH.sub.3C.dbd.O),
1.48-1.35 (2H, m, CH.sub.2), 1.33-1.13 {8H, m, (CH.sub.2).sub.4},
1.12-1.03 (1H, m, CHCH.sub.3), 0.87 {3H, d, J=6.8 Hz,
CH(CH.sub.3)CH.sub.2}, 0.81 {3H, t, J=7.0 Hz,
CH.sub.2(CH.sub.2).sub.3CH.sub.3}. .sup.13C-NMR (100 MHz,
CDCl.sub.3) .delta. 204.58, 160.76, 153.88, 134.47, 117.14, 116.16,
113.86, 36.81, 35.57, 33.08, 32.85, 32.27, 26.64, 22.72, 21.25,
20.76, 19.61, 14.23. IR (KBr) 3391, 2922, 2860, 1610, 1468, 1404,
1356, 1269, 1192, 1119, 1092, 997, 951, 868, 785, 742, 603
cm.sup.-1. HRMS (EI) Found: 326.1659. Calcd. for
C.sub.18H.sub.27ClO.sub.3: 326.1649.
18. Compound 206-12-Opiv
[0333] [Formula 18]
##STR00027##
(E)-8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyyl)-6-octenyl
pivalate (compound 206-12-OPiv)
[0334] To a solution of 1,6-hexanediol (compound 59, 3.369 g, 28.51
mmol) in DMF (30 ml), imidazole (1.724 g, 25.32 mmol), DMAP (cat.
amount) and TBS--Cl (50% in toluene, 3.50 ml, 10.1 mmol) were added
at 0.degree. C. and stirred for 15 hours while returning to room
temperature. After the reaction mixture was diluted with H.sub.2O
to separate and collect the organic layer, the aqueous layer was
extracted twice with Et.sub.2O. The combined organic layers were
washed with sat. aq. NaHCO.sub.3 and sat. aq. NaCl, and then dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography
(hexane:EtOAc=3:1) to give the corresponding silyl ether (1.671 g,
71%).
[0335] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 3.66-3.59 (4H, m,
CH.sub.2OH & CH.sub.2OTBS), 1.60-1.51 (4H, m,
CH.sub.2CH.sub.2OH & CH.sub.2CH.sub.2OTBS), 1.43-1.36 (5H, m,
CH.sub.2CH.sub.2 & OH), 0.89 {9H, s, C(CH.sub.3).sub.3}, 0.05
{6H, s, Si(CH.sub.3).sub.2}.
[0336] To a solution of oxalyl chloride (1.25 ml, 14.6 mmol) in
CHCl.sub.3 (50 ml), DMSO (2.2 ml, 31 mmol) was added dropwise at
-60.degree. C. and stirred for 10 minutes. To this mixture, a
solution of the above alcohol (1.671 g, 7.189 mmol) in CHCl.sub.3
(15 ml) was added dropwise and stirred at the same temperature for
2 hours. Et.sub.3N (6.0 ml, 43 mmol) was further added dropwise and
stirred at the same temperature for 1 hour, followed addition of
H.sub.2O to stop the reaction. After the organic layer was
separated and collected, the aqueous layer was extracted twice with
Et.sub.2O, and the combined organic layers were washed with sat.
aq. NH.sub.4Cl and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=4:1)
to give aldehyde 60 (1.400 g, 85%).
[0337] To a solution of ethyl diethylphosphonoacetate (1.8 ml, 9.1
mmol) in THF (50 ml), MeLi (1.60 M in Et.sub.2O, 6.5 ml, 10.4 mmol)
was added dropwise at -15.degree. C. and stirred for 1 hour while
returning to room temperature. The mixture was cooled again to
-15.degree. C., and a solution of compound 60 (1.460 g, 6.336 mmol)
in THF (10 ml) was added dropwise thereto and then stirred for 20
hours while returning to room temperature. After the reaction
mixture was diluted with H.sub.2O to separate and collect the
organic layer, the aqueous layer was extracted twice with EtOAc.
The combined organic layers were washed with sat. aq. NaHCO.sub.3
and sat. aq. NaCl, and then dried over Na.sub.2SO.sub.4. After the
solvent was distilled off, the residue was purified by silica gel
column chromatography (hexane:EtOAc=15:1) to give the corresponding
unsaturated ester (1.305 g, 69%).
[0338] To a solution of this unsaturated ester (1.305 g, 4.343
mmol) in toluene (50 ml), DIBAL (1.0 M in hexane, 22 ml, 22 mmol)
was added dropwise at -80.degree. C. and stirred for 3 hours while
elevating the temperature to -65.degree. C. After the reaction
mixture was diluted with H.sub.2O to separate and collect the
organic layer, the aqueous layer was extracted with Et.sub.2O. The
combined organic layers were washed with 2 M aq. HCl and sat. aq.
NaCl, and then dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was subjected to silica gel column
chromatography (hexane:EtOAc=3:1) to give the corresponding allyl
alcohol. The resulting product was used for the subsequent reaction
without further purification.
[0339] Namely, the whole allyl alcohol thus obtained was dissolved
in pyridine (10 ml), and Ac.sub.2O (5 ml) was added thereto at room
temperature and stirred for 16 hours. The reaction mixture was
diluted with EtOAc and then poured into H.sub.2O. After the organic
layer was separated and collected, the aqueous layer was extracted
with EtOAc, and the combined organic layers were washed twice with
2 M aq. HCl and once with each of sat. aq. NaCO.sub.3 and sat. aq.
NaCl, and then dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=7:1) to give acetate 61 (1.178 g, 90%
for 2 steps).
[0340] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 5.77 (1H, dt,
J=6.6, 15.4 Hz, AcOCH.sub.2CH.dbd.CH), 5.56 (1H, dt, J=6.6, 15.4
Hz, AcOCH.sub.2CH.dbd.CH), 4.50 (2H, d, J=6.2 Hz,
AcOCH.sub.2CH.dbd.CH), 3.60 (2H, t, J=6.6 Hz, CH.sub.2OTBS), 2.06
(5H, br, CH.sub.3C.dbd.O & CH.dbd.CHCH.sub.2), 1.55-1.48 (2H,
m, CH.sub.2CH.sub.2OTBS), 1.44-1.30 (4H, m, 2.times.CH.sub.2), 0.89
{9H, s, C(CH.sub.3).sub.3}, 0.05 {6H, s, Si(CH.sub.3).sub.2}.
[0341] To a solution of compound 61 (1.178 g, 3.919 mmol) in THF
(15 ml), TBAF (1.0 M in THF, 4.2 ml, 4.2 mmol) was added at room
temperature and stirred for 18 hours. After the reaction mixture
was diluted with H.sub.2O to separate and collect the organic
layer, the aqueous layer was extracted twice with EtOAc. The
combined organic layers were washed with sat. aq. NaCl and dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was purified by silica gel column chromatography
(hexane:EtOAc=3:1.fwdarw.1:1) to give the corresponding primary
alcohol (0.640 g, 88%).
[0342] To a solution of this primary alcohol (0.640 g, 3.436 mmol)
in CH.sub.3Cl (15 ml), Et.sub.3N (0.55 ml, 3.9 mmol), Piv-Cl (0.50
ml, 4.1 mmol) and DMAP (cat. amount) were added at 0.degree. C. and
stirred for 20 hours while returning to room temperature. After the
reaction mixture was diluted with H.sub.2O to separate and collect
the organic layer, the aqueous layer was extracted twice with
EtOAc. The combined organic layers were washed with sat. aq. NaCl
and dried over Na.sub.2SO.sub.4. After the solvent was distilled
off, the residue was purified by silica gel column chromatography
(hexane:EtOAc=5:1) to give the corresponding pivalate (compound 62)
(0.359 g, 39%).
[0343] To a mixed solvent of MeOH (13.5 ml) and CHCl.sub.3 (1.5
ml), guanidine hydrochloride (0.151 g, 1.58 mmol) and NaOMe (19 mg,
0.35 mmol) were added at room temperature under an Ar atmosphere
and stirred for 10 minutes. This solution was added dropwise to a
solution of the pivalate (0.359 g, 1.33 mmol) in a mixture of MeOH
(4.5 ml) and CHCl.sub.3 (0.5 ml), followed by stirring at room
temperature for 5 hours. After the solvent was distilled off, the
residue was diluted with EtOAc and H.sub.2O to separate and collect
the organic layer. The aqueous layer was further extracted with
EtOAc, and the combined organic layers were washed with sat. aq.
NaCl and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=2:1) to give the corresponding allyl
alcohol 63 (0.294 g, 97%).
[0344] To a solution of this allyl alcohol 63 (0.294 g, 1.288 mmol)
in CHCl.sub.3 (20 ml), Ph.sub.3P (0.756 g, 2.88 mmol) and CBr.sub.4
(0.965 g, 2.91 mmol) were added at 0.degree. C. and stirred at the
same temperature for 1.5 hours. After the solvent was distilled
off, the residue was subjected to silica gel column chromatography
(hexane:EtOAc=2:1) to give the corresponding bromide 64. The
resulting product was used for the subsequent reaction without
further purification.
[0345] Namely, to a solution of compound 112 (0.419 g, 2.25 mmol)
in MeOH (3.0 ml), KOH (1.0 M in MeOH, 3.5 ml, 3.5 mmol) was added
and cooled to 0.degree. C. To this mixture, a solution of the above
bromide (crude 64) in MeOH (3.0 ml) and CaCl.sub.2 2H.sub.2O (0.294
g, 2.00 mmol) were added and stirred for 18 hours while returning
to room temperature. The reaction mixture was diluted with
Et.sub.2O to separate and collect the organic layer, and the
aqueous layer was then extracted once with each of Et.sub.2O and
EtOAc. The combined organic layers were washed with 0.1 M aq. KOH
and sat. aq. NaCl, and then dried over Na.sub.2SO.sub.4. After the
solvent was distilled off, the residue was purified by silica gel
column chromatography (hexane:EtOAc=4:1) and then further purified
by recrystallization from hexane to give the desired product
206-12-OPiv (35 mg, 7% for 2 steps).
[0346] Mp 89-90.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.68 (1H, s, Ar--OH), 10.15 (1H, s, CHO), 6.38 (1H, br,
Ar--OH), 5.54-5.51 (2H, m, CH.dbd.CH), 4.02 (2H, t, J=6.6 Hz,
CH.sub.2OPiv), 3.38 (2H, d, J=4.0 Hz, ArCH.sub.2CH.dbd.CH), 2.61
(3H, s, Ar--CH.sub.3), 2.03-1.95 (2H, m, CH.sub.2), 1.63-1.57 (2H,
m, CH.sub.2), 1.40-1.29 {4H, m, (CH.sub.2).sub.2}, 1.18 {9H, s,
C(CH.sub.3).sub.3}. IR (KBr), 3300, 2970, 2916, 1724, 1620, 1481,
1452, 1429, 1286, 1248, 1223, 1175, 1123, 980, 895, 787, 592
cm.sup.-1. HRMS (EI) Found: 396.1684. Calcd. for
C.sub.21H.sub.29ClO.sub.5: 396.1704.
19. Compounds 278-8 and 279-8
[0347] [Formula 19]
##STR00028##
(E)-3-Chloro-4,6-dihydroxy-2-methyl-5-(7-methyl-2,6-octadienyl)-benzaldeh-
yde (compound 278-8)
[0348] Diethyl malonate 65 was prenylated in a standard manner
(Tetrahedron, 2003, 59, 2991-2998) to give compound 66 (84% yield).
Subsequently, a solution of compound 66 (10.00 g, 43.8 mmol) in
DMSO (60 ml) was added to a mixture of NaCl (4.10 g, 70.1 mmol) and
water (3.5 ml), and then stirred at 150.degree. C. for 18 hours.
After cooling to room temperature, the reaction mixture was
extracted with ethyl acetate and dried over Na.sub.2SO.sub.4. After
concentration under reduced pressure, the resulting crude product
was subjected to silica gel column chromatography
(hexane:EtOAc=20:1) to give the corresponding monoester 67 (5.69 g,
83% yield).
[0349] A solution of this monoester 67 (2.30 g, 14.7 mmol) in THF
(30 ml) was added at 0.degree. C. to a suspension of lithium
aluminum hydride (528 mg, 12.8 mmol) in THF (30 ml), followed by
stirring for 10 minutes. After addition of ice (30 g) and 1 M
hydrochloric acid (30 ml), the reaction mixture was extracted with
ethyl acetate and dried over Na.sub.2SO.sub.4, followed by
concentration under reduced pressure to give an alcohol form (1.39
g, 83% yield). This alcohol form was converted into the
corresponding aldehyde 68 through the same oxidation procedure as
used in Scheme 18(b) (51% yield).
[0350] Aldehyde 68 was converted into alcohol 69 whose carbon chain
was extended by two carbons in the same manner as used in Scheme
18(c) and (d) (54% yield for 2 steps).
[0351] Alcohol 69 was further converted into the corresponding
bromide in the same manner as used in Scheme 13(f) and (g), and
then reacted with compound 112 to give the desired product 278-8
(20% yield for 2 steps).
[0352] Mp 131-132.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.37 (1H, s,
Ar--OH), 5.55 (2H, m, CH.dbd.CH), 5.08 {1H, t, J=1.3 Hz,
CH.dbd.C(CH.sub.3).sub.2}, 3.38 (2H, d, J=3.7 Hz, Ar--CH.sub.2),
2.61 (3H, s, Ar--CH.sub.3), 2.01 (4H, br, CH.sub.2CH.sub.2), 1.66
(3H, s, CH.sub.3), 1.57 (3H, s, CH.sub.3). IR (KBr) 3433, 2908,
1624, 1425, 1219, 1111, 781, 529. HRMS (EI) Found: 308.1169. Calcd.
for C.sub.17H.sub.21ClO.sub.3: 308.1179.
3-Chloro-4,6-dihydroxy-2-methyl-5-(7-methyloctyl)benzaldehyde
(compound 279-8)
[0353] Reduction of the compound 278-8 was accomplished in the same
manner as used in Scheme 17(f), i.e., synthesis of 265-8 to give
compound 279-8 (97% yield).
[0354] Mp 93-94.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.65 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.30 (1H, s,
Ar--OH), 2.66 (2H, d, J=7.6 Hz, Ar--CH.sub.2), 2.61 (3H, s,
Ar--CH.sub.3), 1.60-1.46 {3H, m, CH(CH.sub.3).sub.2 &
CH.sub.2}, 1.40-1.23 {6H, m, (CH.sub.2).sub.3}, 1.18-1.11 (2H, m,
CH.sub.2), 0.85 {6H, d, J=6.8 Hz, CH(CH.sub.3).sub.2}. IR (KBr)
3260, 2916, 2847, 1607, 1470, 1421, 1248, 1132, 871, 762, 710, 596,
529 cm.sup.-1. HRMS (EI) Found: 312.1484. Calcd. for
C.sub.17H.sub.25ClO.sub.3: 312.1492.
20. Compounds 278-12-OPiv and 279-12-Opiv
[0355] [Formula 20]
##STR00029##
(2E,6E)-8-(3-Chloro-5-formyvl-2,6-dihydroxy-4-methylphenyl)-2-methyl-2,6--
octadie nyl pivalate (compound 278-12-OPiv)
[0356] A solution of prenyl iodide (obtained from cyclohexyl methyl
ketone as described in literature (Synthesis, 1979, 37-38), 220 mg,
1.05 mmol) in DMPU (1.5 ml) was added at -20.degree. C. to a
reaction mixture containing a solution of
3-(4-methoxybenzyloxy)-1-propyne (282 mg, 1.50 mmol) in THF (1 ml)
and a solution of butyllithium in hexane (2.00 mmol, 1.2 ml), which
had been mixed at -20.degree. C. and stirred for 2 hours. This
mixture was warmed to room temperature while stirring for 12 hours.
The mixture was extracted with ethyl acetate, worked up and then
purified by silica gel column chromatography (hexane:EtOAc=25:1) to
give MPM ether product 70 (203 mg, 40% yield). This product was
converted into 71 by being treated with
2,3-dichloro-5,6-dicyanobenzoquinone in a standard manner (J. Am.
Chem. Soc., 2002, 13670-13671) to remove the protecting group for
alcohol, followed by reduction with Red-Al (Org. Lett., 2004,
1785-1787) to give (E)-7-methylocta-2,6-dien-1-ol (72) (88% yield
for 2 steps).
[0357] To a solution of alcohol 72 (855 mg, 6.10 mmol) in
chloroform (20 ml), triethylamine (1.86 g, 18.3 mmol), acetic
anhydride (1.57 g, 15.2 mmol) and dimethylaminopyridine (80 mg,
0.61 mmol) were added and stirred at room temperature for 16 hours.
The reaction mixture was worked up by extraction and then purified
by silica gel column chromatography (hexane:EtOAc=9:1) to give an
ester in which the hydroxyl group was acetylated (1082 mg, 97%
yield). The resulting ester was oxidized by the selenium
dioxide-catalyzed method (Tetrahedron Lett., 2001, 42, 2205-2208)
to give compound 73 (44% yield).
[0358] Then, compound 73 was converted into a diester (91% yield)
in the same manner as used for synthesis in Scheme 15(c). Among the
two ester linkages, the acetic acid ester was hydrolyzed in the
same manner as used for synthesis in Scheme 15(d) to give the
desired monoester 74 (86% yield).
[0359] This monoester 74 was converted into bromide 75 in the same
manner as used for synthesis in Scheme 15(e), and then reacted with
aromatic ring moiety 112 in the same manner as used for synthesis
in Scheme 15(f) to give compound 278-12-OPiv (25% yield for 2
steps).
[0360] Mp 90-91.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 6.44 (1H, s,
Ar--OH), 5.55-5.51 (2H, m, CH.dbd.CH), 5.40 (1H, m,
CH.dbd.C(CH.sub.3)CH.sub.2OPiv), 4.42 (2H, s, CH.sub.2OPiv), 3.37
(2H, d, J=4.8 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3),
2.09-2.04 (4H, m, CH.sub.2CH.sub.2), 1.60 (3H, s, CH.sub.3), 1.21
(9H, s, C(CH.sub.3).sub.3). IR (KBr) 3293, 2972, 1724, 1622, 1622,
1425, 1283, 1227, 1167, 1117, 976, 893, 781, 592 cm.sup.-1.
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenl)-2-methyloctyl
pivalate (compound 279-12-OPiv)
[0361] In the same manner as used for synthesis in Scheme 15(g),
the compound 278-12-OPiv was reduced to give compound 279-12-OPiv
(84% yield).
[0362] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.66 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.36 (1H, br, Ar--OH), 3.94 (1H,
dd, J=5.8, 10.6 Hz, CH.sub.2OPiv) 3.82 (1H, dd, J=6.6, 10.6 Hz,
CH.sub.2OPiv) 2.66 (2H, t, J=7.9 Hz, Ar--CH.sub.2), 2.61 (3H, s,
Ar--CH.sub.3), 1.82-1.72 (1H, m, CH), 1.60-1.49 (4H, m,
2.times.CH.sub.2), 1.40-1.28 {6H, br, (CH.sub.2).sub.3}, 1.20 {9H,
s, C(CH.sub.3).sub.3}, 0.91 (3H, d, J=6.6 Hz, CH.sub.3). IR (KBr)
3393, 2961, 2930, 2857, 1724, 1717, 1630, 1460, 1422, 1375, 1288,
1248, 1165, 1128, 1034, 982, 806, 772, 710, 590 cm.sup.-1. HRMS
(EI) calcd. for C.sub.22H.sub.33ClO.sub.5 (m/z) 412.2017. found
412.2025.
21. Compounds 287-12-OPiv and 287-12-OCO.sup.iPr
[0363] [Formula 21]
##STR00030##
(2E,6E)-8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenl)-3,6-dimethyl-2,-
6-octadienyl pivalate (compound 287-12-OPiv)
[0364] To a suspension of NaH (60% in oil, 0.820 g, 20.5 mmol) in
THF (30 ml), triethyl phosphonoacetate (3.6 ml, 18 mmol) was added
at 0.degree. C. and stirred for 30 minutes while returning to room
temperature. The reaction mixture was cooled again to 0.degree. C.,
and acetonylacetone (compound 76, 1.0 ml, 8.2 mmol) was added
dropwise thereto and stirred for 15 hours while returning to room
temperature. The reaction was quenched by addition of H.sub.2O,
followed stirring for 5 minutes. The organic layer was then
separated and collected, and the aqueous layer was extracted twice
with EtOAc. The combined organic layers were washed with sat. aq.
NaCl and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was subjected to silica gel column
chromatography (hexane:EtOAc=10:1) to fractionate the corresponding
diester into an (E,E)-isomer, an (E,Z)-isomer, a (Z,Z)-isomer and a
mixture thereof.
[0365] (E,E)-isomer; 0.513 g (25% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 5.67 (2H, s, 2.times.C.dbd.CHCO.sub.2Et), 4.15
(4H, q, J=7.1 Hz, 2.times.CO.sub.2CH.sub.2CH.sub.3), 2.31 (4H, s,
CH.sub.2CH.sub.2), 2.17 (6H, s, 2.times.CH.dbd.CCH.sub.3), 1.28
(6H, t, J=7.1 Hz, .times.CO.sub.2CH.sub.2CH.sub.3).
[0366] To a solution of this diester (0.513 g, 2.017 mmol) in
toluene (20 ml), DIBAL (1.0 M in hexane, 12 ml, 12 mmol) was added
dropwise at -70.degree. C. and stirred at the same temperature for
3 hours. To the reaction mixture, H.sub.2O was added slowly and
then 2 M aq. HCl was further added, followed by stirring for 10
minutes while returning to room temperature. After the organic
layer was separated and collected, the aqueous layer was extracted
twice with EtOAc. The combined organic layers were washed with sat.
aq. NaHCO.sub.3 and sat. aq. NaCl, and then dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the
precipitated crude crystals were recrystallized from toluene to
give a diol (compound 77) (0.320 g, 93%).
[0367] To a solution of compound 77 (0.320 g, 1.88 mol) in
CHCl.sub.3 (20 ml), Et.sub.3N (0.26 ml, 1.9 mmol), DMAP (cat.
amount) and Piv-Cl (0.14 ml, 1.1 mmol) were added at 0.degree. C.
and stirred for 12 hours while returning to room temperature. The
reaction mixture was diluted with sat. aq. NaCl to separate and
collect the organic layer, and the aqueous layer was then extracted
twice with EtOAc. The combined organic layers were dried over
Na.sub.2SO.sub.4. After the solvent was distilled off, the residue
was purified by silica gel column chromatography (hexane:EtOAc=2:1)
to give the corresponding pivalate (compound 78-a) (0.163 g, 58%).
It should be noted that the unreacted starting material was
collected.
[0368] 1H NMR (400 MHz, CDCl.sub.3) .delta. 5.41 (1H, t, J=7.0 Hz,
C.dbd.CHCH.sub.2OPiv), 5.30 (1H, t, J=7.0 Hz, C.dbd.CHCH.sub.2OH),
4.56 (2H, d, J=7.0 Hz, CH.sub.2OPiv), 4.14 (2H, d, J=7.0 Hz,
CH.sub.2OH), 2.15 (4H, s, CH.sub.2CH.sub.2), 1.71 (3H, s,
CH.sub.3), 1.67 (3H, s, CH.sub.3), 1.23 (1H, s, OH), 1.19 {9H, s,
C(CH.sub.3).sub.3}.
[0369] To compound 78-a (0.184 g, 0.723 mmol) in Et.sub.2O (15 ml),
(.sup.nC.sub.8H.sub.17).sub.3P (1.1 ml, 2.5 mmol) and CBr.sub.4
(0.853 g, 2.57 mmol) were added at 0.degree. C. and stirred for 2
hours. The reaction mixture was poured into sat. aq. NaCl to
separate and collect the organic layer, and the aqueous layer was
then extracted with EtOAc. The combined organic layers were dried
over Na.sub.2SO.sub.4. After the solvent was distilled off, the
residue was subjected to silica gel column chromatography
(hexane:EtOAc=7:1) to give the corresponding bromide. The resulting
product was used for the subsequent reaction without further
purification.
[0370] Namely, to a solution of compound 112 (0.413 g, 2.213 mmol)
in KOH (1.0 M in MeOH, 3.3 ml, 3.3 mmol), CaCl.sub.2.2H.sub.2O
(0.251 g, 1.71 mmol) and a solution of the above crude bromide
(whole) in MeOH (4 ml) were added at 0.degree. C. and stirred for
14 hours while returning to room temperature. The reaction mixture
was diluted with EtOAc and filtered through celite. The filtrate
was then poured into 0.1 M aq. KOH. After the organic layer was
separated and collected, the aqueous layer was extracted twice with
EtOAc, and the combined organic layers were washed with sat. aq.
NaCl and dried over Na.sub.2SO.sub.4. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (hexane:EtOAc=4:1) and further recrystallized from
hexane to give the desired product 287-12-OPiv (65 mg, 21% for 2
steps from compound 78-a).
[0371] Mp 78-79.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.48 (1H, s,
Ar--OH), 5.28 (1H, t, J=7.0 Hz, C.dbd.CHCH.sub.2OPiv), 5.22 (1H, t,
J=7.1 Hz, ArCH.sub.2CH.dbd.C), 4.52 (2H, d, J=7.0 Hz,
C.dbd.CHCH.sub.2OPiv), 3.39 (2H, d, J=7.0 Hz, ArCH.sub.2CH.dbd.C),
2.61 (3H, s, Ar--CH.sub.3), 2.10 (4H, br, CH.sub.2CH.sub.2), 1.78
(3H, s, CH.sub.3), 1.66 (3H, s, CH.sub.3), 1.19 {9H, s,
C(CH.sub.3).sub.3}. IR (KBr) 3356, 2970, 2932, 1728, 1620, 1526,
1479, 1460, 1424, 1373, 1281, 1231, 1207, 1153, 1113, 1033, 964,
903, 868, 789, 594, 581 cm.sup.-1.
[0372] It should be noted that the aqueous layer was acidified with
2 M aq. HCl and then extracted with EtOAc to thereby collect the
unreacted compound 112.
(2E,6E)-8-(3-Chloro-5-formyvl-2,6-dihydroxy-4-methylphenyl)-3,6-dimethyl-2-
,6-octa dienyl isobutvlate (compound 287-12-OCO.sup.IPr)
[0373] Mp 62-63.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.69 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.48 (1H, s,
Ar--OH), 5.28 (1H, t, J=6.8 Hz, C.dbd.CHCH.sub.2O), 5.22 (1H, t,
J=7.3 Hz, ArCH.sub.2CH.dbd.C), 4.53 (2H, d, J=6.8 Hz,
C.dbd.CHCH.sub.2O), 3.39 (2H, d, J=7.3 Hz, ArCH.sub.2CH.dbd.C),
2.61 (3H, s, Ar--CH.sub.3), 2.57-2.50 {1H, m, CH(CH.sub.3).sub.2},
2.10 (4H, br, CH.sub.2CH.sub.2), 1.78 (3H, s, CH.sub.3), 1.66 (3H,
s, CH.sub.3), 1.16 {6H, d, J=7.3 Hz, CH(CH.sub.3).sub.2}. IR (KBr)
3273, 2974, 2934, 1732, 1620, 1526, 1470, 1452, 1425, 1376, 1283,
1256, 1231, 1209, 1153, 1109, 1065, 961, 889, 791, 716, 629, 586
cm.sup.-1.
22. Compounds 284-8 and 285-8
[0374] [Formula 22]
##STR00031##
3-Chloro-4,6-dihydroxy-5-(2-octvnyl)-2-methylbenzaldehyde (compound
284-8)
[0375] Aromatic ring moiety 112 and commercially available
1-bromo-2-octyne (compound 79) were used as starting materials and
reacted by the same operation as used for synthesis in Scheme 15(f)
using magnesium chloride as an additive to give the desired product
284-8 (21% yield).
[0376] Mp 135-136.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.81 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 7.03 (1H, s,
Ar--OH), 3.59 (2H, d, J=2.6 Hz, Ar--CH.sub.2), 2.62 (3H, s,
Ar--CH.sub.3), 2.16-2.13 (2H, m, CCCH.sub.2), 1.49 (2H, m,
CH.sub.2), 1.35-1.25 (4H, m, CH.sub.2CH.sub.2), 0.88 (3H, t, J=7.0
Hz, CH.sub.2CH.sub.3). IR (KBr) 3200, 2963, 2930, 1610, 1460, 1425,
1285, 1227, 1194, 1132, 1119, 887, 759, 713, 637, 584, 536
cm.sup.-1.
3-Chloro-4,6-dihydroxy-2-methyl-5-(7-methyl-6-octen-2-vnyl)benzaldehyde
(compound 285-8)
[0377] Alcohol 71 synthesized in Scheme 20 above was used as a
starting material for side chain synthesis, and the same operations
as used in Scheme 20(h) and (i) were repeated to synthesize the
desired product 285-8.
[0378] Mp 138.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3) 12.81
(1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 7.04 (1H, s, Ar--OH), 5.12
{1H, m, CH.dbd.C(CH.sub.3).sub.2}, 3.59 (2H, s, Ar--CH.sub.2), 2.62
(3H, s, Ar--CH.sub.3), 2.16 (4H, br, CH.sub.2CH.sub.2), 1.68 (3H,
s, CH.sub.3), 1.59 (3H, s, CH.sub.3). IR (KBr) 3198, 2967, 2924,
1618, 1452, 1429, 1285, 1229, 1186, 1113, 893, 791, 588, 538
cm.sup.-1. HRMS (EI) calcd. for C.sub.17H.sub.19ClO.sub.3 (m/z)
306.1023. found 306.1049.
23. Compounds 288-12-Piv and 215-12-Piv
[0379] [Formula 23]
##STR00032##
3-Chloro-4,6-dihydroxy-5-((E,E)-11,11-dimethyl-10-oxo-2,8-dodecadienyl)-2-
-methylbenzaldehyde (compound 288-12-Piv)
[0380] In the manner known from literature (K. Mori and S. Takechi,
Tetrahedron, 1985, 41, 3049-3062), aldehyde 8 and
3,3-dimethyl-2-butanone were reacted to give adduct 80 (59%
yield).
[0381] Then, the secondary hydroxyl group was acetylated in the
same manner as used in Scheme 20(e) and then treated with DBU to
give compound 81 (98% yield for 2 steps).
[0382] Then, the primary hydroxyl group was deprotected in the same
manner as used in Scheme 2(d), and then the primary hydroxyl group
was oxidized in the same manner as used in Scheme 1(d) to give
aldehyde 82 (91% yield for 2 steps).
[0383] Subsequently, the side chain was introduced into aromatic
ring starting material 112 in the same manner as used in Scheme
1(e) and (f) to give the desired product 288-12-Piv (36% yield for
2 steps).
[0384] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 13.06 (1H, s,
Ar--OH), 10.15 (1H, s, Ar--CHO), 6.95 (1H, dt, J=15.0, 7.3 Hz),
6.68 (1H, s, Ar--OH, 6.64 (1H, dt, J=16.1, 6.8 Hz), 6.52 (1H, d,
J=16.1 Hz), 6.50 (1H, d, J=15.0 Hz), 2.62 (3H, s, Ar--CH.sub.3),
2.19-2.30 (4H, m, allylic CH.sub.2), 1.60-1.35 (6H, m,
--(CH.sub.2).sub.3--), 1.15 (9H, s, C(CH.sub.3).sub.3).
3-Chloro-4,6-dihydroxy-5-(11,11-dimethyl-10-oxo-dodecyl)-2-methylbenzaldeh-
yde (compound 215-12-Piv)
[0385] The compound 288-12-Piv was reduced in the same manner as
used in Scheme 1(g) to give the desired product 215-12-Piv (79%
yield).
[0386] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.40 (1H, br s, Ar--OH), 2.71-2.57
(6H, m+s (.delta.2.60)), 2.49-2.35 (1H, m), 1.61-1.20 (14H,
--(CH.sub.2).sub.7--), 1.13 (9H, s, C(CH.sub.3).sub.3).
24. Compounds 289-12-OPiv and 290-12-Opiv.
##STR00033##
[0387]
(2E,6E)-8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-6-methyl-
-2,6-octadie nvl pivalate (compound 289-12-OPiv)
[0388] THP ether 83 known from literature (Tetrahedron Lett., 2001,
42, 2205-2208) (5.56 g, 21.2 mmol) was dissolved in
CH.sub.2Cl.sub.2 (115 ml), and pyridine (5.1 ml, 63.6 mmol) was
added thereto and cooled to -80.degree. C. This solution was
vigorously stirred with ozone bubbling for 5 hours. After the
reactor was purged with argon, Ph.sub.3P (16.603 g, 63.6 mmol, 3.0
eq.) was added thereto and stirred for 12 hours while returning to
room temperature. The residue obtained upon work-up was purified by
silica gel column chromatography (hexane:EtOAc=10:1) to give
aldehyde 84 (1.96 g, 44% yield).
[0389] This aldehyde 84 was converted into pivalic acid ester 85 by
procedures (b) and (c) (the same procedures as used for synthesis
in Scheme 18(c) and (d) above) and the subsequent procedure (d)
(the same procedure as used for synthesis in Scheme 15(c) above)
(87% yield for 3 steps).
[0390] Then, pivalic acid ester 85 was deprotected by procedure (e)
(the same procedure as used for synthesis in Scheme 2(d) above) to
give alcohol 86 (95% yield). Alcohol 86 was converted into the
desired product 289-12-OPiv by procedures (f) and (g) (the same
procedures as used for synthesis in Scheme 15(e) and (f) above)
(25% yield for 2 steps).
[0391] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.70 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.46 (1H, s, Ar--OH), 5.69 (1H.
dt, J=6.0, 15.4 Hz, CH.dbd.C), 5.22 (1H. dt, J=5.8, 15.4 Hz,
CH.dbd.C), 5.22 (1H, t, J=7.0 Hz, ArCH.sub.2CH.dbd.C), 4.46 (2H, d,
J=5.9 Hz, CH.sub.2OPiv), 3.39 (2H, d, J=7.3 Hz, Ar--CH.sub.2), 2.61
(3H, s, Ar--CH.sub.3), 2.18-2.12 (2H, m, CH.sub.2), 2.07-2.03 (2H,
m, C2H, m, CH.sub.2), 1.78 (3H, s, CH.sub.3), 1.56 (3H, s,
CH.sub.3), 1.19 {9H, s, C(CH.sub.3).sub.3}. IR (KBr) 3273, 2974,
2932, 1728, 1618, 1479, 1452, 1424, 1281, 1229, 1159, 1107, 963,
905, 783, 714, 592, 538 cm.sup.-1.
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-6-methloctyl
pivalate (compound 290-12-OPiv)
[0392] 289-12-OPiv was reduced by procedure (h) (the same procedure
as used for synthesis in Scheme 15(g) above) to give the desired
product 290-12-OPiv (63% yield).
[0393] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.38 (1H, s, Ar--OH), 4.05 (2H, t,
J=6.6 Hz, CH.sub.2OPiv), 2.67-2.63 (2H, m, Ar--CH.sub.2), 2.61 (3H,
s, Ar--CH.sub.3), 1.64-1.61 (2H, m, CH.sub.2), 1.55-1.30 (7H, m,
CHCH.sub.3 & CH.sub.2CH.sub.2), 1.23-1.17 (2H, m, CH.sub.2),
1.19 {9H, s, C(CH.sub.3).sub.3}, 0.95 {3H, d, J=6.6 Hz,
CH(CH.sub.3)CH.sub.2}. IR (KBr) 3380, 2932, 2868, 1717, 1630, 1460,
142, 1375, 1327, 1290, 1248, 1163, 1126, 802, 709, 629, 592
cm.sup.-1. HRMS (EI) calcd. for C.sub.22H.sub.33ClO.sub.5 (m/z)
412.2017. found 412.2041.
25. Compound 231-9-OMe
##STR00034##
[0395] [Formula 25]
3-Chloro-4,6-dihydroxy-5-[(E)-7-methoxv-3,7-dimethyl-2-octenv]-2-methyl
benzaldehyde (compound 231-9-OMe)
[0396] To a solution of 216 synthesized in Scheme 6 above
(Colletochlorin B, 74 mg, 0.23 mmol) in methanol (5 ml),
concentrated sulfuric acid (23 mg, 0.23 mmol) was added. After
stirring at 30.degree. C. for 15 hours, the reaction mixture was
neutralized with saturated aqueous sodium bicarbonate, extracted
with ethyl acetate and then worked up to give a crude product (109
mg), which was then purified by preparative TLC (hexane:EtOAc=3/1)
to give the desired product 231-9-OMe (39 mg, 48% yield).
[0397] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 1.11 (s, 6H,
C(OCH.sub.3)(CH.sub.3).sub.2), 1.34-1.43 (m, 4H,
--CH.dbd.C(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--), 1.78 (s, 3H,
--CH.dbd.C(CH.sub.3)--), 1.91-2.00 (m, 2H,
--CH.dbd.C(CH.sub.3)CH.sub.2--), 2.60 (s, 3H, Ar--CH.sub.3), 3.14
(s, 3H, C(OCH.sub.3)(CH.sub.3).sub.2), 3.40 (d, J=7.0 Hz, 2H,
Ar--CH.sub.2CH.dbd.C(CH.sub.3)--), 5.22 (t, J=7.0 Hz, 1H,
ArCH.sub.2CH.dbd.C(CH.sub.3)--), 6.39 (br s, 1H, Ar--OH), 10.14 (s,
1H, Ar--CHO), 12.69 (s, 1H, Ar--OH).
26. Compounds 236-13-OTHP, 236-9-OH, 236-12-OTHF, 236-12-OMOM,
274-9 and 281-12
##STR00035## ##STR00036##
[0399] [Formula 26]
3-Chloro-5-[(2E,6E)-3,7-dimethyl-8-(tetrahydropran-2-yl
ox)-tadienl]-4,6-dihydroxy-2-methylbenzaldehyde (compound
236-13-OTHP)
[0400] By standard procedure (a) (the same procedure as used in
Scheme 2(a) above), alcohol 30 known from literature (J. Braz.
Chem. Soc. 2003, 14, 975-981) was converted into compound 87 whose
alcohol moiety was protected (96% yield). To a solution of this
compound 87 (1.32 g, 4.46 mmol) in MeOH (8 ml), H.sub.2O (10 ml)
and K.sub.2CO.sub.3 (1.24 g, 8.92 mmol) were added and stirred for
16 hours. The crude product obtained upon work-up by ether
extraction was purified by column chromatography
(n-hexane/EtOAc=1/1) to give alcohol 90 (664 mg, 60% yield).
[0401] Alcohol 90 was converted into the desired product
236-13-OTHP by procedures (e) and (f) (the same procedures as used
for synthesis in Scheme 15(e) and (f) above) (30% yield for 2
steps).
[0402] Mp 44-45.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.66 (1H, s,
Ar--OH), 5.37 (1H, t, J=6.8 Hz, CH.sub.2CH.dbd.C), 5.22 (1H, t,
J=7.1 Hz, CH.sub.2CH.dbd.C), 4.61 (1H, t, J=3.5 Hz, THP(2)-H), 4.05
(1H, d, J=11.9 Hz, C(CH.sub.3)CH.sub.2O), 3.83-3.90 (1H, m,
THP(6)-H), 3.83 (1H, d, J=11.9 Hz, C(CH.sub.3)CH.sub.2O), 3.48-3.54
(1H, m, THP(6)-H), 3.37-3.41 (2H, m, Ar--CH.sub.2), 2.61 (3H, s,
Ar--CH.sub.3), 2.0-2.2 (4H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 1.6-1.9 (12H, m+s
(.delta.1.77, CH.sub.3)+s (.delta.1.62, CH.sub.3),
THP(3,4,5)-H.sub.2). IR (KBr) 3200-3500, 1613, 1424, 1281, 1250,
1233, 1111 cm.sup.-1. Calcd for C.sub.23H.sub.31ClO.sub.5: C,
65.32; H, 7.39; Cl, 8.38%. Found: C, 65.18; H, 7.36; Cl, 8.41%.
3-Chloro-4,6-dihydroxy-5-[(2E,6E)-8-hydroxy-3,7-dimethyl-2,6-octadienyl]-2-
-methylbenzaldehyde (compound 236-9-OH)
[0403] The compound 236-13-OTHP obtained above was treated to
remove THP by procedure (g) (the same procedure as used in Scheme
2(d) above) to give the desired product 236-9-OH (90% yield).
[0404] Mp 99.0-99.7.degree. C. H-NMR (400 MHz, CDCl.sub.3) .delta.
12.72 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 5.34 (1H, t, J=6.6
Hz, CH.sub.2CH.dbd.C), 5.22 (1H, t, J=6.9 Hz, CH.sub.2CH.dbd.C),
3.97 (2H, d, J=6.9 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3),
2.0-2.2 (4H, m, C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 1.78 (3H, s,
CH.sub.3), 1.64 (3H, s, CH.sub.3). HRMS (DART) calcd for
C.sub.18H.sub.22ClO.sub.3 (M-OH) 321.1257. found 321.1235.
3-Chloro-5-[(2E,6E)-3,7-dimethyl-8-(tetrahydrofuran-2-yloxy)-2,6-octadieny-
l]-4,6-dihydroxy-2-methylbenzaldehyde (compound 236-12-OTHF)
[0405] The above alcohol 30 was treated by standard procedure (b)
(the same procedure as used in Scheme 2(a) above, except that
dihydropyran (DHP) was replaced with dihydrofuran (DHF)) to modify
the alcohol moiety with THF to thereby give compound 88 (97%
yield). Subsequently, the above procedure (d) was repeated to
convert this compound into similar alcohol 91 (60% yield). Then,
the procedures (e) and (f) (the same procedures as used for
synthesis in Scheme 15(e) and (f) above) were repeated to give the
desired product 236-12-OTHF (13% yield for 2 steps).
[0406] Mp 35-36.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.71 (1H, s,
Ar--OH), 5.36 (1H, t, J=7.0 Hz, CH.sub.2CH.dbd.C), 5.22 (1H, t,
J=7.0 Hz, CH.sub.2CH.dbd.C), 5.11 (1H, dd, J=2.6, 4.0 Hz,
THF(2)-H), 3.98 (1H, d, J=11.7 Hz, C(CH.sub.3)CHO20), 3.85-3.94
(2H, m, THF(5)-H.sub.2), 3.81 (1H, d, J=11.7 Hz,
C(CH.sub.3)CH.sub.2O), 3.34-3.44 (2H, m, Ar--CH.sub.2), 2.61 (3H,
s, Ar--CH.sub.3), 1.8-2.2 (8H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C and THF(3,4)-H.sub.2), 1.77 (s,
CH.sub.3), 1.60 (s, CH.sub.3). IR (KBr) 3150-3350, 1613, 1422,
1283, 1250, 1234, 1109, 1024 cm.sup.-1. HRMS (DART) calcd for
C.sub.22H.sub.30ClO.sub.5 (MH.sup.+) 409.1782. found: 409.1758.
3-Chloro-5-[(2E,6E)-3,7-dimethvl-8-(methoxymethoxy)-2,6-octadienyl)-4,6-di-
hydro xy-2-methylbenzaldehyde (236-12-OMOM)
[0407] The above alcohol 30 was methoxymethylated by standard
procedure (c) (J. Am. Chem. Soc. 1977, 99, 1275-1276) to give
compound 89 (71% yield). Subsequently, the above procedure (d) was
repeated to convert this compound into alcohol 92 (80% yield).
Then, 92 was treated by the procedures (e) and (f) (the same
procedures as used for synthesis in Scheme 15(e) and (f) above) to
give the desired product 236-12-OMOM (12% yield for 2 steps).
[0408] Mp 49-50.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.65 (1H, s,
Ar--OH), 5.37 (1H, t, J=6.4 Hz, CH.sub.2CH.dbd.C), 5.24 (1H, t,
J=6.4 Hz, CH.sub.2CH.dbd.C), 4.59 (2H, s, OCH.sub.2O), 3.89 (2H, s,
C(CH.sub.3)CH.sub.2O), 3.39 (2H, d, J=6.4 Hz, Ar--CH.sub.2), 3.38
(3H, s, OCH.sub.3), 2.61 (3H, s, Ar--CH.sub.3), 2.11-2.17 (2H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 2.01-2.06 (2H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 1.77 (s, CH.sub.3), 1.63 (s,
CH.sub.3). IR (KBr) 3200-3400, 1631, 1422, 1288, 1254, 1022, 903
cm.sup.-1. Calcd for C.sub.20H.sub.27ClO.sub.5: C, 62.74; H, 7.11;
Cl, 9.26%. Found: C, 62.64; H, 7.09; Cl, 9.22%.
3-Chloro-5-[(2E,6E)-3,7-dimethyl-8-oxo-2,6-octadienyl]-4,6-dihydroxy-2-met-
hylbenzaldehyde (compound 274-9)
[0409] Aldehyde 31 known from literature (Tetrahedron 1974, 30,
715-718) was deacetylated by the above procedure (d) to give
compound 93 (90% yield). Then, 93 was treated by the procedures (e)
and (f) (the same procedures as used for synthesis in Scheme 15(e)
and (f) above) to give the desired product 274-9 (27% yield for 2
steps).
[0410] Mp 111.2-111.4.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 9.31 (1H, s,
C(CH.sub.3)--CHO), 6.41 (1H, t, J=7.4 Hz, CH.sub.2CH.dbd.C), 6.35
(1H, s, Ar--OH), 5.26 (1H, t, J=6.8 Hz, CH.sub.2CH.dbd.C), 3.40
(2H, d, J=7.4 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3),
2.4-2.5 (2H, m, C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 2.1-2.2 (2H,
m, C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 1.81 (3H, s, CH.sub.3),
1.70 (3H, s, CH.sub.3). MS (EI) m/z 338 (5, M+2), 336 (13,
M.sup.+).
3-Chloro-5-[(2E,6E)-3,7-dimethl-9-(3,3-dimethyloxiran-2-yl)-2,6-nonadienyl-
]-4,6-dihydroxy-2-methylbenzaldehyde (compound 281-12)
[0411] Alcohol 94 known from literature (Org. Lett. 2006, 8,
5649-5652) was used and treated by the procedures (e) and (f) (the
same procedures as used for synthesis in Scheme 15(e) and (f)
above) to give the desired product 281-12 (4% yield for 2
steps).
[0412] Mp 36-37.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.57 (1H, s,
Ar--OH), 5.21 (1H, t, J=7.1 Hz, CH.sub.2CH.dbd.C), 5.11 (1H, t,
J=6.2 Hz, CH.sub.2CH.dbd.C), 3.39 (2H, d, J=7.1 Hz, Ar--CH.sub.2),
2.69 (1H, t, J=6.2 Hz, oxiran(2)-H), 2.61 (3H, s, Ar--CH.sub.3),
1.96-2.12 (6H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C(CH.sub.3)CH.sub.2), 1.78 (s,
CH.sub.3), 1.56-1.64 (5H, m+s (.delta. 1.59), nonadienyl(9)-H.sub.2
and CH.sub.3), 1.30 (s, CH.sub.3), 1.25 (s, CH.sub.3). IR (KBr)
3300-3500, 1614, 1418, 1281, 1250, 1233, 1109 cm.sup.-1.
27. Compound 509-11
[0413] [Formula 27]
##STR00037##
3-Chloro-5-((2E,6E)-7-(4,5-dimethyl-1,3-dioxolan-2-yl)-3-methyl-2,6-octad-
ieny)-4,6-dihydroxy-2-methylbenzaldehyde (compound 509-11)
[0414] Aldehyde 95 known from literature (J. Am. Chem. Soc. 2005,
127, 7014-7024), which can be obtained from commercially available
29 by procedure (a), was converted into 30 whose carbon chain was
extended by procedure (b) (Org. Lett. 2007, 9, 1461-1464) (55%
yield for 2 steps).
[0415] Then, in accordance with standard procedure (c) (also
described in J. Am. Chem. Soc. 2005, 127, 7014-7024), compound 30
was acetalized with 2,3-butanediol to give compound 96.
Subsequently, the resulting compound was deacetylated by procedure
(d) (the same procedure as used in Scheme 26(d) above) to give
alcohol 97 (56% yield for 2 steps).
[0416] Alcohol 97 was converted into bromide 98 by procedure (e)
(the procedure described in the above literature with
modifications: Tetrahedron 1984, 40, 2711-2720) and then treated by
procedure (f) (the same procedure as used for synthesis in Scheme
15(f) above) to give the desired product 509-11 (18% yield for 2
steps).
[0417] Mp. 91.5-92.3.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, CHO), 6.67 (1H, s,
Ar--OH), 5.54 (1H, t, J=7.3 Hz, CH.dbd.C), 5.23 (1H, s,
dioxolan(2)-H), 5.19 (1H, t, J=7.2 Hz, CH.dbd.C), 3.51-3.71 (2H, m,
dioxolan(4,5)-H), 3.33-3.44 (2H, m, Ar--CH.sub.2), 2.60 (3H, s,
Ar--CH.sub.3), 2.14-2.20 (2H, m, CH.sub.2), 2.01-2.07 (2H, m,
CH.sub.2), 1.76 (3H, s, CH.sub.3), 1.61 (3H, s, CH.sub.3),
1.31-1.33 (3H, m, CH.sub.3), 1.25-1.27 (3H, m, CH.sub.3). IR (KBr)
3100-3400, 1618, 1424, 1279, 1250, 1231, 1109, 1086, 667 cm.sup.-1.
HRMS (DART) calcd for C.sub.22H.sub.30ClO.sub.5 (MH.sup.+)
409.1782. found 409.1757.
28. Compound 503-12-OPiv
[0418] [Formula 28]
##STR00038##
(2E,6E)-8-(3-Chloro-2,6-dihydroxy-5-hydroxymethyl-4-methylphenyl)-2,6-dim-
ethyl-2,6-octadienyl pivalate (compound 503-12-OPiv)
[0419] 234-12-OPiv obtained in Scheme 15 above was treated by
procedure (a) (the same procedure as used for synthesis in Scheme
15(b) above) to give the desired product 503-12-OPiv (40%
yield).
[0420] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.54 (1H, s,
ArOH), 5.72 (1H, s, ArOH), 5.34 (1H, t, J=7.0 Hz,
CH.sub.2CH.dbd.C), 5.23 (1H, t, J=7.0 Hz, ArCH.sub.2CH.dbd.C), 4.86
(2H, s, ArCH.sub.2OH), 4.32 (2H, s, CH.sub.2OPiv), 3.41 (2H, d,
J=7.0 Hz, ArCH.sub.2), 2.74 (1H, br s, ArCH.sub.2OH), 2.31 (3H, s,
ArCH.sub.3), 2.12-2.18 (2H, m, CH.sub.2), 2.03-2.08 (2H, m,
CH.sub.2), 1.79 (3H, s, CH.sub.3), 1.57 (3H, s, CH.sub.3), 1.19
(9H, s, C(CH.sub.3).sub.3); IR (KBr) 3300-3500, 1715, 1614, 1456,
1285, 1231, 1159, 1096 cm.sup.-1. HRMS (DART) calcd for
C.sub.23H.sub.32ClO.sub.5 (M-H) 423.1938. found 423.1912.
24. Compounds 289-12-OPiv and 290-12-Opiv
[0421] [Formula 29]
##STR00039##
(2E,6E)-8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-6-methyl-2,6-o-
ctadienyl pivalate (compound 289-12-OPiv)
[0422] THP ether 83 known from literature (Tetrahedron Lett., 2001,
42, 2205-2208) (5.56 g, 21.2 mmol) was dissolved in
CH.sub.2Cl.sub.2 (115 ml), and pyridine (5.1 ml, 63.6 mmol) was
added thereto and cooled to -80.degree. C. This solution was
vigorously stirred with ozone bubbling for 5 hours. After the
reactor was purged with argon, Ph.sub.3P (16.603 g, 63.6 mmol, 3.0
eq.) was added thereto and stirred for 12 hours while returning to
room temperature. The residue obtained upon work-up was purified by
silica gel column chromatography (hexane:EtOAc=10:1) to give
aldehyde 84 (1.96 g, 44% yield).
[0423] This 84 was converted into pivalic acid ester 85 by
procedures (b) and (c) (the same procedures as used for synthesis
in Scheme 18(c) and (d) above) and the subsequent procedure (d)
(the same procedure as used for synthesis in Scheme 15(c) above)
(87% yield for 3 steps).
[0424] Then, 85 was deprotected by procedure (e) (the same
procedure as used for synthesis in Scheme 2(d) above) to give 86
(95% yield). Alcohol 86 was converted into the desired product
289-12-OPiv by procedures (f) and (g) (the same procedures as used
for synthesis in Scheme 15(e) and (f) above) (25% yield for 2
steps).
[0425] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.70 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.46 (1H, s, Ar--OH), 5.69 (1H.
dt, J=6.0, 15.4 Hz, CH.dbd.C), 5.22 (1H. dt, J=5.8, 15.4 Hz,
CH.dbd.C), 5.22 (1H, t, J=7.0 Hz, ArCH.sub.2CH.dbd.C), 4.46 (2H, d,
J=5.9 Hz, CH.sub.2OPiv), 3.39 (2H, d, J=7.3 Hz, Ar--CH.sub.2), 2.61
(3H, s, Ar--CH.sub.3), 2.18-2.12 (2H, m, CH.sub.2), 2.07-2.03 (2H,
m, CH.sub.2), 1.78 (3H, s, CH.sub.3), 1.56 (3H, s, CH.sub.3), 1.19
{9H, s, C(CH.sub.3).sub.3}. IR (KBr) 3273, 2974, 2932, 1728, 1618,
1479, 1452, 1424, 1281, 1229, 1159, 1107, 963, 905, 783, 714, 592,
538 cm.sup.-1.
8-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-6-methyloctyl
pivalate (compound 290-12-OPiv)
[0426] 289-12-OPiv was reduced by procedure (h) (the same procedure
as used for synthesis in Scheme 15(g) above) to give the desired
product 290-12-OPiv (63% yield).
[0427] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (1H, s,
Ar--OH), 10.14 (1H, s, Ar--CHO), 6.38 (1H, s, Ar--OH), 4.05 (2H, t,
J=6.6 Hz, CH.sub.2OPiv), 2.67-2.63 (2H, m, Ar--CH.sub.2), 2.61 (3H,
s, Ar--CH.sub.3), 1.64-1.61 (2H, m, CH.sub.2), 1.55-1.30 (7H, m,
CHCH.sub.3 & CH.sub.2CH.sub.2), 1.23-1.17 (2H, m, CH.sub.2),
1.19 {9H, s, C(CH.sub.3).sub.3}, 0.95 {3H, d, J=6.6 Hz,
CH(CH.sub.3)CH.sub.2}. IR (KBr) 3380, 2932, 2868, 1717, 1630, 1460,
142, 1375, 1327, 1290, 1248, 1163, 1126, 802, 709, 629, 592
cm.sup.-1. HRMS (EI) calcd. for C.sub.22H.sub.33ClO.sub.5 (m/z)
412.2017. found 412.2041.
25. Compound 231-9-Ome
[0428] [Formula 30]
##STR00040##
3-Chloro-4,6-dihydroxy-5-[(E)-7-methoxv-3,7-dimethyl-2-octenv]-2-methyl
benzaldehyde (compound 231-9-OMe)
[0429] To a solution of compound 216 synthesized in Scheme 6 above
(Colletochlorin B, 74 mg, 0.23 mmol) in methanol (5 ml),
concentrated sulfuric acid (23 mg, 0.23 mmol) was added. After
stirring at 30.degree. C. for 15 hours, the reaction mixture was
neutralized with saturated aqueous sodium bicarbonate, extracted
with ethyl acetate and then worked up to give a crude product (109
mg), which was then purified by preparative TLC (hexane:EtOAc=3/1)
to give the desired product 231-9-OMe (39 mg, 48% yield).
[0430] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 1.11 (s, 6H,
C(OCH.sub.3)(CH.sub.3).sub.2), 1.34-1.43 (m, 4H,
--CH.dbd.C(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--), 1.78 (s, 3H,
--CH.dbd.C(CH.sub.3)--), 1.91-2.00 (m, 2H,
--CH.dbd.C(CH.sub.3)CH.sub.2--), 2.60 (s, 3H, Ar--CH.sub.3), 3.14
(s, 3H, C(OCH.sub.3)(CH.sub.3).sub.2), 3.40 (d, J=7.0 Hz, 2H,
Ar--CH.sub.2CH.dbd.C(CH.sub.3)--), 5.22 (t, J=7.0 Hz, 1H,
ArCH.sub.2CH.dbd.C(CH.sub.3)--), 6.39 (br s, 1H, Ar--OH), 10.14 (s,
1H, Ar--CHO), 12.69 (s, 1H, Ar--OH).
26. Compounds 236-13-OTHP, 236-9-OH, 236-12-OTHF, 236-12-OMOM,
274-9 and 281-12
[0431] [Formula 31]
##STR00041## ##STR00042##
3-Chloro-5-[(2E,6E)-3,7-dimethyl-8-(tetrahydropyran-2-yloxy)-2,6-octadien-
yl]-4,6-d ihydroxy-2-methylbenzaldehyde (compound 236-13-OTHP)
[0432] By standard procedure (a) (the same procedure as used in
Scheme 2(a) above), alcohol 30 known from literature (J. Braz.
Chem. Soc. 2003, 14, 975-981) was converted into compound 87 whose
alcohol moiety was protected (96% yield). To a solution of this
compound 87 (1.32 g, 4.46 mmol) in MeOH (8 ml), H.sub.2O (10 ml)
and K.sub.2CO.sub.3 (1.24 g, 8.92 mmol) were added and stirred for
16 hours. The crude product obtained upon work-up by ether
extraction was purified by column chromatography
(n-hexane/EtOAc=1/1) to give alcohol 90 (664 mg, 60% yield).
[0433] Alcohol 90 was converted into the desired product
236-13-OTHP by procedures (e) and (f) (the same procedures as used
for synthesis in Scheme 15(e) and (f) above) (30% yield for 2
steps).
[0434] Mp 44-45.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.66 (1H, s,
Ar--OH), 5.37 (1H, t, J=6.8 Hz, CH.sub.2CH.dbd.C), 5.22 (1H, t,
J=7.1 Hz, CH.sub.2CH.dbd.C), 4.61 (1H, t, J=3.5 Hz, THP(2)-H), 4.05
(1H, d, J=11.9 Hz, C(CH.sub.3)CH.sub.2O), 3.83-3.90 (1H, m,
THP(6)-H), 3.83 (1H, d, J=11.9 Hz, C(CH.sub.3)CH.sub.2O), 3.48-3.54
(1H, m, THP(6)-H), 3.37-3.41 (2H, m, Ar--CH.sub.2), 2.61 (3H, s,
Ar--CH.sub.3), 2.0-2.2 (4H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 1.6-1.9 (12H, m+s
(.delta.1.77, CH.sub.3)+s (.delta.1.62, CH.sub.3),
THP(3,4,5)-H.sub.2). IR (KBr) 3200-3500, 1613, 1424, 1281, 1250,
1233, 1111 cm.sup.-1. Calcd for C.sub.23H.sub.31ClO.sub.5: C,
65.32; H, 7.39; Cl, 8.38%. Found: C, 65.18; H, 7.36; Cl, 8.41%.
3-Chloro-4,6-dihydroxy-5-[(2E,6E)-8-hydroxy-3,7-dimethyl-2,6-octadienyl]-2-
-meth ylbenzaldehyde (compound 236-9-OH)
[0435] 236-13-OTHP obtained above was treated to remove THP by
procedure (g) (the same procedure as used in Scheme 2(d) above) to
give the desired product 236-9-OH (90% yield).
[0436] Mp 99.0-99.7.degree. C. H-NMR (400 MHz, CDCl.sub.3) .delta.
12.72 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 5.34 (1H, t, J=6.6
Hz, CH.sub.2CH.dbd.C), 5.22 (1H, t, J=6.9 Hz, CH.sub.2CH.dbd.C),
3.97 (2H, d, J=6.9 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3),
2.0-2.2 (4H, m, C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 1.78 (3H, s,
CH.sub.3), 1.64 (3H, s, CH.sub.3). HRMS (DART) calcd for
Ci.sub.8H.sub.22ClO.sub.3 (M-OH) 321.1257. found 321.1235.
3-Chloro-5-[(2E,6E)-3,7-dimethyl-8-(tetrahydrofuran-2-yloxy)-2,6-octadieny-
l]-4,6-d ihydroxy-2-methylbenzaldehyde (compound 236-12-OTHF)
[0437] The above alcohol 30 was treated by standard procedure (b)
(the same procedure as used in Scheme 2(a) above, except that
dihydropyran (DHP) was replaced with dihydrofuran (DHF)) to modify
the alcohol moiety with THF to thereby give compound 88 (97%
yield). Subsequently, the above procedure (d) was repeated to
convert this compound into similar alcohol 91 (60% yield). Then,
the procedures (e) and (f) (the same procedures as used for
synthesis in Scheme 15(e) and (f) above) were repeated to give the
desired product 236-12-OTHF (13% yield for 2 steps).
[0438] Mp 35-36.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.71 (1H, s,
Ar--OH), 5.36 (1H, t, J=7.0 Hz, CH.sub.2CH.dbd.C), 5.22 (1H, t,
J=7.0 Hz, CH.sub.2CH.dbd.C), 5.11 (1H, dd, J=2.6, 4.0 Hz,
THF(2)-H), 3.98 (1H, d, J=11.7 Hz, C(CH.sub.3)CH.sub.2O), 3.85-3.94
(2H, m, THF(5)-H.sub.2), 3.81 (1H, d, J=11.7 Hz,
C(CH.sub.3)CH.sub.2O), 3.34-3.44 (2H, m, Ar--CH.sub.2), 2.61 (3H,
s, Ar--CH.sub.3), 1.8-2.2 (8H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C and THF(3,4)-H.sub.2), 1.77 (s,
CH.sub.3), 1.60 (s, CH.sub.3). IR (KBr) 3150-3350, 1613, 1422,
1283, 1250, 1234, 1109, 1024 cm.sup.-1. HRMS (DART) calcd for
C.sub.22H.sub.30ClO.sub.5 (MH.sup.+) 409.1782. found: 409.1758.
3-Chloro-5-[(2E,6E)-3,7-dimethyl-8-(methoxymethoxy)-2,6-octadienyl]-4,6-di-
hydro xy-2-methylbenzaldehyde (compound 236-12-OMOM)
[0439] The above alcohol 30 was methoxymethylated by standard
procedure (c) (J. Am. Chem. Soc. 1977, 99, 1275-1276) to give
compound 89 (71% yield). Subsequently, the above procedure (d) was
repeated to convert this compound into alcohol 92 (80% yield).
Then, 92 was treated by the procedures (e) and (f) (the same
procedures as used for synthesis in Scheme 15(e) and (f) above) to
give the desired product 236-12-OMOM (12% yield for 2 steps).
[0440] Mp 49-50.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.65 (1H, s,
Ar--OH), 5.37 (1H, t, J=6.4 Hz, CH.sub.2CH.dbd.C), 5.24 (1H, t,
J=6.4 Hz, CH.sub.2CH.dbd.C), 4.59 (2H, s, OCH.sub.2O O), 3.89 (2H,
s, C(CH.sub.3)CH.sub.2O), 3.39 (2H, d, J=6.4 Hz, Ar--CH.sub.2),
3.38 (3H, s, OCH.sub.3), 2.61 (3H, s, Ar--CH.sub.3), 2.11-2.17 (2H,
m, C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 2.01-2.06 (2H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 1.77 (s, CH.sub.3), 1.63 (s,
CH.sub.3). IR (KBr) 3200-3400, 1631, 1422, 1288, 1254, 1022, 903
cm.sup.-1. Calcd for C.sub.20H.sub.27ClO.sub.5: C, 62.74; H, 7.11;
Cl, 9.26%. Found: C, 62.64; H, 7.09; Cl, 9.22%.
3-Chloro-5-[(2E,6E)-3,7-dimethyl-8-oxo-2,6-octadienyl]-4,6-dihydroxy-2-met-
hylben zaldehyde (compound 274-9)
[0441] Aldehyde 31 known from literature (Tetrahedron 1974, 30,
715-718) was deacetylated by the above procedure (d) to give
compound 93 (90% yield). Then, 93 was treated by the procedures (e)
and (f) (the same procedures as used for synthesis in Scheme 15(e)
and (f) above) to give the desired product 274-9 (27% yield for 2
steps).
[0442] Mp 111.2-111.4.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.15 (1H, s, Ar--CHO), 9.31 (1H, s,
C(CH.sub.3)--CHO), 6.41 (1H, t, J=7.4 Hz, CH.sub.2CH.dbd.C), 6.35
(1H, s, Ar--OH), 5.26 (1H, t, J=6.8 Hz, CH.sub.2CH.dbd.C), 3.40
(2H, d, J=7.4 Hz, Ar--CH.sub.2), 2.61 (3H, s, Ar--CH.sub.3),
2.4-2.5 (2H, m, C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 2.1-2.2 (2H,
m, C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C), 1.81 (3H, s, CH.sub.3),
1.70 (3H, s, CH.sub.3). MS (EI) m/z 338 (5, M+2), 336 (13,
M.sup.+).
3-Chloro-5-[(2E,6E)-3,7-dimethyl-9-(3,3-dimethyloxiran-2-yl)-2,6-nonadienl-
l]-4,6-dihydroxy-2-methylbenzaldehyde (compound 281-12)
[0443] Alcohol 94 known from literature (Org. Lett. 2006, 8,
5649-5652) was used and treated by the procedures (e) and (f) (the
same procedures as used for synthesis in Scheme 15(e) and (f)
above) to give the desired product 281-12 (4% yield for 2
steps).
[0444] Mp 36-37.degree. C. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 12.70 (1H, s, Ar--OH), 10.14 (1H, s, Ar--CHO), 6.57 (1H, s,
Ar--OH), 5.21 (1H, t, J=7.1 Hz, CH.sub.2CH.dbd.C), 5.11 (1H, t,
J=6.2 Hz, CH.sub.2CH.dbd.C), 3.39 (2H, d, J=7.1 Hz, Ar--CH.sub.2),
2.69 (1H, t, J=6.2 Hz, oxiran(2)-H), 2.61 (3H, s, Ar--CH.sub.3),
1.96-2.12 (6H, m,
C(CH.sub.3)CH.sub.2CH.sub.2CH.dbd.C(CH.sub.3)CH.sub.2), 1.78 (s,
CH.sub.3), 1.56-1.64 (5H, m+s (.delta.1.59), nonadienyl(9)-H.sub.2
and CH.sub.3), 1.30 (s, CH.sub.3), 1.25 (s, CH.sub.3). IR (KBr)
3300-3500, 1614, 1418, 1281, 1250, 1233, 1109 cm.sup.-1.
EXAMPLES
[0445] The DHOD inhibitor of the present invention will be further
described in more detail by way of the following illustrative
examples. It should be noted that the present invention is not
limited in any way by these examples.
Example 1
Measurement of DHOD Inhibitory Activity
[0446] The compounds of the present invention were used and
measured for their DHOD inhibitory activity at concentrations of
200 nM and 1000 nM.
[0447] Assay buffer (100 mM HEPES pH 8.0, 150 mM NaCl, 5% glycerol,
0.05% Triton X-100, 200 .mu.M dihydroorotate, 120 .mu.M DCIP, 11
.mu.M decylubiquinone) (190 .mu.l) and a DMSO solution of each
inhibitor (5 .mu.l) were added, and a 8 .mu.g/ml human DHOD
solution (5 .mu.l) was added thereto to initiate the enzyme
reaction (final concentration of human DHOD: 0.2 .mu.g/ml (4 nM)).
Reduction of DCIP was measured at 600 nm over 20 minutes. Based on
a change in absorbance at 600 nm between 0 minutes and 20 minutes,
each compound was measured for its human DHOD inhibition rate at
concentrations of 200 nM and 1000 nM by using the value obtained in
the presence of the DMSO solution alone as a control in the end
point assay. Moreover, the concentration (nM) required to inhibit
50% of human DHOD activity was determined as IC50 (50% inhibitory
concentration). The results obtained are shown in Table 1.
TABLE-US-00001 TABLE 1 DHOD inhibition rate (%) Compound 200 nM 100
nM IC50 (nM) Ascofuranone (control) 73 95 38 .+-. 12 07-11-116-4 57
87 146 .+-. 19 200-12-OCOiPr 51 85 326 .+-. 41 231-9-OMe 75 98 67
.+-. 7 234-12-OPiv 72 102 98 .+-. 5 236-12-OTHF 86 97 33 .+-. 3
236-9-OH 82 103 44 .+-. 5 264-11-OPiv 58 94 123 .+-. 18 264-8 74 90
71 .+-. 2 271-12 76 95 60 .+-. 21 274-9 90 98 31 .+-. 3
275-10-COOMe 100 100 4.2 .+-. 0.4 276-9 87 96 24 .+-. 3 277-11-OAc
97 103 6.5 .+-. 0.2 277-9-OH 75 107 64 .+-. 11 280-12 104 94 6.0
.+-. 0.5 281-12 79 100 50 .+-. 5 287-12-OCOiPr 101 109 21.5 .+-.
0.3 287-12-OPiv 82 104 67 .+-. 3 CC-B 69 100 1052 .+-. 214
Example 2
Anticancer Effect
[0448] Conventional anticancer agents are designed to directly act
on the process of cell division, but they have been significantly
disadvantageous in developing serious side effects due to their low
specificity to tumor cells and strong cytotoxicity on normal cells.
After that, molecular targeted drugs have appeared, which are
designed to target molecules involved in the growth, invasion and
metastasis of tumor cells and thereby allow not only suppression of
tumor cell growth and tumor cell progression, but also suppression
of tumor metastasis.
[0449] For these reasons, screening was conducted by cancer cell
growth inhibition test using a panel of 39 types of human cancer
cell lines (JFCR39) and by cancer cell informatics based on
information analysis (Kong D., T. Yamori; Bioorganic & Med.
Chem., 20, 1947-51, 2012). The concentration (.mu.M) required to
inhibit 50% of human cancer cell growth was determined as GI50 (50%
inhibitory concentration).
[0450] The results obtained are shown in Table 2.
[0451] Inhibitory effects on various human cancer cells
TABLE-US-00002 TABLE 2 G[50 (.mu.M) Ascofuranone 287-12-OCOiPr
280-12 277-11-Oac 277-9-OH 275-10-COO Me Br HBC-4 9.1 9.4 2.2 5.0
37.0 5.6 (Breast) BSY-1 16.0 16.0 13.0 20.0 59.0 27.0 HBC-5 28.0
18.0 16.0 25.0 61.0 28.0 MCF-7 9.0 6.7 1.3 4.9 36.0 7.3 MDA-MB-231
7.4 10.0 2.8 11.0 36.0 14.0 CNS U251 1.5 4.9 0.43 1.5 5.1 0.97
(Central SF-268 7.0 9.5 0.93 5.0 12.0 8.1 Nervous SF-295 5.3 16.0
1.3 8.0 16.0 11.0 Syste SF-539 1.7 2.2 0.24 0.27 5.3 0.54 SNB-75
23.0 28.0 0.70 22.0 59.0 9.7 SNB-78 23.0 28.0 16.0 21.0 43.0 8.8 Co
HCC2998 17.0 15.0 12.0 13.0 43.0 17.0 (Colon) KM-12 9.3 10.0 2.0
5.7 32.0 6.4 HT-29 6.6 5.8 1.1 3.2 39.0 6.5 HCT -15 1.3 1.9 0.043
0.58 6.2 0.83 HCT -116 5.1 4:6 0.46 1.5 14.0 2.5 Lu NC I -H23 15.0
13.0 2.8 15.0 39.0 7.8 (Lung) NCI -H226 15.0 8.0 10.0 11.0 24.0
13.0 NCI -H522 8.4 4.2 1.2 4.9 22.0 5.3 NCI -H460 2.0 4.5 0.21 0.94
12.0 4.3 A549 7.6 7.1 0.77 3.3 37.0 4.7 DMS273 5.9 3.6 0.45 0.91
18.0 3.0 DMS114 19.0 12.0 2.5 14.0 35.0 15.0 Me (Melanoma) LOX- I
MV I 2.8 3.4 0.61 1.5 13.0 2.1 Ov OVCAR-3 8.0 7.1 1.9 13.0 27.0 5.3
(Ovarian) OVCAR-4 5.9 19.0 13.0 27.0 39.0 11.0 OVCAR-5 7.6 22.0 6.6
18.0 58.0 12.0 OVCAR-8 9.5 9.1 0.97 8.8 25.0 4.4 SK-OV-3 13.0 49.0
37.0 12.0 27.0 11.0 Re RXF-631L 12.0 16.0 11.0 7.5 45.0 8.4 (Renal)
ACHN 10.0 16.0 0.79 9.9 22.0 9.9 St St-4 14.0 17.0 1.1 13.0 44.0
7.5 (Stomac) MKN1 14.0 12.0 8.2 16.0 44.0 14.0 MKN7 15.0 16.0 2.1
16.0 36.0 13.0 MKN28 9.7 10.0 1.3 11.0 36.0 12.0 MKN45 10.0 24.0
6.4 20.0 65.0 14.0 MKN74 13.0 14.0 1.9 11.0 26.0 14.0 xPg DU-145
11.0 23.0 0.26 14.0 25.0 10.0 (Prostate) PC-3 13.0 13.0 1.2 15.0
22.0 22.0 IC50 (nM) HsDHOD 38.0 21.5 6.0 6:5 64.0 4.2
Example 3
Anticancer Effect Under Hypoxic and Subnutritional Conditions
[0452] Until now, various studies have been attempted to overcome
cancers. As a result, outcomes of early cancer treatment have been
dramatically improved. However, treatment of progressive cancers is
still difficult, and hence cancers hold the top spot among causes
of death in Japanese patients. This is because areas having
internal environments including hypoxia and subnutrition (hypoxic
areas) are found widely in progressive solid cancers due to
perfusion insufficiency induced by incomplete vascular
construction. Namely, many anticancer agents used for clinical
purposes have been found to clearly reduce their anticancer effect
under hypoxic and subnutritional conditions (Lue J. et. al.; Cancer
Sci., 95, 6; 547-552, 2004). In such areas, drugs are difficult to
reach, a new character is acquired to avoid cell death, and cell
division is less active. Due to these features, progressive solid
cancers are considered to be resistant to conventional
chemotherapies.
[0453] For these reasons, cells of colorectal and pancreatic
cancers, each being regarded as intractable, were used to test the
inhibitory effect of compounds under hypoxic and subnutritional
conditions. Moreover, the same test was also performed on normal
skin cells.
[0454] The cells used were two types of cancer cells, i.e., DLD-1
cells (human colorectal cancer cells) and Panc-1 cells (human
pancreatic cells), as well as HDF cells (human dermal fibroblast
cells). Culture conditions were set as follows: 21% oxygen with
glucose and glutamic acid (+10% FBS) for the control group, and 1%
oxygen without glucose and glutamic acid (+10% FBS) for the hypoxic
and subnutritional group. The results obtained are shown in Tables
3, 4 and 5, as well as FIGS. 1, 2 and 3.
[0455] Inhibitory effect on DLD-1 cells
TABLE-US-00003 TABLE 3 IC.sub.50 DLD-1 [.mu.M] bovine time HsDHDD
complex II-III compound [hours] 21% O.sub.2 glc(+) gln(+) 1%
O.sub.2 glc(-)gln(-) Selectivity [nM] [nM] 280-12 24 76 0.069 1100
6.0 260 48 37 0.025 1480 277-11-OAc 24 >100 1.9 >53 6.5 4500
48 >100 0.92 >109 275-10-COOMe 24 >100 1.7 >59 4.2 1900
48 >100 0.64 >156 Selectivity = 21% glc (+) gln (+)
IC.sub.50/1% glc (-) gln (-) IC.sub.50
[0456] Inhibitory Effect on Panc-1 Cells
TABLE-US-00004 TABLE 4 IC.sub.50 [.mu.M] 21% O.sub.2 1% O.sub.2
glc(+)gln(+) glc(-)gln(-) Selectivity AF >100 1.4 >71
Selectivity = 21% glc(+)gln(+) IC.sub.50/1% glc(-)gln(-)
IC.sub.50
[0457] Inhibitory Effect on HDF Cells
TABLE-US-00005 TABLE 5 IC.sub.50 [.mu.M] 21% O.sub.2 1% O.sub.2
compound glc(+)gln(+) glc(-)gln(-) Selectivity AF >100 1.6
>63 280-12 60 0.17 353 277-11-OAc >100 4.0 >25
275-10-COOMe >100 3.1 >32 Selectivity = 21% glc(+)gln(+)
IC.sub.50/1% glc(-)gln(-)IC.sub.50
[0458] The above results indicated that ascofuranone and
derivatives thereof showed an inhibitory effect specifically and
even at low concentration against human cultured cells under
hypoxic and subnutritional environment.
[0459] One or two or more of the compounds of the present invention
can be used to prepare a pharmaceutical composition comprising one
or more pharmaceutically acceptable carriers. Such a pharmaceutical
composition can be administered in any dosage form as appropriate
for the intended route of administration. The route of
administration may be either parenteral or oral. For example,
formulation examples as shown below can be presented.
FORMULATION EXAMPLES
(a) Tablet 1 (Amount Per Tablet)
TABLE-US-00006 [0460] The compound(s) of the present invention 100
mg Lactose 182.75 mg Croscarmellose sodium 12 mg Corn starch paste
(5% w/v paste) 2.25 mg Magnesium stearate 3 mg
(b) Tablet 2 (Amount Per Tablet)
TABLE-US-00007 [0461] The compound(s) of the present invention 50
mg Lactose 223.75 mg Croscarmellose sodium 6 mg Corn starch 15 mg
Polyvinylpyrrolidone 2.25 mg Magnesium stearate 3 mg
(c) Tablet 3 (Amount Per Tablet)
TABLE-US-00008 [0462] The compound(s) of the present invention 1 mg
Lactose 93.25 mg Croscarmellose sodium 4 mg Corn starch paste (5%
w/v paste) 0.75 mg Magnesium stearate 1 mg
(d) Capsule (Amount Per Capsule)
TABLE-US-00009 [0463] The compound(s) of the present invention 10
mg Lactose 488.5 mg Magnesium stearate 1.5 mg
(e) Injection 1 (Amount Per Ml)
TABLE-US-00010 [0464] The compound(s) of the present invention 1%
w/v Sodium phosphate 3.6% w/v 0.1M Aqueous sodium hydroxide 15% v/v
Injectable water balanced to 100%
(f) Injection 2 (Amount Per Ml)
TABLE-US-00011 [0465] The compound(s) of the present invention 0.1%
w/v Sodium phosphate 2.26% w/v Citric acid 0.38% w/v Polyethylene
glycol 400 3.5% w/v Injectable water balanced to 100%.
[0466] The above formulations can be obtained by prior art
techniques well known in the pharmaceutical industry. Tablets 1 to
3 can be enteric-coated, e.g., by using shellac, cellulose acetate,
monophthalic acid ester, phenyl salicylate, polyvinylpyrrolidone,
keratin or the like. Likewise, the capsules can also be designed to
be soluble in the intestinal tract by using enteric capsules (e.g.,
glutoid capsules).
INDUSTRIAL APPLICABILITY
[0467] Because of having high DHOD inhibitory activity, the above
dihydroxybenzene derivatives represented by formula (I) are
extremely useful as DHOD inhibitors for use in therapeutic agents
for various DHOD-related diseases, such as various types of
cancers, rheumatism, graft rejection in organ transplantation,
diabetes, virus-induced diseases and H. pylori-induced diseases.
Moreover, the dihydroxybenzene derivatives can be synthesized more
easily than ascofuranone and hence are also very advantageous in
the industrial aspect.
* * * * *